Medicinal uses of cyclic peptide compounds

Abstract

The present invention provides an innovative group of peptide compounds that suppress Ras activation and inhibit the growth of cancer cells accompanied by Ras mutations or Ras gene abnormalities, and a pharmaceutical composition containing said group of peptide compounds. The present invention provides a cyclic peptide compound that interacts with Ras, and a pharmaceutical composition comprising the cyclic peptide compound, a salt thereof, or a solvate thereof.

Description

[Technical Field]

[0001] The present invention relates to a cyclic peptide compound having Ras inhibitory activity, and the cyclic peptide compound or a salt thereof or a solvate thereof; a pharmaceutical composition or a therapeutic or preventive agent for a disease comprising the cyclic peptide compound or a salt thereof or a solvate thereof; and the use thereof in the manufacture of a medicament for the treatment or prevention of a disease. [Background technology]

[0002] Ras is a protein belonging to the small GTPase family, and is classified as Kras, Nras, or Hras. Ras's inactive or active state is determined by its binding state to GDP or GTP. It is activated by the exchange of GDP for GTP by GEFs (guanine nucleotide exchange factors) and inactivated by the hydrolysis of GTP by GAPs (GTPase-activating proteins) (Non-Patent Document 1). Activated Ras induces cell proliferation, survival, and differentiation by activating various downstream signals, including the MAPK pathway, PI3K / Akt pathway, and RAL pathway. Constitutive activation of Ras plays an important role in the development and progression of cancer. It is known that the Ras-RAF-MEK-ERK pathway is activated in cancer due to activation of upstream Ras signals, constitutive activation of Ras, and / or activating mutations of Ras (Non-Patent Document 2). These activating Ras mutations have been observed in numerous types of cancer. G12, G13, and Q61 are known as hotspots for Ras mutations, with high frequency mutations observed at G12 in Kras and Q61 in Nras. These mutations are also known to be associated with patient prognosis (Non-Patent Document 3).

[0003] Compared to small molecules, medium-molecular-weight compounds (molecular weight 500-2000) may be superior in accessing tough targets, such as inhibiting protein-protein interactions. Furthermore, compared to antibodies, medium-molecular-weight compounds may also be superior in terms of their ability to be transported into cells. Among physiologically active medium-molecular-weight compounds, peptide drugs are highly valuable molecular species, with over 40 types already on the market (Non-Patent Document 4). Representative examples of these peptide drugs include cyclosporin A and polymyxin B. These are peptides containing several unnatural amino acids. Unnatural amino acids are amino acids that are not naturally encoded on mRNA, and it is particularly interesting that naturally-occurring cyclosporin A and polymyxin B contain unnatural amino acids that are not encoded on mRNA.

[0004] Since it was discovered that naturally occurring peptides are useful as medicines, attention has been focused on peptides that have pharmacological activity and can be absorbed by the body, and peptides with molecular weights of approximately 500 to 2000 have been actively researched (Non-Patent Document 5).

[0005] Conditions for improving membrane permeability and metabolic stability (conditions necessary for satisfying drug-likeness), which may contribute to improving the pharmacokinetics of medium-sized peptides, have been reported (Patent Document 1).

[0006] Furthermore, the conditions necessary for a medium-sized peptide to satisfy the drug-likeness of a cyclic peptide have been clarified as conditions that can contribute to the improvement of pharmacokinetics (Patent Document 2).

[0007] Peptides that bind to Ras have been discovered, and the binding site between cyclic peptides and Ras has been analyzed by X-ray structural analysis (Non-Patent Document 6, Non-Patent Document 7, Non-Patent Document 8, Non-Patent Document 9). In addition, cyclic peptides that suggest inhibition of binding between Ras and SOS have also been discovered (Patent Document 3). Furthermore, in a competitive assay of binding between a specific compound and Ras, cyclic peptides that suggest inhibition of binding to Ras have been discovered (Patent Document 4). [Prior art documents] [Chartered documents]

[0008]

Patent Document 1

Patent document 2

Patent Document 3

Patent document 4

Non-licensed literature

[0009] [Non-licensed document 1] Nat. Rev. Drug Discov. 2014 Nov;13(11):828-851. [Non-licensed document 2] Nat. Rev. Drug Discov. 2014 Dec;13(12):928-942. [Non-licensed document 3] Nat. Rev. Drug Discov. 2016 Nov;15(11):771-785.

Non-licensed Document 4

Non-licensed Document 5

Non-licensed Document 6

Non-licensed Document 7

[0010] The present invention provides a compound that is effective against cancers associated with Ras mutations or abnormalities in the Ras gene, and a pharmaceutical composition comprising the cyclic peptide compound or a salt thereof, or a solvate thereof; a pharmaceutical composition or a therapeutic or preventive agent for a disease comprising the cyclic peptide compound or a salt thereof, or a solvate thereof; use of the cyclic peptide compound or a salt thereof in the manufacture of a medicament for the treatment or prevention of a disease; and the like. Patent Documents 1 and 2 describe drug-like peptides, but do not describe peptides that have antitumor effects against cancers, including cancers associated with Ras mutations or abnormalities in the Ras gene. Patent Document 3 describes the inhibition of binding between Ras and SOS, and Patent Document 4 describes a peptide that competes with a compound that binds to Ras, but these documents do not disclose any pharmacological action, particularly an action on tumor cells, and do not describe any drug-like peptides.

[0011] The relationship between Ras and cancer is described in detail in Non-Patent Document 1. This document describes molecules that bind to Ras, and although their effectiveness has been demonstrated in preclinical studies, no compounds have been shown to be effective as pharmaceuticals specifically against Ras-mutated cancers, and no drug-like cyclic peptides have been disclosed. Non-Patent Document 2 provides a detailed description of Ras and the RAF-MEK-ERK pathway downstream of Ras. Although this document suggests the possibility of treating Ras-mutated cancers with inhibitors of RAF, MEK, and ERK, it does not disclose any compounds that directly inhibit Ras. Non-Patent Document 3 describes compounds that bind to the GTP / GDP binding site of Ras and inhibit Ras function, and the mechanism behind this. This document provides a detailed explanation of the interaction with the GTP / GDP binding site, but does not disclose pharmacological actions, particularly effects on tumor cells. Non-Patent Document 4 describes peptides used as medicines, but does not describe drug-like peptides or peptides useful for Ras mutant cancers. Non-Patent Document 5 describes the molecular form of cyclic peptides and their pharmacokinetics, but does not describe compounds that are useful for Ras mutant cancers. Non-Patent Documents 6 to 9 describe peptides that bind to Ras, but their effects on tumor cells are limited, and there is no description of drug-like peptides.

[0012] There are no effective treatments for cancers associated with Ras mutations or abnormalities in the Ras gene, and although these are diseases with significant unmet medical needs, no drugs that directly inhibit Ras and demonstrate clinical therapeutic effects have been developed, and no peptides that satisfy drug-like properties have been found.

[0013] The present invention is directed to a group of innovative peptide compounds that suppress Ras activation through a mechanism of action in which they directly bind to Ras and inhibit its interaction with SOS, thereby inhibiting the growth of cancer cells with Ras mutations or abnormalities in the Ras gene, as well as pharmaceutical compositions containing said group of peptide compounds. [Means for solving the problem]

[0014] The present inventors have conducted extensive research into the discovery of cyclic peptide compounds with Ras inhibitory activity, and have now discovered for the first time a cyclic peptide compound that interacts with Ras in a novel and unique manner. Specifically, the present inventors have discovered for the first time that the cyclic peptide compound interacts with at least one amino acid residue selected from the group consisting of Val8, Gly10, Lys16, Glu37, Leu56, Gln70, Tyr71, and Glu98 of Ras. Furthermore, the present inventors have found that the cyclic peptide compound inhibits the binding of Ras to SOS. Furthermore, the present inventors have found that the cyclic peptide compound has a pharmacological effect of inhibiting the growth of cancer cells with Ras mutations or Ras gene abnormalities. Furthermore, the present inventors have identified the amino acid site in the Ras protein that interacts with the cyclic peptide compound.

[0015] In one non-limiting specific embodiment, the present invention includes the following. [1] A pharmaceutical composition comprising a cyclic peptide compound represented by the following formula (1), or a salt thereof, or a solvate thereof: [ka] During the ceremony, L1 is a single bond, or -CHM1-, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2) n S(O)2(CH2) m wherein n and m are each independently 1 or 2; R1 is hydrogen, C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, or C3-C8 cycloalkoxyC1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino), and C1-C6 alkylsulfonyl; or R1 and P1 together with the carbon atom to which R1 is attached and the nitrogen atom to which P1 is attached form a 4- to 7-membered saturated heterocyclic ring; or R1 and Q1 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or R1 and M1 together with the carbon atom to which R1 is bonded and the carbon atom to which M1 is bonded form a 3- to 8-membered alicyclic ring; Except when R1 and P1 form a 4- to 7-membered saturated heterocycle, P1 is hydrogen or C1-C6 alkyl, which C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q1 is hydrogen or C1-C6 alkyl, except when R1 and Q1 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; and M1 is hydrogen, except when R1 and M1 form a 3- to 8-membered alicyclic ring; R2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, or C3-C8 cycloalkoxyC1-C6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, cyano, and C1-C6 alkylsulfonyl; or R2 and P2 together with the carbon atom to which R2 is attached and the nitrogen atom to which P2 is attached form a 4- to 7-membered saturated heterocyclic ring; or R2 and Q2 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R2 and P2 form a 4- to 7-membered saturated heterocycle, P2 is hydrogen or C1-C6 alkyl, which C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q2 is hydrogen or C1-C6 alkyl, except when R2 and Q2 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R3 is hydrogen, C1-C6 alkyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C3-C8 cycloalkoxyC1-C6 alkyl, or C7-C 14 aralkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of hydroxy, and aminocarbonyl, where the amino is -NH, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino; or R3 and P3 together with the carbon atom to which R3 is attached and the nitrogen atom to which P3 is attached form a 4- to 7-membered saturated heterocyclic ring; or R3 and Q3 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R3 and P3 form a 4- to 7-membered saturated heterocycle, P3 is hydrogen, C1-C6 alkyl, C1-C6 alkoxyC1-C6 alkyl, or C3-C8 cycloalkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and C1-C6 aminoalkyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, which is optionally substituted with one or more halogens); Q3 is hydrogen or C1-C6 alkyl, except when R3 and Q3 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R4 is hydrogen or C1-C6 alkyl, or R4 and P4 together with the carbon atom to which R4 is attached and the nitrogen atom to which P4 is attached form a 4- to 7-membered saturated heterocyclic ring; or R4 and Q4 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R4 and P4 form a 4- to 7-membered saturated heterocycle, P4 is hydrogen, C1-C6 alkyl, or C1-C6 alkoxyC1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q4 is hydrogen or C1-C6 alkyl, except when R4 and Q4 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R5 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C3-C8 cycloalkoxyC1-C6 alkyl, C7-C 14 Aralkyl, C6-C 10 Aryloxy C1-C6 alkyl, C7-C 14 aralkoxyC1-C6 alkyl, or 5- to 10-membered heteroarylC1-C6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, cyano, and C1-C6 alkylsulfonyl, or R5 together with R8 form a C4-C8 alkylene, or R5 and P5 together with the carbon atom to which R5 is attached and the nitrogen atom to which P5 is attached form a 4- to 7-membered saturated heterocyclic ring; or R5 and Q5 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R5 and P5 form a 4- to 7-membered saturated heterocycle, P5 is hydrogen or C1-C6 alkyl, which C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q5 is hydrogen or C1-C6 alkyl, except when R5 and Q5 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R6 is hydrogen or C1-C6 alkyl; or R6 and P6 together with the carbon atom to which R6 is attached and the nitrogen atom to which P6 is attached form a 4- to 7-membered saturated heterocyclic ring; or R6 and Q6 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R6 and P6 form a 4- to 7-membered saturated heterocycle, P6 is C1-C6 alkyl or C3-C8 cycloalkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q6 is hydrogen or C1-C6 alkyl, except when R6 and Q6 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R7 is C6-C 10 Aryloxy C1-C6 alkyl, C7-C 14 Aralkyl, C7-C 14aralkoxyC1-C6 alkyl, or 5- to 10-membered heteroarylC1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkoxy, cyano, C1-C6 alkylsulfonyl, and SF5; or R7 and P7 together with the carbon atom to which R7 is attached and the nitrogen atom to which P7 is attached form a 4- to 7-membered saturated heterocyclic ring; or R7 and Q7 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R7 and P7 form a 4- to 7-membered saturated heterocycle, P7 is hydrogen or C1-C6 alkyl, which C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q7 is hydrogen or C1-C6 alkyl, except when R7 and Q7 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R8 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C2-C6 alkenyloxycarbonylC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C6-C 10 Aryloxy C1-C6 alkyl, C7-C 14 Aralkyl, C7-C 14aralkoxyC1-C6 alkyl, 5- to 10-membered heteroarylC1-C6 alkyl, or 5- to 10-membered heteroarylC1-C6 alkoxyC1-C6 alkyl, each of which is halogen, hydroxy, carboxy, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkoxy, cyano, amino (said amino is -NH2, protected amino, monoC1-C6 alkylamino, diC1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is substituted with halogen). or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; R8 and P8 together with the carbon atom to which R8 is bonded and the nitrogen atom to which P8 is bonded form a 4- to 7-membered saturated heterocycle, which may be condensed with a saturated carbocycle or an aromatic ring, and which may be condensed with a halogen, oxo, C6-C 10 and optionally substituted by aryl, 5- to 10-membered heteroaryl, 4- to 8-membered cyclic amino (the cyclic amino may be substituted by one or more halogens), or OS8, and S8 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C7-C 14 aralkyl, which may be optionally substituted by one or more halogen, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy, or a 5- to 10-membered heteroarylC1-C6 alkyl; or R8 and Q8 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R8 and P8 together form a 4- to 7-membered saturated heterocycle, P8 is hydrogen, C1-C6 alkyl, C1-C6 alkoxyC1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxyC2-C6 alkenyl, C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, 4- to 7-membered heterocyclylC1-C6 alkyl, C6-C 10 Aryl, C7-C 14 aralkyl, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl-C1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen or C1-C6 alkyl), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q8 is hydrogen or C1-C6 alkyl, except when R8 and Q8 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R9 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkylC1-C6 alkyl, C7-C 14 aralkyl, or 5-10 membered heteroaryl C1-C6 alkoxyC1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4-8 membered cyclic amino), and C1-C6 alkylsulfonyl; or R9 and P9 together with the carbon atom to which R9 is attached and the nitrogen atom to which P9 is attached form a 4- to 7-membered saturated heterocyclic ring; or R9 and Q9 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R9 and P9 form a 4- to 7-membered saturated heterocycle, P9 is hydrogen or C1-C6 alkyl, which C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q9 is hydrogen or C1-C6 alkyl, except when R9 and Q9 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R 10 is C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C3-C8 cycloalkoxyC1-C6 alkyl, or C7-C 14 aralkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, and C1-C6 alkylsulfonyl; or R 10 and P 10 is R 10 and P 10 together with the nitrogen atom to which it is attached to form a 4- to 7-membered saturated heterocyclic ring, or R 10 and Q 10 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, or R 10 and P 10 P forms a 4- to 7-membered saturated heterocyclic ring, 10is hydrogen or C1-C6 alkyl, and the C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); R 10 and Q 10 Q forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, 10 is hydrogen or C1-C6 alkyl, and L 11 is a single bond or -CHM 11 -, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2) n S(O)2(CH2) m wherein n and m are each independently 1 or 2; R 11 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkyl, C7-C 14 aralkyl, or aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino), each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, oxo, hydroxy, C1-C6 alkyl, 4- to 7-membered heterocyclyl, aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino), and C1-C6 alkylsulfonyl; or R 11 is a peptide chain containing 1 to 4 amino acid residues, or R 11 and P11 is R 11 and P 11 together with the nitrogen atom to which it is attached to form a 4- to 7-membered saturated heterocyclic ring, or R 11 and Q 11 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, or R 11 and M 11 is R 11 and the carbon atom to which M is bonded 11 forms a 3- to 8-membered alicyclic ring together with the carbon atom to which it is bonded, R 11 and P 11 P forms a 4- to 7-membered saturated heterocyclic ring, 11 is hydrogen or C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); R 11 and Q 11 Q forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, 11 is hydrogen or C1-C6 alkyl, R 11 and M 11 forms a 3- to 8-membered alicyclic ring, M 11 is hydrogen, where L1 is a single bond, 11 -CHM 11 -, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2) nS(O)2(CH2) m -, and L1 is -CHM1-, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2) n S(O)2(CH2) m -If L 11 is a single bond, and P1~P 11 At least three of these are not hydrogen. [2] The pharmaceutical composition according to [1], wherein the cyclic peptide compound is represented by the following formula (2): [ka] During the ceremony, R1 is C1-C6 alkyl; P1 is C1-C6 alkyl; R2 is C1-C6 alkyl; P2 is hydrogen, R3 is hydrogen or C1-C6 alkyl; P3 is C1-C6 alkyl; R4 is hydrogen, or R4 and P4 together with the nitrogen atom to which P4 is bonded and the carbon atom to which R4 is bonded form a 4- to 7-membered saturated heterocycle; P4 is C1-C6 alkyl, except when R4 and P4 form a 4- to 7-membered saturated heterocycle; R5 is C3-C8 cycloalkyl, C1-C6 alkyl, or C7-C optionally substituted by C1-C6 alkyl. 14 is aralkyl, P5 is C1-C6 alkyl; R6 is hydrogen; P6 is C1-C6 alkyl; R7 is a C7-C6 haloalkyl group optionally substituted with one or more groups independently selected from the group consisting of halogen and C1-C6 haloalkyl. 14 is aralkyl, Q7 is hydrogen, P7 is hydrogen, R8 and P8 together with the nitrogen atom to which P8 is bonded and the carbon atom to which R8 is bonded form a 4- to 7-membered saturated heterocycle, which is optionally substituted by C1-C6 alkoxy; R9 and Q9 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring; P9 is hydrogen R 10 is C3-C8 cycloalkyl, P 10 is C1-C6 alkyl, R 11 is diC1-C6 alkylaminocarbonyl or 4- to 8-membered cyclic aminocarbonyl, M 11 is hydrogen, P 11 is C1-C6 alkyl. [3] The pharmaceutical composition according to [2], wherein the cyclic peptide compound is represented by the following formula: [ka] During the ceremony, R3 is hydrogen or methyl; R4 is hydrogen and P4 is methyl, or R4 and P4 together with the nitrogen atom to which P4 is bonded and the carbon atom to which R4 is bonded form an azetidine ring; R5 is cyclohexylmethyl or 4-methylbenzyl; P5 is methyl or ethyl; R 7A , R 7B , and R 7C is independently selected from the group consisting of hydrogen, fluorine, chlorine, and trifluoromethyl; R 8A is hydrogen or ethoxy, R 10 is cyclopentyl or cyclohexyl, R 11A , and R 11B are both methyl or R 11A , and R 11B together with the nitrogen atom to which they are attached form a piperidine ring or a morpholine ring. [4] The pharmaceutical composition according to any one of [1] to [3], wherein the cyclic peptide compound is selected from the group consisting of: (1217) (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)- 4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, (1201) (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nona Methyl-4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, (558) (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecaone, and (926) (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine-4 -carbonyl)docosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone. [5] The cyclic peptide compound is (1217) (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)- 4,7,10,13,17,20,23,28,31,34,37-Undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide The pharmaceutical composition according to any one of [1] to [4], [6] The cyclic peptide compound is (1201) (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nonamethyl-4,7,10,13 The pharmaceutical composition according to any one of [1] to [4], wherein the compound is 17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide. [7] The cyclic peptide compound is (558) (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecanone The pharmaceutical composition according to any one of [1] to [4], [8] The cyclic peptide compound is (926) (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine- 4-carbonyl)docosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone The pharmaceutical composition according to any one of [1] to [4], [8-1] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)-4,7,10,13,17,2 A pharmaceutical composition comprising 0,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a salt thereof, or a solvate thereof. [8-2] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)-4,7,10,13,17, A pharmaceutical composition comprising 20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a salt thereof, or a hydrate thereof. [8-3] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)-4,7,10,13 ,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a hydrate thereof. [8-4] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)-4,7, A pharmaceutical composition comprising 10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide. [8-5] (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nonamethyl-4,7,10,13, A pharmaceutical composition comprising 17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a salt thereof, or a solvate thereof. [8-6] (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nonamethyl-4,7,10,13, A pharmaceutical composition comprising 17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a salt thereof, or a hydrate thereof. [8-7] (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nonamethyl-4,7,1 A pharmaceutical composition comprising 0,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a hydrate thereof. [8-8] (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nonamethyl-4 1. A pharmaceutical composition comprising 1,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide. [8-9] A pharmaceutical composition comprising (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecaone, or a salt thereof, or a solvate thereof. [8-10] A pharmaceutical composition comprising (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecaone, or a salt thereof, or a hydrate thereof. [8-11] A pharmaceutical composition comprising (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecaone, or a hydrate thereof. [8-12] 1. A pharmaceutical composition comprising: (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecaone. [8-13] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine-4-carbonyl)docosahydro- A pharmaceutical composition comprising 2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone, or a salt thereof, or a solvate thereof. [8-14] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine-4-carbonyl)docosahydro A pharmaceutical composition comprising -2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone, or a salt thereof, or a hydrate thereof. [8-15] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine-4-carbonyl)doco A pharmaceutical composition comprising sahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone, or a hydrate thereof. [8-16] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine-4-carbo 1. A pharmaceutical composition comprising: (14H,22H)-undecahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone. [9] The pharmaceutical composition according to any one of [1] to [8] and [8-1] to [8-16], which is a Ras inhibitor.

[10] The pharmaceutical composition according to [9], wherein the Ras inhibitor is one or more Ras inhibitors selected from the group consisting of Kras inhibitors, Nras inhibitors, and Hras inhibitors.

[11] The pharmaceutical composition according to any one of [1] to

[10] , for treating or preventing cancer.

[12] The pharmaceutical composition according to

[11] , wherein the cancer is a solid cancer or a blood cancer.

[13] The pharmaceutical composition according to

[11] or

[12] , wherein the cancer is selected from the group consisting of lung cancer, esophageal cancer, gastric cancer, colon cancer, uterine cancer, ovarian cancer, pancreatic cancer, bladder cancer, thyroid cancer, skin cancer, leukemia, malignant lymphoma, and multiple myeloma.

[14] The pharmaceutical composition according to any one of

[11] to

[13] , wherein the cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, colon cancer, rectal cancer, uterine cancer, endometrial cancer, cervical cancer, AML (acute myeloid leukemia), CML (chronic myeloid leukemia), ALL (acute lymphocytic leukemia), CLL (chronic lymphocytic leukemia), Hodgkin lymphoma, and non-Hodgkin lymphoma.

[15] The pharmaceutical composition according to any one of

[11] to

[14] , wherein the cancer is associated with an abnormality in the Ras gene.

[16] The pharmaceutical composition according to

[15] , wherein the abnormality in the Ras gene is a mutation in the coding region of the Ras gene and / or an amplification of the copy number of the Ras gene.

[17] The pharmaceutical composition according to

[15] or

[16] , wherein the Ras gene is one or more Ras genes selected from the group consisting of Kras genes, Nras genes, and Hras genes.

[18] The pharmaceutical composition according to

[17] , wherein the Ras gene is a Kras gene.

[19] The pharmaceutical composition according to any one of

[11] to

[18] , wherein the cancer is associated with the production of a mutant Ras protein and / or increased production of a Ras protein.

[20] The pharmaceutical composition according to

[19] , wherein the cancer is associated with the production of a mutant Ras protein. 〔twenty one〕 The pharmaceutical composition according to

[19] or

[20] , wherein the mutant Ras protein is one or more mutant Ras proteins selected from the group consisting of mutant Kras proteins, mutant Nras proteins, and mutant Hras proteins. 〔twenty two〕 The pharmaceutical composition according to

[21] , wherein the mutant Ras protein is a mutant Kras protein. 〔twenty three〕 A pharmaceutical composition described in any of

[19] to

[22] , wherein the mutant Ras protein has a mutation at at least one amino acid position selected from the group consisting of G12, G13 and Q61 in the amino acid sequence set forth in SEQ ID NO: 6, 7 or 8. 〔twenty four〕 A pharmaceutical composition according to any one of

[19] to

[23] , wherein the mutant Ras protein is a mutant Kras protein and has at least one amino acid mutation selected from the group consisting of G12A, G12C, G12D, G12S, G12V, G13D, Q61H, and Q61K compared to the amino acid sequence set forth in SEQ ID NO: 6. 〔twenty five〕 A pharmaceutical composition described in any of

[19] to

[23] , wherein the mutant Ras protein is a mutant Nras protein and has at least one amino acid mutation selected from the group consisting of G12C, G12D, G13D, G13V, Q61K, and Q61L compared to the amino acid sequence set forth in SEQ ID NO: 7.

[26] A pharmaceutical composition according to any one of

[19] to

[23] , wherein the mutant Ras protein is a mutant Hras protein and has an amino acid mutation of G13R compared to the amino acid sequence set forth in SEQ ID NO: 8.

[27] A therapeutic or preventive agent for a disease, comprising a cyclic peptide compound represented by the following formula (1), or a salt thereof, or a solvate thereof: [ka] During the ceremony, L1 is a single bond, or -CHM1-, -(CH2) n S(CH2)m -, -(CH2) n S(O)(CH2) m - or -(CH2) n S(O)2(CH2) m wherein n and m are each independently 1 or 2; R1 is hydrogen, C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, or C3-C8 cycloalkoxyC1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino), and C1-C6 alkylsulfonyl; or R1 and P1 together with the carbon atom to which R1 is attached and the nitrogen atom to which P1 is attached form a 4- to 7-membered saturated heterocyclic ring; or R1 and Q1 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or R1 and M1 together with the carbon atom to which R1 is bonded and the carbon atom to which M1 is bonded form a 3- to 8-membered alicyclic ring; Except when R1 and P1 form a 4- to 7-membered saturated heterocycle, P1 is hydrogen or C1-C6 alkyl, which C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q1 is hydrogen or C1-C6 alkyl, except when R1 and Q1 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; and M1 is hydrogen, except when R1 and M1 form a 3- to 8-membered alicyclic ring; R2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, or C3-C8 cycloalkoxyC1-C6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, cyano, and C1-C6 alkylsulfonyl; or R2 and P2 together with the carbon atom to which R2 is attached and the nitrogen atom to which P2 is attached form a 4- to 7-membered saturated heterocyclic ring; or R2 and Q2 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R2 and P2 form a 4- to 7-membered saturated heterocycle, P2 is hydrogen or C1-C6 alkyl, which C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q2 is hydrogen or C1-C6 alkyl, except when R2 and Q2 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R3 is hydrogen, C1-C6 alkyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C3-C8 cycloalkoxyC1-C6 alkyl, or C7-C 14aralkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of hydroxy, and aminocarbonyl, where the amino is -NH, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino; or R3 and P3 together with the carbon atom to which R3 is attached and the nitrogen atom to which P3 is attached form a 4- to 7-membered saturated heterocyclic ring; or R3 and Q3 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R3 and P3 form a 4- to 7-membered saturated heterocycle, P3 is hydrogen, C1-C6 alkyl, C1-C6 alkoxyC1-C6 alkyl, or C3-C8 cycloalkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and C1-C6 aminoalkyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, which is optionally substituted with one or more halogens); Q3 is hydrogen or C1-C6 alkyl, except when R3 and Q3 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R4 is hydrogen or C1-C6 alkyl, or R4 and P4 together with the carbon atom to which R4 is attached and the nitrogen atom to which P4 is attached form a 4- to 7-membered saturated heterocyclic ring; or R4 and Q4 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R4 and P4 form a 4- to 7-membered saturated heterocycle, P4 is hydrogen, C1-C6 alkyl, or C1-C6 alkoxyC1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q4 is hydrogen or C1-C6 alkyl, except when R4 and Q4 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R5 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C3-C8 cycloalkoxyC1-C6 alkyl, C7-C 14 Aralkyl, C6-C 10 Aryloxy C1-C6 alkyl, C7-C 14 aralkoxyC1-C6 alkyl, or 5- to 10-membered heteroarylC1-C6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, cyano, and C1-C6 alkylsulfonyl, or R5 together with R8 form a C4-C8 alkylene, or R5 and P5 together with the carbon atom to which R5 is attached and the nitrogen atom to which P5 is attached form a 4- to 7-membered saturated heterocyclic ring; or R5 and Q5 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R5 and P5 form a 4- to 7-membered saturated heterocycle, P5 is hydrogen or C1-C6 alkyl, which C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q5 is hydrogen or C1-C6 alkyl, except when R5 and Q5 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R6 is hydrogen or C1-C6 alkyl; or R6 and P6 together with the carbon atom to which R6 is attached and the nitrogen atom to which P6 is attached form a 4- to 7-membered saturated heterocyclic ring; or R6 and Q6 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R6 and P6 form a 4- to 7-membered saturated heterocycle, P6 is C1-C6 alkyl or C3-C8 cycloalkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q6 is hydrogen or C1-C6 alkyl, except when R6 and Q6 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R7 is C6-C 10 Aryloxy C1-C6 alkyl, C7-C 14 Aralkyl, C7-C 14aralkoxyC1-C6 alkyl, or 5- to 10-membered heteroarylC1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkoxy, cyano, C1-C6 alkylsulfonyl, and SF5; or R7 and P7 together with the carbon atom to which R7 is attached and the nitrogen atom to which P7 is attached form a 4- to 7-membered saturated heterocyclic ring; or R7 and Q7 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R7 and P7 form a 4- to 7-membered saturated heterocycle, P7 is hydrogen or C1-C6 alkyl, which C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q7 is hydrogen or C1-C6 alkyl, except when R7 and Q7 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R8 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C2-C6 alkenyloxycarbonylC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C6-C 10 Aryloxy C1-C6 alkyl, C7-C 14 Aralkyl, C7-C 14aralkoxyC1-C6 alkyl, 5- to 10-membered heteroarylC1-C6 alkyl, or 5- to 10-membered heteroarylC1-C6 alkoxyC1-C6 alkyl, each of which is halogen, hydroxy, carboxy, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkoxy, cyano, amino (said amino is -NH2, protected amino, monoC1-C6 alkylamino, diC1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is substituted with halogen). or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; R8 and P8 together with the carbon atom to which R8 is bonded and the nitrogen atom to which P8 is bonded form a 4- to 7-membered saturated heterocycle, which may be condensed with a saturated carbocycle or an aromatic ring, and which may be condensed with a halogen, oxo, C6-C 10 and optionally substituted by aryl, 5- to 10-membered heteroaryl, 4- to 8-membered cyclic amino (the cyclic amino may be substituted by one or more halogens), or OS8, and S8 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C7-C 14 aralkyl, which may be optionally substituted by one or more halogen, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy, or a 5- to 10-membered heteroarylC1-C6 alkyl; or R8 and Q8 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R8 and P8 together form a 4- to 7-membered saturated heterocycle, P8 is hydrogen, C1-C6 alkyl, C1-C6 alkoxyC1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxyC2-C6 alkenyl, C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, 4- to 7-membered heterocyclylC1-C6 alkyl, C6-C 10 Aryl, C7-C 14 aralkyl, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl-C1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen or C1-C6 alkyl), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q8 is hydrogen or C1-C6 alkyl, except when R8 and Q8 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R9 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkylC1-C6 alkyl, C7-C 14 aralkyl, or 5-10 membered heteroaryl C1-C6 alkoxyC1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4-8 membered cyclic amino), and C1-C6 alkylsulfonyl; or R9 and P9 together with the carbon atom to which R9 is attached and the nitrogen atom to which P9 is attached form a 4- to 7-membered saturated heterocyclic ring; or R9 and Q9 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R9 and P9 form a 4- to 7-membered saturated heterocycle, P9 is hydrogen or C1-C6 alkyl, which C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q9 is hydrogen or C1-C6 alkyl, except when R9 and Q9 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R 10 is C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C3-C8 cycloalkoxyC1-C6 alkyl, or C7-C 14 aralkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, and C1-C6 alkylsulfonyl; or R 10 and P 10 is R 10 and P 10 together with the nitrogen atom to which it is attached to form a 4- to 7-membered saturated heterocyclic ring, or R 10 and Q 10 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, or R 10 and P 10 P forms a 4- to 7-membered saturated heterocyclic ring, 10is hydrogen or C1-C6 alkyl, and the C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); R 10 and Q 10 Q forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, 10 is hydrogen or C1-C6 alkyl, and L 11 is a single bond or -CHM 11 -, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2) n S(O)2(CH2) m wherein n and m are each independently 1 or 2; R 11 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkyl, C7-C 14 aralkyl, or aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino), each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, oxo, hydroxy, C1-C6 alkyl, 4- to 7-membered heterocyclyl, aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino), and C1-C6 alkylsulfonyl; or R 11 is a peptide chain containing 1 to 4 amino acid residues, or R 11 and P11 is R 11 and P 11 together with the nitrogen atom to which it is attached to form a 4- to 7-membered saturated heterocyclic ring, or R 11 and Q 11 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, or R 11 and M 11 is R 11 and the carbon atom to which M is bonded 11 forms a 3- to 8-membered alicyclic ring together with the carbon atom to which it is bonded, R 11 and P 11 P forms a 4- to 7-membered saturated heterocyclic ring, 11 is hydrogen or C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); R 11 and Q 11 Q forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, 11 is hydrogen or C1-C6 alkyl, R 11 and M 11 forms a 3- to 8-membered alicyclic ring, M 11 is hydrogen, where L1 is a single bond, 11 -CHM 11 -, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2) nS(O)2(CH2) m -, and L1 is -CHM1-, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2) n S(O)2(CH2) m -If L 11 is a single bond, and P1~P 11 At least three of these are not hydrogen.

[28] The therapeutic or prophylactic agent according to

[27] , wherein the cyclic peptide compound is represented by the following formula (2): [ka] During the ceremony, R1 is C1-C6 alkyl; P1 is C1-C6 alkyl; R2 is C1-C6 alkyl; P2 is hydrogen, R3 is hydrogen or C1-C6 alkyl; P3 is C1-C6 alkyl; R4 is hydrogen, or R4 and P4 together with the nitrogen atom to which P4 is bonded and the carbon atom to which R4 is bonded form a 4- to 7-membered saturated heterocycle; P4 is C1-C6 alkyl, except when R4 and P4 form a 4- to 7-membered saturated heterocycle; R5 is C3-C8 cycloalkyl, C1-C6 alkyl, or C7-C optionally substituted by C1-C6 alkyl. 14 is aralkyl, P5 is C1-C6 alkyl; R6 is hydrogen; P6 is C1-C6 alkyl; R7 is a C7-C6 haloalkyl group optionally substituted with one or more groups independently selected from the group consisting of halogen and C1-C6 haloalkyl. 14 is aralkyl, Q7 is hydrogen, P7 is hydrogen, R8 and P8 together with the nitrogen atom to which P8 is bonded and the carbon atom to which R8 is bonded form a 4- to 7-membered saturated heterocycle, which is optionally substituted by C1-C6 alkoxy; R9 and Q9 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring; P9 is hydrogen R 10 is C3-C8 cycloalkyl, P 10 is C1-C6 alkyl, R 11 is diC1-C6 alkylaminocarbonyl or 4- to 8-membered cyclic aminocarbonyl, M 11 is hydrogen, P 11 is C1-C6 alkyl.

[29] The therapeutic or prophylactic agent according to

[28] , wherein the cyclic peptide compound is represented by the following formula: [ka] During the ceremony, R3 is hydrogen or methyl; R4 is hydrogen and P4 is methyl, or R4 and P4 together with the nitrogen atom to which P4 is bonded and the carbon atom to which R4 is bonded form an azetidine ring; R5 is cyclohexylmethyl or 4-methylbenzyl; P5 is methyl or ethyl; R 7A , R 7B , and R 7C is independently selected from the group consisting of hydrogen, fluorine, chlorine, and trifluoromethyl; R 8A is hydrogen or ethoxy, R 10is cyclopentyl or cyclohexyl, R 11A , and R 11B are both methyl or R 11A , and R 11B together with the nitrogen atom to which they are attached form a piperidine ring or a morpholine ring.

[30] The therapeutic or prophylactic agent according to any one of

[27] to

[29] , wherein the cyclic peptide compound is selected from the group consisting of: (1217) (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)- 4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, (1201) (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nona Methyl-4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, (558) (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecaone, and (926) (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine-4 -carbonyl)docosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone.

[31] The cyclic peptide compound is (1217) (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)- 4,7,10,13,17,20,23,28,31,34,37-Undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide The therapeutic or prophylactic agent according to any one of

[27] to

[30] ,

[32] The cyclic peptide compound is (1201) (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nonamethyl-4,7,10,13,17 The therapeutic or preventive agent according to any one of

[27] to

[30] , wherein the compound is 20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide.

[33] The cyclic peptide compound is (558) (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecanone The therapeutic or prophylactic agent according to any one of

[27] to

[30] ,

[34] The cyclic peptide compound is (926) (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine- 4-carbonyl)docosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone The therapeutic or prophylactic agent according to any one of

[27] to

[30] , [34-1] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)-4,7,10,13,17,20,23 A therapeutic or preventive agent for a disease, comprising 28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a salt thereof, or a solvate thereof. [34-2] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)-4,7,10,13,17,20,2 A therapeutic or preventive agent for a disease, comprising 3,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a salt thereof, or a hydrate of the same. [34-3] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)-4,7,10,13,17, A therapeutic or preventive agent for a disease, comprising 20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide or a hydrate thereof. [34-4] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)-4,7,10,1 A therapeutic or preventive agent for a disease, comprising 3,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide. [34-5] (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nonamethyl-4,7,10,13,17,2 A therapeutic or preventive agent for a disease, comprising 0,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a salt thereof, or a solvate thereof. [34-6] (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nonamethyl-4,7,10,13,17, A therapeutic or preventive agent for a disease, comprising 20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a salt thereof, or a hydrate of the same. [34-7] (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nonamethyl-4,7,10,13 A therapeutic or preventive agent for a disease, comprising 17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a hydrate thereof. [34-8] (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nonamethyl-4,7, A therapeutic or preventive agent for a disease, comprising 10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide. [34-9] A therapeutic or preventive agent for a disease, comprising (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecaone, or a salt thereof, or a solvate thereof. [34-10] A therapeutic or preventive agent comprising (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecaone, or a salt thereof, or a hydrate thereof. [34-11] A therapeutic or preventive agent for a disease, comprising (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecaone, or a hydrate thereof. [34-12] A therapeutic or preventive agent for a disease, comprising (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecaone. [34-13] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine-4-carbonyl)docosahydro-2H, A therapeutic or preventive agent for a disease, comprising 4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone, or a salt thereof, or a solvate thereof. [34-14] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine-4-carbonyl)docosahydro-2H, A therapeutic or preventive agent for a disease, comprising 4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone, or a salt thereof, or a hydrate thereof. [34-15] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine-4-carbonyl)docosahyde 1. A therapeutic or preventive agent for a disease, comprising 14H,22H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone, or a hydrate thereof. [34-16] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine-4-carbonyl)de A therapeutic or preventive agent for a disease, comprising cosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone.

[35] The therapeutic or prophylactic agent according to any one of

[27] to

[34] and [34-1] to [34-16], which is a Ras inhibitor.

[36] The therapeutic or prophylactic agent according to

[35] , wherein the Ras inhibitor is one or more Ras inhibitors selected from the group consisting of Kras inhibitors, Nras inhibitors, and Hras inhibitors.

[37] The therapeutic or prophylactic agent according to any one of

[27] to

[36] , for treating or preventing cancer.

[38] The therapeutic or preventive agent according to

[37] , wherein the cancer is a solid cancer or a blood cancer.

[39] The therapeutic or preventive agent according to

[37] or

[38] , wherein the cancer is selected from the group consisting of lung cancer, esophageal cancer, gastric cancer, colon cancer, uterine cancer, ovarian cancer, pancreatic cancer, bladder cancer, thyroid cancer, skin cancer, leukemia, malignant lymphoma, and multiple myeloma.

[40] The therapeutic or preventive agent according to any one of

[37] to

[39] , wherein the cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, colon cancer, rectal cancer, uterine cancer, endometrial cancer, cervical cancer, AML (acute myeloid leukemia), CML (chronic myeloid leukemia), ALL (acute lymphocytic leukemia), CLL (chronic lymphocytic leukemia), Hodgkin lymphoma, and non-Hodgkin lymphoma.

[41] The therapeutic or preventive agent according to any one of

[37] to

[40] , wherein the cancer is associated with an abnormality in the Ras gene.

[42] The therapeutic or prophylactic agent according to

[41] , wherein the abnormality in the Ras gene is a mutation in the coding region of the Ras gene and / or an amplification of the copy number of the Ras gene.

[43] The therapeutic or prophylactic agent according to

[41] or

[42] , wherein the Ras gene is one or more Ras genes selected from the group consisting of Kras genes, Nras genes, and Hras genes.

[44] The therapeutic or prophylactic agent according to

[43] , wherein the Ras gene is a Kras gene.

[45] The therapeutic or prophylactic agent according to any one of

[37] to

[44] , wherein the cancer is associated with the production of mutant Ras protein and / or increased production of Ras protein.

[46] The therapeutic or preventive agent according to

[45] , wherein the cancer is associated with the production of a mutant Ras protein.

[47] A therapeutic or preventive agent according to

[45] or

[46] , wherein the mutant Ras protein is one or more mutant Ras proteins selected from the group consisting of mutant Kras proteins, mutant Nras proteins, and mutant Hras proteins.

[48] The therapeutic or prophylactic agent according to

[47] , wherein the mutant Ras protein is a mutant Kras protein.

[49] A therapeutic or preventive agent described in any of

[45] to

[48] , wherein the mutant Ras protein has a mutation at at least one amino acid position selected from the group consisting of G12, G13 and Q61 in the amino acid sequence set forth in SEQ ID NO: 6, 7 or 8.

[50] A therapeutic or preventive agent according to any one of

[45] to

[49] , wherein the mutant Ras protein is a mutant Kras protein and has at least one amino acid mutation selected from the group consisting of G12A, G12C, G12D, G12S, G12V, G13D, Q61H, and Q61K compared to the amino acid sequence set forth in SEQ ID NO: 6.

[51] A therapeutic or preventive agent according to any one of

[45] to

[49] , wherein the mutant Ras protein is a mutant Nras protein and has at least one amino acid mutation selected from the group consisting of G12C, G12D, G13D, G13V, Q61K, and Q61L compared to the amino acid sequence set forth in SEQ ID NO: 7.

[52] A therapeutic or preventive agent according to any one of

[45] to

[49] , wherein the mutant Ras protein is a mutant Hras protein and has an amino acid mutation of G13R compared to the amino acid sequence set forth in SEQ ID NO: 8.

[53] A cyclic peptide compound represented by the following formula (1), or a salt thereof, or a solvate thereof, for use in treating or preventing a disease: [ka] During the ceremony, L1 is a single bond, or -CHM1-, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2) n S(O)2(CH2) m wherein n and m are each independently 1 or 2; R1 is hydrogen, C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, or C3-C8 cycloalkoxyC1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino), and C1-C6 alkylsulfonyl; or R1 and P1 together with the carbon atom to which R1 is attached and the nitrogen atom to which P1 is attached form a 4- to 7-membered saturated heterocyclic ring; or R1 and Q1 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or R1 and M1 together with the carbon atom to which R1 is bonded and the carbon atom to which M1 is bonded form a 3- to 8-membered alicyclic ring; Except when R1 and P1 form a 4- to 7-membered saturated heterocycle, P1 is hydrogen or C1-C6 alkyl, which C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q1 is hydrogen or C1-C6 alkyl, except when R1 and Q1 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; and M1 is hydrogen, except when R1 and M1 form a 3- to 8-membered alicyclic ring; R2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, or C3-C8 cycloalkoxyC1-C6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, cyano, and C1-C6 alkylsulfonyl; or R2 and P2 together with the carbon atom to which R2 is attached and the nitrogen atom to which P2 is attached form a 4- to 7-membered saturated heterocyclic ring; or R2 and Q2 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R2 and P2 form a 4- to 7-membered saturated heterocycle, P2 is hydrogen or C1-C6 alkyl, which C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q2 is hydrogen or C1-C6 alkyl, except when R2 and Q2 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R3 is hydrogen, C1-C6 alkyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C3-C8 cycloalkoxyC1-C6 alkyl, or C7-C 14aralkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of hydroxy, and aminocarbonyl, where the amino is -NH, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino; or R3 and P3 together with the carbon atom to which R3 is attached and the nitrogen atom to which P3 is attached form a 4- to 7-membered saturated heterocyclic ring; or R3 and Q3 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R3 and P3 form a 4- to 7-membered saturated heterocycle, P3 is hydrogen, C1-C6 alkyl, C1-C6 alkoxyC1-C6 alkyl, or C3-C8 cycloalkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and C1-C6 aminoalkyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, which is optionally substituted with one or more halogens); Q3 is hydrogen or C1-C6 alkyl, except when R3 and Q3 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R4 is hydrogen or C1-C6 alkyl, or R4 and P4 together with the carbon atom to which R4 is attached and the nitrogen atom to which P4 is attached form a 4- to 7-membered saturated heterocyclic ring; or R4 and Q4 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R4 and P4 form a 4- to 7-membered saturated heterocycle, P4 is hydrogen, C1-C6 alkyl, or C1-C6 alkoxyC1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q4 is hydrogen or C1-C6 alkyl, except when R4 and Q4 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R5 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C3-C8 cycloalkoxyC1-C6 alkyl, C7-C 14 Aralkyl, C6-C 10 Aryloxy C1-C6 alkyl, C7-C 14 aralkoxyC1-C6 alkyl, or 5- to 10-membered heteroarylC1-C6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, cyano, and C1-C6 alkylsulfonyl, or R5 together with R8 form a C4-C8 alkylene, or R5 and P5 together with the carbon atom to which R5 is attached and the nitrogen atom to which P5 is attached form a 4- to 7-membered saturated heterocyclic ring; or R5 and Q5 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R5 and P5 form a 4- to 7-membered saturated heterocycle, P5 is hydrogen or C1-C6 alkyl, which C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q5 is hydrogen or C1-C6 alkyl, except when R5 and Q5 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R6 is hydrogen or C1-C6 alkyl; or R6 and P6 together with the carbon atom to which R6 is attached and the nitrogen atom to which P6 is attached form a 4- to 7-membered saturated heterocyclic ring; or R6 and Q6 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R6 and P6 form a 4- to 7-membered saturated heterocycle, P6 is C1-C6 alkyl or C3-C8 cycloalkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q6 is hydrogen or C1-C6 alkyl, except when R6 and Q6 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R7 is C6-C 10 Aryloxy C1-C6 alkyl, C7-C 14 Aralkyl, C7-C 14aralkoxyC1-C6 alkyl, or 5- to 10-membered heteroarylC1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkoxy, cyano, C1-C6 alkylsulfonyl, and SF5; or R7 and P7 together with the carbon atom to which R7 is attached and the nitrogen atom to which P7 is attached form a 4- to 7-membered saturated heterocyclic ring; or R7 and Q7 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R7 and P7 form a 4- to 7-membered saturated heterocycle, P7 is hydrogen or C1-C6 alkyl, which C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q7 is hydrogen or C1-C6 alkyl, except when R7 and Q7 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R8 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C2-C6 alkenyloxycarbonylC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C6-C 10 Aryloxy C1-C6 alkyl, C7-C 14 Aralkyl, C7-C 14aralkoxyC1-C6 alkyl, 5- to 10-membered heteroarylC1-C6 alkyl, or 5- to 10-membered heteroarylC1-C6 alkoxyC1-C6 alkyl, each of which is halogen, hydroxy, carboxy, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkoxy, cyano, amino (said amino is -NH2, protected amino, monoC1-C6 alkylamino, diC1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is substituted with halogen). or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; R8 and P8 together with the carbon atom to which R8 is bonded and the nitrogen atom to which P8 is bonded form a 4- to 7-membered saturated heterocycle, which may be condensed with a saturated carbocycle or an aromatic ring, and which may be condensed with a halogen, oxo, C6-C 10 and optionally substituted by aryl, 5- to 10-membered heteroaryl, 4- to 8-membered cyclic amino (the cyclic amino may be substituted by one or more halogens), or OS8, and S8 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C7-C 14 aralkyl, which may be optionally substituted by one or more halogen, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy, or a 5- to 10-membered heteroarylC1-C6 alkyl; or R8 and Q8 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R8 and P8 together form a 4- to 7-membered saturated heterocycle, P8 is hydrogen, C1-C6 alkyl, C1-C6 alkoxyC1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxyC2-C6 alkenyl, C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, 4- to 7-membered heterocyclylC1-C6 alkyl, C6-C 10 Aryl, C7-C 14 aralkyl, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl-C1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen or C1-C6 alkyl), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q8 is hydrogen or C1-C6 alkyl, except when R8 and Q8 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R9 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkylC1-C6 alkyl, C7-C 14 aralkyl, or 5-10 membered heteroaryl C1-C6 alkoxyC1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4-8 membered cyclic amino), and C1-C6 alkylsulfonyl; or R9 and P9 together with the carbon atom to which R9 is attached and the nitrogen atom to which P9 is attached form a 4- to 7-membered saturated heterocyclic ring; or R9 and Q9 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R9 and P9 form a 4- to 7-membered saturated heterocycle, P9 is hydrogen or C1-C6 alkyl, which C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q9 is hydrogen or C1-C6 alkyl, except when R9 and Q9 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R 10 is C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C3-C8 cycloalkoxyC1-C6 alkyl, or C7-C 14 aralkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, and C1-C6 alkylsulfonyl; or R 10 and P 10 is R 10 and P 10 together with the nitrogen atom to which it is attached to form a 4- to 7-membered saturated heterocyclic ring, or R 10 and Q 10 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, or R 10 and P 10 P forms a 4- to 7-membered saturated heterocyclic ring, 10is hydrogen or C1-C6 alkyl, and the C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); R 10 and Q 10 Q forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, 10 is hydrogen or C1-C6 alkyl, and L 11 is a single bond or -CHM 11 -, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2) n S(O)2(CH2) m wherein n and m are each independently 1 or 2; R 11 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkyl, C7-C 14 aralkyl, or aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino), each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, oxo, hydroxy, C1-C6 alkyl, 4- to 7-membered heterocyclyl, aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino), and C1-C6 alkylsulfonyl; or R 11 is a peptide chain containing 1 to 4 amino acid residues, or R 11 and P11 is R 11 and P 11 together with the nitrogen atom to which it is attached to form a 4- to 7-membered saturated heterocyclic ring, or R 11 and Q 11 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, or R 11 and M 11 is R 11 and the carbon atom to which M is bonded 11 forms a 3- to 8-membered alicyclic ring together with the carbon atom to which it is bonded, R 11 and P 11 P forms a 4- to 7-membered saturated heterocyclic ring, 11 is hydrogen or C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); R 11 and Q 11 Q forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, 11 is hydrogen or C1-C6 alkyl, R 11 and M 11 forms a 3- to 8-membered alicyclic ring, M 11 is hydrogen, where L1 is a single bond, 11 -CHM 11 -, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2) nS(O)2(CH2) m -, and L1 is -CHM1-, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2) n S(O)2(CH2) m -If L 11 is a single bond, and P1~P 11 At least three of these are not hydrogen.

[54] A cyclic peptide compound for use according to

[53] , represented by the following formula (2), or a salt thereof, or a solvate thereof: [ka] During the ceremony, R1 is C1-C6 alkyl; P1 is C1-C6 alkyl; R2 is C1-C6 alkyl; P2 is hydrogen, R3 is hydrogen or C1-C6 alkyl; P3 is C1-C6 alkyl; R4 is hydrogen, or R4 and P4 together with the nitrogen atom to which P4 is bonded and the carbon atom to which R4 is bonded form a 4- to 7-membered saturated heterocycle; P4 is C1-C6 alkyl, except when R4 and P4 form a 4- to 7-membered saturated heterocycle; R5 is C3-C8 cycloalkyl, C1-C6 alkyl, or C7-C optionally substituted by C1-C6 alkyl. 14 is aralkyl, P5 is C1-C6 alkyl; R6 is hydrogen; P6 is C1-C6 alkyl; R7 is a C7-C6 haloalkyl group optionally substituted with one or more groups independently selected from the group consisting of halogen and C1-C6 haloalkyl. 14is aralkyl, Q7 is hydrogen, P7 is hydrogen, R8 and P8 together with the nitrogen atom to which P8 is bonded and the carbon atom to which R8 is bonded form a 4- to 7-membered saturated heterocycle, which is optionally substituted by C1-C6 alkoxy; R9 and Q9 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring; P9 is hydrogen R 10 is C3-C8 cycloalkyl, P 10 is C1-C6 alkyl, R 11 is diC1-C6 alkylaminocarbonyl or 4- to 8-membered cyclic aminocarbonyl, M 11 is hydrogen, P 11 is C1-C6 alkyl.

[55] A cyclic peptide compound for use according to

[54] , represented by the following formula, or a salt thereof, or a solvate thereof: [ka] During the ceremony, R3 is hydrogen or methyl; R4 is hydrogen and P4 is methyl, or R4 and P4 together with the nitrogen atom to which P4 is bonded and the carbon atom to which R4 is bonded form an azetidine ring; R5 is cyclohexylmethyl or 4-methylbenzyl; P5 is methyl or ethyl; R 7A , R 7B , and R 7C is independently selected from the group consisting of hydrogen, fluorine, chlorine, and trifluoromethyl; R 8A is hydrogen or ethoxy, R10 is cyclopentyl or cyclohexyl, R 11A , and R 11B are both methyl or R 11A , and R 11B together with the nitrogen atom to which they are attached form a piperidine ring or a morpholine ring.

[56] A cyclic peptide compound for use according to any one of

[53] to

[55] , or a salt thereof, or a solvate thereof, selected from the group consisting of: (1217) (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)- 4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, (1201) (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nona Methyl-4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, (558) (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecaone, and (926) (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine-4 -carbonyl)docosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone.

[57] (1217) (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)- 4,7,10,13,17,20,23,28,31,34,37-Undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide The cyclic peptide compound for use according to any one of

[53] to

[56] , or a salt thereof, or a solvate thereof,

[58] (1201) (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nonamethyl-4,7,10,13,17,20,23,28,31 ,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a salt thereof, or a solvate thereof, for use according to any one of

[53] to

[56] .

[59] (558) (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecanone The cyclic peptide compound for use according to any one of

[53] to

[56] , or a salt thereof, or a solvate thereof,

[60] (926) (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine- 4-carbonyl)docosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone The cyclic peptide compound for use according to any one of

[53] to

[56] , or a salt thereof, or a solvate thereof, [60-1] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl) for use in the treatment or prevention of disease. -4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a salt thereof, or a solvate thereof. [60-2] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl) ... )-4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a salt thereof, or a hydrate thereof. [60-3] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methyl benzyl)-4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a hydrate thereof. [60-4] 2. The compound (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-( 4-Methylbenzyl)-4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide. [60-5] (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-no Namethyl-4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a salt thereof, or a solvate thereof. [60-6] (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36- nonamethyl-4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a salt thereof, or a hydrate thereof. [60-7] (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33 ,36-Nonamethyl-4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a hydrate thereof. [60-8] (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16, 19,33,36-Nonamethyl-4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide. [60-9] 1. (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecaone, or a salt or solvate thereof, for use in the treatment or prevention of a disease. [60-10] 1. (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecaone, or a salt or hydrate thereof, for use in the treatment or prevention of a disease. [60-11] 1. (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecane, or a hydrate thereof, for use in the treatment or prevention of a disease. [60-12] (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecaone for use in the treatment or prevention of disease. [60-13] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine) for use in the treatment or prevention of disease -4-carbonyl)docosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone, or a salt thereof, or a solvate thereof. [60-14] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine) for use in the treatment or prevention of disease -4-carbonyl)docosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecane, or a salt thereof, or a hydrate thereof. [60-15] for use in the treatment or prevention of a disease, (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine-4-carbo nyl)docosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecane, or a hydrate thereof. [60-16] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl- 15-(Morpholine-4-carbonyl)docosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone.

[61] A cyclic peptide compound for use according to any one of

[53] to

[60] and [60-1] to [60-16], or a salt thereof, or a solvate thereof, which is a Ras inhibitor.

[62] The cyclic peptide compound, or a salt thereof, or a solvate thereof, for use according to

[61] , wherein the Ras inhibitor is one or more Ras inhibitors selected from the group consisting of Kras inhibitors, Nras inhibitors, and Hras inhibitors.

[63] The cyclic peptide compound, or a salt thereof, or a solvate thereof for use according to any one of

[53] to

[62] , wherein the disease is cancer.

[64] The cyclic peptide compound, or a salt thereof, or a solvate thereof for use according to

[63] , wherein the cancer is a solid cancer or a blood cancer.

[65] The cyclic peptide compound, or a salt or solvate thereof, for use according to

[63] or

[64] , wherein the cancer is selected from the group consisting of lung cancer, esophageal cancer, gastric cancer, colorectal cancer, uterine cancer, ovarian cancer, pancreatic cancer, bladder cancer, thyroid cancer, skin cancer, leukemia, malignant lymphoma, and multiple myeloma.

[66] The cyclic peptide compound, or a salt or solvate thereof, for use according to any one of

[63] to

[65] , wherein the cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, colon cancer, rectal cancer, uterine cancer, endometrial cancer, cervical cancer, AML (acute myeloid leukemia), CML (chronic myeloid leukemia), ALL (acute lymphocytic leukemia), CLL (chronic lymphocytic leukemia), Hodgkin lymphoma, and non-Hodgkin lymphoma.

[67] The cyclic peptide compound, or a salt or solvate thereof, for use according to any one of

[63] to

[66] , wherein the cancer is associated with an abnormality in the Ras gene.

[68] The cyclic peptide compound, or a salt thereof, or a solvate thereof for use according to

[67] , wherein the abnormality in the Ras gene is a mutation in the coding region of the Ras gene and / or an amplification of the copy number of the Ras gene.

[69] A cyclic peptide compound, or a salt or solvate thereof, for use according to

[67] or

[68] , wherein the Ras gene is one or more Ras genes selected from the group consisting of Kras genes, Nras genes and Hras genes.

[70] The cyclic peptide compound, or a salt or solvate thereof, for use according to

[69] , wherein the Ras gene is a Kras gene.

[71] The cyclic peptide compound, or a salt or solvate thereof, for use according to any one of

[63] to

[70] , wherein the cancer is associated with the production of mutant Ras proteins and / or increased production of Ras proteins.

[72] The cyclic peptide compound, or a salt or solvate thereof, for use according to

[71] , wherein the cancer is associated with the production of a mutant Ras protein.

[73] A cyclic peptide compound, or a salt or solvate thereof, for use according to

[71] or

[20] , wherein the mutant Ras protein is one or more mutant Ras proteins selected from the group consisting of mutant Kras proteins, mutant Nras proteins, and mutant Hras proteins.

[74] The cyclic peptide compound, or a salt or solvate thereof, for use according to

[73] , wherein the mutant Ras protein is a mutant Kras protein.

[75] A cyclic peptide compound for use according to any one of

[71] to

[74] , or a salt thereof, or a solvate thereof, wherein the mutant Ras protein has a mutation at at least one amino acid position selected from the group consisting of G12, G13, and Q61 in the amino acid sequence set forth in SEQ ID NO: 6, 7, or 8.

[76] A cyclic peptide compound for use according to any one of

[71] to

[75] , or a salt thereof, or a solvate thereof, wherein the mutant Ras protein is a mutant Kras protein and has at least one amino acid mutation selected from the group consisting of G12A, G12C, G12D, G12S, G12V, G13D, Q61H, and Q61K compared to the amino acid sequence set forth in SEQ ID NO: 6.

[77] A cyclic peptide compound for use according to any one of

[71] to

[75] , or a salt thereof, or a solvate thereof, wherein the mutant Ras protein is a mutant Nras protein and has at least one amino acid mutation selected from the group consisting of G12C, G12D, G13D, G13V, Q61K, and Q61L compared to the amino acid sequence set forth in SEQ ID NO: 7.

[78] A cyclic peptide compound for use according to any one of

[71] to

[75] , or a salt thereof, or a solvate thereof, wherein the mutant Ras protein is a mutant Hras protein and has an amino acid mutation of G13R compared to the amino acid sequence set forth in SEQ ID NO: 8.

[79] A method for treating or preventing a disease, comprising administering to a subject a cyclic peptide compound represented by the following formula (1), or a salt thereof, or a solvate thereof: [ka] During the ceremony, L1 is a single bond, or -CHM1-, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2) n S(O)2(CH2) m wherein n and m are each independently 1 or 2; R1 is hydrogen, C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, or C3-C8 cycloalkoxyC1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino), and C1-C6 alkylsulfonyl; or R1 and P1 together with the carbon atom to which R1 is attached and the nitrogen atom to which P1 is attached form a 4- to 7-membered saturated heterocyclic ring; or R1 and Q1 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or R1 and M1 together with the carbon atom to which R1 is bonded and the carbon atom to which M1 is bonded form a 3- to 8-membered alicyclic ring; Except when R1 and P1 form a 4- to 7-membered saturated heterocycle, P1 is hydrogen or C1-C6 alkyl, which C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q1 is hydrogen or C1-C6 alkyl, except when R1 and Q1 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; and M1 is hydrogen, except when R1 and M1 form a 3- to 8-membered alicyclic ring; R2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, or C3-C8 cycloalkoxyC1-C6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, cyano, and C1-C6 alkylsulfonyl; or R2 and P2 together with the carbon atom to which R2 is attached and the nitrogen atom to which P2 is attached form a 4- to 7-membered saturated heterocyclic ring; or R2 and Q2 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R2 and P2 form a 4- to 7-membered saturated heterocycle, P2 is hydrogen or C1-C6 alkyl, which C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q2 is hydrogen or C1-C6 alkyl, except when R2 and Q2 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R3 is hydrogen, C1-C6 alkyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C3-C8 cycloalkoxyC1-C6 alkyl, or C7-C 14 aralkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of hydroxy, and aminocarbonyl, where the amino is -NH, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino; or R3 and P3 together with the carbon atom to which R3 is attached and the nitrogen atom to which P3 is attached form a 4- to 7-membered saturated heterocyclic ring; or R3 and Q3 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R3 and P3 form a 4- to 7-membered saturated heterocycle, P3 is hydrogen, C1-C6 alkyl, C1-C6 alkoxyC1-C6 alkyl, or C3-C8 cycloalkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and C1-C6 aminoalkyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, which is optionally substituted with one or more halogens); Q3 is hydrogen or C1-C6 alkyl, except when R3 and Q3 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R4 is hydrogen or C1-C6 alkyl, or R4 and P4 together with the carbon atom to which R4 is attached and the nitrogen atom to which P4 is attached form a 4- to 7-membered saturated heterocyclic ring; or R4 and Q4 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R4 and P4 form a 4- to 7-membered saturated heterocycle, P4 is hydrogen, C1-C6 alkyl, or C1-C6 alkoxyC1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q4 is hydrogen or C1-C6 alkyl, except when R4 and Q4 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R5 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C3-C8 cycloalkoxyC1-C6 alkyl, C7-C 14 Aralkyl, C6-C 10 Aryloxy C1-C6 alkyl, C7-C 14 aralkoxyC1-C6 alkyl, or 5- to 10-membered heteroarylC1-C6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, cyano, and C1-C6 alkylsulfonyl, or R5 together with R8 form a C4-C8 alkylene, or R5 and P5 together with the carbon atom to which R5 is attached and the nitrogen atom to which P5 is attached form a 4- to 7-membered saturated heterocyclic ring; or R5 and Q5 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R5 and P5 form a 4- to 7-membered saturated heterocycle, P5 is hydrogen or C1-C6 alkyl, which C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q5 is hydrogen or C1-C6 alkyl, except when R5 and Q5 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R6 is hydrogen or C1-C6 alkyl; or R6 and P6 together with the carbon atom to which R6 is attached and the nitrogen atom to which P6 is attached form a 4- to 7-membered saturated heterocyclic ring; or R6 and Q6 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R6 and P6 form a 4- to 7-membered saturated heterocycle, P6 is C1-C6 alkyl or C3-C8 cycloalkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q6 is hydrogen or C1-C6 alkyl, except when R6 and Q6 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R7 is C6-C 10 Aryloxy C1-C6 alkyl, C7-C 14 Aralkyl, C7-C 14 aralkoxyC1-C6 alkyl, or 5- to 10-membered heteroarylC1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkoxy, cyano, C1-C6 alkylsulfonyl, and SF5; or R7 and P7 together with the carbon atom to which R7 is attached and the nitrogen atom to which P7 is attached form a 4- to 7-membered saturated heterocyclic ring; or R7 and Q7 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R7 and P7 form a 4- to 7-membered saturated heterocycle, P7 is hydrogen or C1-C6 alkyl, which C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q7 is hydrogen or C1-C6 alkyl, except when R7 and Q7 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R8 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C2-C6 alkenyloxycarbonylC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C6-C 10 Aryloxy C1-C6 alkyl, C7-C 14 Aralkyl, C7-C 14aralkoxyC1-C6 alkyl, 5- to 10-membered heteroarylC1-C6 alkyl, or 5- to 10-membered heteroarylC1-C6 alkoxyC1-C6 alkyl, each of which is halogen, hydroxy, carboxy, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkoxy, cyano, amino (said amino is -NH2, protected amino, monoC1-C6 alkylamino, diC1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is substituted with halogen). or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; R8 and P8 together with the carbon atom to which R8 is bonded and the nitrogen atom to which P8 is bonded form a 4- to 7-membered saturated heterocycle, which may be condensed with a saturated carbocycle or an aromatic ring, and which may be condensed with a halogen, oxo, C6-C 10 and optionally substituted by aryl, 5- to 10-membered heteroaryl, 4- to 8-membered cyclic amino (the cyclic amino may be substituted by one or more halogens), or OS8, and S8 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C7-C 14 aralkyl, which may be optionally substituted by one or more halogen, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy, or a 5- to 10-membered heteroarylC1-C6 alkyl; or R8 and Q8 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R8 and P8 together form a 4- to 7-membered saturated heterocycle, P8 is hydrogen, C1-C6 alkyl, C1-C6 alkoxyC1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxyC2-C6 alkenyl, C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, 4- to 7-membered heterocyclylC1-C6 alkyl, C6-C 10 Aryl, C7-C 14 aralkyl, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl-C1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen or C1-C6 alkyl), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q8 is hydrogen or C1-C6 alkyl, except when R8 and Q8 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R9 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkylC1-C6 alkyl, C7-C 14 aralkyl, or 5-10 membered heteroaryl C1-C6 alkoxyC1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4-8 membered cyclic amino), and C1-C6 alkylsulfonyl; or R9 and P9 together with the carbon atom to which R9 is attached and the nitrogen atom to which P9 is attached form a 4- to 7-membered saturated heterocyclic ring; or R9 and Q9 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R9 and P9 form a 4- to 7-membered saturated heterocycle, P9 is hydrogen or C1-C6 alkyl, which C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q9 is hydrogen or C1-C6 alkyl, except when R9 and Q9 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R 10 is C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C3-C8 cycloalkoxyC1-C6 alkyl, or C7-C 14 aralkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, and C1-C6 alkylsulfonyl; or R 10 and P 10 is R 10 and P 10 together with the nitrogen atom to which it is attached to form a 4- to 7-membered saturated heterocyclic ring, or R 10 and Q 10 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, or R 10 and P 10 P forms a 4- to 7-membered saturated heterocyclic ring, 10is hydrogen or C1-C6 alkyl, and the C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); R 10 and Q 10 Q forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, 10 is hydrogen or C1-C6 alkyl, and L 11 is a single bond or -CHM 11 -, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2) n S(O)2(CH2) m wherein n and m are each independently 1 or 2; R 11 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkyl, C7-C 14 aralkyl, or aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino), each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, oxo, hydroxy, C1-C6 alkyl, 4- to 7-membered heterocyclyl, aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino), and C1-C6 alkylsulfonyl; or R 11 is a peptide chain containing 1 to 4 amino acid residues, or R 11 and P11 is R 11 and P 11 together with the nitrogen atom to which it is attached to form a 4- to 7-membered saturated heterocyclic ring, or R 11 and Q 11 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, or R 11 and M 11 is R 11 and the carbon atom to which M is bonded 11 forms a 3- to 8-membered alicyclic ring together with the carbon atom to which it is bonded, R 11 and P 11 P forms a 4- to 7-membered saturated heterocyclic ring, 11 is hydrogen or C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); R 11 and Q 11 Q forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, 11 is hydrogen or C1-C6 alkyl, R 11 and M 11 forms a 3- to 8-membered alicyclic ring, M 11 is hydrogen, where L1 is a single bond, 11 -CHM 11 -, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2) nS(O)2(CH2) m -, and L1 is -CHM1-, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2) n S(O)2(CH2) m -If L 11 is a single bond, and P1~P 11 At least three of these are not hydrogen.

[80] The method according to

[79] , wherein the cyclic peptide compound is represented by the following formula (2): [ka] During the ceremony, R1 is C1-C6 alkyl; P1 is C1-C6 alkyl; R2 is C1-C6 alkyl; P2 is hydrogen, R3 is hydrogen or C1-C6 alkyl; P3 is C1-C6 alkyl; R4 is hydrogen, or R4 and P4 together with the nitrogen atom to which P4 is bonded and the carbon atom to which R4 is bonded form a 4- to 7-membered saturated heterocycle; P4 is C1-C6 alkyl, except when R4 and P4 form a 4- to 7-membered saturated heterocycle; R5 is C3-C8 cycloalkyl, C1-C6 alkyl, or C7-C optionally substituted by C1-C6 alkyl. 14 is aralkyl, P5 is C1-C6 alkyl; R6 is hydrogen; P6 is C1-C6 alkyl; R7 is a C7-C6 haloalkyl group optionally substituted with one or more groups independently selected from the group consisting of halogen and C1-C6 haloalkyl. 14 is aralkyl, Q7 is hydrogen, P7 is hydrogen, R8 and P8 together with the nitrogen atom to which P8 is bonded and the carbon atom to which R8 is bonded form a 4- to 7-membered saturated heterocycle, which is optionally substituted by C1-C6 alkoxy; R9 and Q9 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring; P9 is hydrogen R 10 is C3-C8 cycloalkyl, P 10 is C1-C6 alkyl, R 11 is diC1-C6 alkylaminocarbonyl or 4- to 8-membered cyclic aminocarbonyl, M 11 is hydrogen, P 11 is C1-C6 alkyl.

[81] The method according to

[80] , wherein the cyclic peptide compound is represented by the following formula: [ka] During the ceremony, R3 is hydrogen or methyl; R4 is hydrogen and P4 is methyl, or R4 and P4 together with the nitrogen atom to which P4 is bonded and the carbon atom to which R4 is bonded form an azetidine ring; R5 is cyclohexylmethyl or 4-methylbenzyl; P5 is methyl or ethyl; R 7A , R 7B , and R 7C is independently selected from the group consisting of hydrogen, fluorine, chlorine, and trifluoromethyl; R 8A is hydrogen or ethoxy, R 10 is cyclopentyl or cyclohexyl, R 11A , and R 11B are both methyl or R 11A , and R 11B together with the nitrogen atom to which they are attached form a piperidine ring or a morpholine ring.

[82] The method according to any one of

[79] to

[81] , wherein the cyclic peptide compound is selected from the group consisting of: (1217) (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)- 4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, (1201) (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nona Methyl-4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, (558) (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecaone, and (926) (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine-4 -carbonyl)docosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone.

[83] The cyclic peptide compound is (1217) (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)- 4,7,10,13,17,20,23,28,31,34,37-Undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide The method according to any one of

[79] to

[82] ,

[84] The cyclic peptide compound is (1201) (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nonamethyl-4,7,10,1 The method according to any one of

[79] to

[82] , wherein the compound is 3,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide.

[85] The cyclic peptide compound is (558) (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecanone The method according to any one of

[79] to

[82] ,

[86] The cyclic peptide compound is (926) (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine- 4-carbonyl)docosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone The method according to any one of

[79] to

[82] , [86-1] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)-4,7,10,13,17,20,23,28,31 A method for treating or preventing a disease, comprising administering 1,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a salt thereof, or a solvate thereof to a subject. [86-2] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)-4,7,10,13,17,20,23,28,3 A method for treating or preventing a disease, comprising administering 1,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a salt thereof, or a hydrate thereof to a subject. [86-3] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)-4,7,10,13,17,20,23, A method for treating or preventing a disease, comprising administering 28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a hydrate thereof, to a subject. [86-4] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)-4,7,10,13,17,2 A method for treating or preventing a disease, comprising administering 0,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide to a subject. [86-5] (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nonamethyl-4,7,10,13,17,20,23,2 A method for treating or preventing a disease, comprising administering 8,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a salt thereof, or a solvate thereof to a subject. [86-6] (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nonamethyl-4,7,10,13,17,20,23, A method for treating or preventing a disease, comprising administering 28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a salt thereof, or a hydrate thereof to a subject. [86-7] (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nonamethyl-4,7,10,13,17,20 A method for treating or preventing a disease, comprising administering 23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a hydrate thereof, to a subject. [86-8] (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nonamethyl-4,7,10,13, A method for treating or preventing a disease, comprising administering 17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide to a subject. [86-9] A method for treating or preventing a disease, comprising administering (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecaone, or a salt thereof, or a solvate thereof to a subject. [86-10] A method for treating or preventing a disease, comprising administering (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecaone, or a salt thereof, or a hydrate thereof to a subject. [86-11] A method for treating or preventing a disease, comprising administering (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecaone, or a hydrate thereof, to a subject. [86-12] A method for treating or preventing a disease, comprising administering (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecaone to a subject. [86-13] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine-4-carbonyl)docosahydro-2H,4H-spiro A method for treating or preventing a disease, comprising administering to a subject [azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone, or a salt thereof, or a solvate thereof. [86-14] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine-4-carbonyl)docosahydro-2H,4H-spiro A method for treating or preventing a disease, comprising administering [azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone, or a salt thereof, or a hydrate thereof to a subject. [60-15] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine-4-carbonyl)docosahydro-2H,4 A method for treating or preventing a disease, comprising administering H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone, or a hydrate thereof, to a subject. [86-16] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine-4-carbonyl)docosahydro- A method for treating or preventing a disease, comprising administering 2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone to a subject.

[87] The method according to any one of

[79] to

[86] and [86-1] to [86-16], wherein the cyclic peptide compound, or a salt thereof, or a solvate thereof is a Ras inhibitor.

[88] The method of

[87] , wherein the Ras inhibitor is one or more Ras inhibitors selected from the group consisting of Kras inhibitors, Nras inhibitors, and Hras inhibitors.

[89] The method according to any one of

[79] to

[88] , wherein the disease is cancer.

[90] The method according to

[89] , wherein the cancer is a solid cancer or a blood cancer.

[91] The method according to

[89] or

[90] , wherein the cancer is selected from the group consisting of lung cancer, esophageal cancer, gastric cancer, colon cancer, uterine cancer, ovarian cancer, pancreatic cancer, bladder cancer, thyroid cancer, skin cancer, leukemia, malignant lymphoma, and multiple myeloma.

[92] The method according to any one of

[89] to

[91] , wherein the cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, colon cancer, rectal cancer, uterine cancer, endometrial cancer, cervical cancer, AML (acute myeloid leukemia), CML (chronic myeloid leukemia), ALL (acute lymphocytic leukemia), CLL (chronic lymphocytic leukemia), Hodgkin lymphoma, and non-Hodgkin lymphoma.

[93] The method according to any one of

[89] to

[92] , wherein the cancer is associated with an abnormality in the Ras gene.

[94] The method described in

[93] , wherein the abnormality in the Ras gene is a mutation in the coding region of the Ras gene and / or an amplification of the copy number of the Ras gene.

[95] The method of

[93] or

[94] , wherein the Ras gene is one or more Ras genes selected from the group consisting of Kras genes, Nras genes, and Hras genes.

[96] The method described in

[95] , wherein the Ras gene is a Kras gene.

[97] The method according to any one of

[89] to

[96] , wherein the cancer is associated with the production of mutant Ras proteins and / or increased production of Ras proteins.

[98] The method of claim 97, wherein the cancer is associated with the production of a mutant Ras protein.

[99] The method of

[97] or

[98] , wherein the mutant Ras protein is one or more mutant Ras proteins selected from the group consisting of mutant Kras proteins, mutant Nras proteins, and mutant Hras proteins.

[100] The method according to

[99] , wherein the mutant Ras protein is a mutant Kras protein.

[101] A method described in any of

[97] to

[100] , wherein the mutant Ras protein has a mutation at at least one amino acid position selected from the group consisting of G12, G13 and Q61 in the amino acid sequence set forth in SEQ ID NO: 6, 7 or 8.

[102] A method according to any one of

[97] to

[101] , wherein the mutant Ras protein is a mutant Kras protein and has at least one amino acid mutation selected from the group consisting of G12A, G12C, G12D, G12S, G12V, G13D, Q61H, and Q61K compared to the amino acid sequence set forth in SEQ ID NO: 6.

[103] A method described in any of

[97] to

[101] , wherein the mutant Ras protein is a mutant Nras protein and has at least one amino acid mutation selected from the group consisting of G12C, G12D, G13D, G13V, Q61K, and Q61L compared to the amino acid sequence set forth in SEQ ID NO: 7.

[104] A method according to any one of

[97] to

[101] , wherein the mutant Ras protein is a mutant Hras protein and has an amino acid mutation of G13R compared to the amino acid sequence set forth in SEQ ID NO: 8.

[105] Use of a cyclic peptide compound represented by the following formula (1), or a salt thereof, or a solvate thereof in the manufacture of a medicament for treating or preventing a disease: [ka] During the ceremony, L1 is a single bond, or -CHM1-, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2) n S(O)2(CH2) m wherein n and m are each independently 1 or 2; R1 is hydrogen, C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, or C3-C8 cycloalkoxyC1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino), and C1-C6 alkylsulfonyl; or R1 and P1 together with the carbon atom to which R1 is attached and the nitrogen atom to which P1 is attached form a 4- to 7-membered saturated heterocyclic ring; or R1 and Q1 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or R1 and M1 together with the carbon atom to which R1 is bonded and the carbon atom to which M1 is bonded form a 3- to 8-membered alicyclic ring; Except when R1 and P1 form a 4- to 7-membered saturated heterocycle, P1 is hydrogen or C1-C6 alkyl, which C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q1 is hydrogen or C1-C6 alkyl, except when R1 and Q1 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; and M1 is hydrogen, except when R1 and M1 form a 3- to 8-membered alicyclic ring; R2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, or C3-C8 cycloalkoxyC1-C6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, cyano, and C1-C6 alkylsulfonyl; or R2 and P2 together with the carbon atom to which R2 is attached and the nitrogen atom to which P2 is attached form a 4- to 7-membered saturated heterocyclic ring; or R2 and Q2 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R2 and P2 form a 4- to 7-membered saturated heterocycle, P2 is hydrogen or C1-C6 alkyl, which C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q2 is hydrogen or C1-C6 alkyl, except when R2 and Q2 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R3 is hydrogen, C1-C6 alkyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C3-C8 cycloalkoxyC1-C6 alkyl, or C7-C 14 aralkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of hydroxy, and aminocarbonyl, where the amino is -NH, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino; or R3 and P3 together with the carbon atom to which R3 is attached and the nitrogen atom to which P3 is attached form a 4- to 7-membered saturated heterocyclic ring; or R3 and Q3 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R3 and P3 form a 4- to 7-membered saturated heterocycle, P3 is hydrogen, C1-C6 alkyl, C1-C6 alkoxyC1-C6 alkyl, or C3-C8 cycloalkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and C1-C6 aminoalkyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, which is optionally substituted with one or more halogens); Q3 is hydrogen or C1-C6 alkyl, except when R3 and Q3 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R4 is hydrogen or C1-C6 alkyl, or R4 and P4 together with the carbon atom to which R4 is attached and the nitrogen atom to which P4 is attached form a 4- to 7-membered saturated heterocyclic ring; or R4 and Q4 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R4 and P4 form a 4- to 7-membered saturated heterocycle, P4 is hydrogen, C1-C6 alkyl, or C1-C6 alkoxyC1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q4 is hydrogen or C1-C6 alkyl, except when R4 and Q4 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R5 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C3-C8 cycloalkoxyC1-C6 alkyl, C7-C 14 Aralkyl, C6-C 10 Aryloxy C1-C6 alkyl, C7-C 14 aralkoxyC1-C6 alkyl, or 5- to 10-membered heteroarylC1-C6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, cyano, and C1-C6 alkylsulfonyl, or R5 together with R8 form a C4-C8 alkylene, or R5 and P5 together with the carbon atom to which R5 is attached and the nitrogen atom to which P5 is attached form a 4- to 7-membered saturated heterocyclic ring; or R5 and Q5 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R5 and P5 form a 4- to 7-membered saturated heterocycle, P5 is hydrogen or C1-C6 alkyl, which C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q5 is hydrogen or C1-C6 alkyl, except when R5 and Q5 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R6 is hydrogen or C1-C6 alkyl; or R6 and P6 together with the carbon atom to which R6 is attached and the nitrogen atom to which P6 is attached form a 4- to 7-membered saturated heterocyclic ring; or R6 and Q6 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R6 and P6 form a 4- to 7-membered saturated heterocycle, P6 is C1-C6 alkyl or C3-C8 cycloalkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q6 is hydrogen or C1-C6 alkyl, except when R6 and Q6 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R7 is C6-C 10 Aryloxy C1-C6 alkyl, C7-C 14 Aralkyl, C7-C 14aralkoxyC1-C6 alkyl, or 5- to 10-membered heteroarylC1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkoxy, cyano, C1-C6 alkylsulfonyl, and SF5; or R7 and P7 together with the carbon atom to which R7 is attached and the nitrogen atom to which P7 is attached form a 4- to 7-membered saturated heterocyclic ring; or R7 and Q7 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R7 and P7 form a 4- to 7-membered saturated heterocycle, P7 is hydrogen or C1-C6 alkyl, which C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q7 is hydrogen or C1-C6 alkyl, except when R7 and Q7 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R8 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C2-C6 alkenyloxycarbonylC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C6-C 10 Aryloxy C1-C6 alkyl, C7-C 14 Aralkyl, C7-C 14aralkoxyC1-C6 alkyl, 5- to 10-membered heteroarylC1-C6 alkyl, or 5- to 10-membered heteroarylC1-C6 alkoxyC1-C6 alkyl, each of which is halogen, hydroxy, carboxy, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkoxy, cyano, amino (said amino is -NH2, protected amino, monoC1-C6 alkylamino, diC1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is substituted with halogen). or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; or R8 taken together with R5 form a C4-C8 alkylene; R8 and P8 together with the carbon atom to which R8 is bonded and the nitrogen atom to which P8 is bonded form a 4- to 7-membered saturated heterocycle, which may be condensed with a saturated carbocycle or an aromatic ring, and which may be condensed with a halogen, oxo, C6-C 10 and optionally substituted by aryl, 5- to 10-membered heteroaryl, 4- to 8-membered cyclic amino (the cyclic amino may be substituted by one or more halogens), or OS8, and S8 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C7-C 14 aralkyl, which may be optionally substituted by one or more halogen, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy, or a 5- to 10-membered heteroarylC1-C6 alkyl; or R8 and Q8 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R8 and P8 together form a 4- to 7-membered saturated heterocycle, P8 is hydrogen, C1-C6 alkyl, C1-C6 alkoxyC1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxyC2-C6 alkenyl, C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, 4- to 7-membered heterocyclylC1-C6 alkyl, C6-C 10 Aryl, C7-C 14 aralkyl, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl-C1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen or C1-C6 alkyl), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q8 is hydrogen or C1-C6 alkyl, except when R8 and Q8 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R9 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkylC1-C6 alkyl, C7-C 14 aralkyl, or 5-10 membered heteroaryl C1-C6 alkoxyC1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4-8 membered cyclic amino), and C1-C6 alkylsulfonyl; or R9 and P9 together with the carbon atom to which R9 is attached and the nitrogen atom to which P9 is attached form a 4- to 7-membered saturated heterocyclic ring; or R9 and Q9 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; or Except when R9 and P9 form a 4- to 7-membered saturated heterocycle, P9 is hydrogen or C1-C6 alkyl, which C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); Q9 is hydrogen or C1-C6 alkyl, except when R9 and Q9 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring; R 10 is C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C3-C8 cycloalkoxyC1-C6 alkyl, or C7-C 14 aralkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, and C1-C6 alkylsulfonyl; or R 10 and P 10 is R 10 and P 10 together with the nitrogen atom to which it is attached to form a 4- to 7-membered saturated heterocyclic ring, or R 10 and Q 10 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, or R 10 and P 10 P forms a 4- to 7-membered saturated heterocyclic ring, 10is hydrogen or C1-C6 alkyl, and the C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); R 10 and Q 10 Q forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, 10 is hydrogen or C1-C6 alkyl, and L 11 is a single bond or -CHM 11 -, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2) n S(O)2(CH2) m wherein n and m are each independently 1 or 2; R 11 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkyl, C7-C 14 aralkyl, or aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino), each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, oxo, hydroxy, C1-C6 alkyl, 4- to 7-membered heterocyclyl, aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino), and C1-C6 alkylsulfonyl; or R 11 is a peptide chain containing 1 to 4 amino acid residues, or R 11 and P11 is R 11 and P 11 together with the nitrogen atom to which it is attached to form a 4- to 7-membered saturated heterocyclic ring, or R 11 and Q 11 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, or R 11 and M 11 is R 11 and the carbon atom to which M is bonded 11 forms a 3- to 8-membered alicyclic ring together with the carbon atom to which it is bonded, R 11 and P 11 P forms a 4- to 7-membered saturated heterocyclic ring, 11 is hydrogen or C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino); R 11 and Q 11 Q forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, 11 is hydrogen or C1-C6 alkyl, R 11 and M 11 forms a 3- to 8-membered alicyclic ring, M 11 is hydrogen, where L1 is a single bond, 11 -CHM 11 -, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2) nS(O)2(CH2) m -, and L1 is -CHM1-, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2) n S(O)2(CH2) m -If L 11 is a single bond, and P1~P 11 At least three of these are not hydrogen.

[106] The use according to

[105] , wherein the cyclic peptide compound is represented by the following formula (2): [ka] During the ceremony, R1 is C1-C6 alkyl; P1 is C1-C6 alkyl; R2 is C1-C6 alkyl; P2 is hydrogen, R3 is hydrogen or C1-C6 alkyl; P3 is C1-C6 alkyl; R4 is hydrogen, or R4 and P4 together with the nitrogen atom to which P4 is bonded and the carbon atom to which R4 is bonded form a 4- to 7-membered saturated heterocycle; P4 is C1-C6 alkyl, except when R4 and P4 form a 4- to 7-membered saturated heterocycle; R5 is C3-C8 cycloalkyl, C1-C6 alkyl, or C7-C optionally substituted by C1-C6 alkyl. 14 is aralkyl, P5 is C1-C6 alkyl; R6 is hydrogen; P6 is C1-C6 alkyl; R7 is a C7-C6 haloalkyl group optionally substituted with one or more groups independently selected from the group consisting of halogen and C1-C6 haloalkyl. 14 is aralkyl, Q7 is hydrogen, P7 is hydrogen, R8 and P8 together with the nitrogen atom to which P8 is bonded and the carbon atom to which R8 is bonded form a 4- to 7-membered saturated heterocycle, which is optionally substituted by C1-C6 alkoxy; R9 and Q9 together with the carbon atoms to which they are attached form a 3- to 8-membered alicyclic ring; P9 is hydrogen R 10 is C3-C8 cycloalkyl, P 10 is C1-C6 alkyl, R 11 is diC1-C6 alkylaminocarbonyl or 4- to 8-membered cyclic aminocarbonyl, M 11 is hydrogen, P 11 is C1-C6 alkyl.

[107] The use according to

[106] , wherein the cyclic peptide compound is represented by the following formula: [ka] During the ceremony, R3 is hydrogen or methyl; R4 is hydrogen and P4 is methyl, or R4 and P4 together with the nitrogen atom to which P4 is bonded and the carbon atom to which R4 is bonded form an azetidine ring; R5 is cyclohexylmethyl or 4-methylbenzyl; P5 is methyl or ethyl; R 7A , R 7B , and R 7C is independently selected from the group consisting of hydrogen, fluorine, chlorine, and trifluoromethyl; R 8A is hydrogen or ethoxy, R 10is cyclopentyl or cyclohexyl, R 11A , and R 11B are both methyl or R 11A , and R 11B together with the nitrogen atom to which they are attached form a piperidine ring or a morpholine ring.

[108] The use according to any one of

[105] to

[107] , wherein the cyclic peptide compound is selected from the group consisting of: (1217) (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)- 4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, (1201) (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nona Methyl-4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, (558) (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecaone, and (926) (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine-4 -carbonyl)docosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone.

[109] The cyclic peptide compound is (1217) (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)- 4,7,10,13,17,20,23,28,31,34,37-Undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide The use according to any one of

[105] to

[108] ,

[110] The cyclic peptide compound is (1201) (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nonamethyl-4,7,10,13 The use according to any one of

[105] to

[108] , wherein the compound is 17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide.

[111] The cyclic peptide compound is (558) (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecanone The use according to any one of

[105] to

[108] ,

[112] The cyclic peptide compound is (926) (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine- 4-carbonyl)docosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone The use according to any one of

[105] to

[108] , [112-1] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)- in the manufacture of a medicament for the treatment or prevention of a disease Use of 4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a salt thereof, or a solvate thereof. [112-2] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)- in the manufacture of a medicament for the treatment or prevention of a disease Use of 4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a salt thereof, or a hydrate thereof. [112-3] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)- 2. Use of benzoyl)-4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a hydrate thereof. [112-4] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4- Use of methylbenzyl)-4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide. [112-5] (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nonaphthalene-2-ol in the manufacture of a medicament for the treatment or prevention of a disease Use of methyl-4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a salt thereof, or a solvate thereof. [112-6] (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nonaphthalene-2-ol in the manufacture of a medicament for the treatment or prevention of a disease Use of methyl-4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a salt thereof, or a hydrate thereof. [112-7] (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33, Use of 36-nonamethyl-4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, or a hydrate thereof. [112-8] (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19 in the manufacture of a medicament for the treatment or prevention of a disease ,33,36-Nonamethyl-4,7,10,13,17,20,23,28,31,34,37-Undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide. [112-9] Use of (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecaone, or a salt thereof, or a solvate thereof, in the manufacture of a medicament for the treatment or prevention of a disease. [112-10] Use of (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecane, or a salt thereof, or a hydrate thereof, in the manufacture of a medicament for the treatment or prevention of a disease. [112-11] Use of (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecane, or a hydrate thereof, in the manufacture of a medicament for the treatment or prevention of a disease. [112-12] Use of (3S,9S,18S,21S,25S,28S,34S)-3-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-28-cyclohexyl-9-(cyclohexylmethyl)-21-isobutyl-7,10,13,16,22,26,29-heptamethyl-18-[(1S)-1-methylpropyl]-25-(piperidine-1-carbonyl)spiro[1,4,7,10,13,16,19,22,26,29,32-undecazabicyclo[32.3.0]heptatriacontane-31,1'-cyclopentane]-2,5,8,11,14,17,20,23,27,30,33-undecaone in the manufacture of a medicament for the treatment or prevention of a disease. [112-13] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine-4 -carbonyl)docosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone, or a salt thereof, or a solvate thereof. [112-14] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(morpholine- Use of 4-carbonyl)docosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone, or a salt thereof, or a hydrate thereof. [112-15] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-15-(mol) Use of (14H,22H)-undecahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone, or a hydrate thereof. [112-16] (5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-18-cyclopentyl-11-isobutyl-5,6,12,16,19,33,36-heptamethyl-1 Use of 5-(morpholine-4-carbonyl)docosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone.

[113] The use according to any one of

[105] to

[112] and [112-1] to [112-16], wherein the cyclic peptide compound, or a salt thereof, or a solvate thereof is a Ras inhibitor.

[114] The use according to

[113] , wherein the Ras inhibitor is one or more Ras inhibitors selected from the group consisting of Kras inhibitors, Nras inhibitors, and Hras inhibitors.

[115] The use according to any one of

[105] to

[114] , wherein the disease is cancer.

[116] The use according to

[115] , wherein the cancer is a solid cancer or a blood cancer.

[117] The use according to

[115] or

[116] , wherein the cancer is selected from the group consisting of lung cancer, esophageal cancer, gastric cancer, colorectal cancer, uterine cancer, ovarian cancer, pancreatic cancer, bladder cancer, thyroid cancer, skin cancer, leukemia, malignant lymphoma, and multiple myeloma.

[118] The use according to any one of

[115] to

[117] , wherein the cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, colon cancer, rectal cancer, uterine cancer, endometrial cancer, cervical cancer, AML (acute myeloid leukemia), CML (chronic myeloid leukemia), ALL (acute lymphocytic leukemia), CLL (chronic lymphocytic leukemia), Hodgkin lymphoma, and non-Hodgkin lymphoma.

[119] The use according to any one of

[115] to

[118] , wherein the cancer is associated with an abnormality in the Ras gene.

[120] The use according to

[119] , wherein the abnormality in the Ras gene is a mutation in the coding region of the Ras gene and / or an amplification of the copy number of the Ras gene.

[121] The use according to

[119] or

[120] , wherein the Ras gene is one or more Ras genes selected from the group consisting of Kras genes, Nras genes, and Hras genes.

[122] The use according to

[121] , wherein the Ras gene is a Kras gene. 〔one two three〕 The use according to any one of

[115] to

[122] , wherein the cancer is associated with the production of mutant Ras proteins and / or increased production of Ras proteins.

[124] The use described in

[123] , wherein the cancer is associated with the production of mutant Ras protein.

[125] The use according to

[123] or

[124] , wherein the mutant Ras protein is one or more mutant Ras proteins selected from the group consisting of mutant Kras proteins, mutant Nras proteins, and mutant Hras proteins.

[126] The use according to

[125] , wherein the mutant Ras protein is a mutant Kras protein.

[127] The use described in any of

[123] to

[126] , wherein the mutant Ras protein has a mutation at at least one amino acid position selected from the group consisting of G12, G13, and Q61 in the amino acid sequence set forth in SEQ ID NO: 6, 7, or 8.

[128] The use of any of

[123] to

[127] , wherein the mutant Ras protein is a mutant Kras protein and has at least one amino acid mutation selected from the group consisting of G12A, G12C, G12D, G12S, G12V, G13D, Q61H, and Q61K compared to the amino acid sequence set forth in SEQ ID NO: 6.

[129] The use described in any of

[123] to

[127] , wherein the mutant Ras protein is a mutant Nras protein and has at least one amino acid mutation selected from the group consisting of G12C, G12D, G13D, G13V, Q61K, and Q61L compared to the amino acid sequence set forth in SEQ ID NO: 7.

[130] The use according to any one of

[123] to

[127] , wherein the mutant Ras protein is a mutant Hras protein and has an amino acid mutation of G13R compared to the amino acid sequence set forth in SEQ ID NO: 8.

[131] A cyclic peptide compound containing 8 to 15 amino acid residues that binds to a Ras protein and includes the amino acid sequence set forth in SEQ ID NO: 9, i) at least three N-substituted amino acid residues; ii) at least one non-N-substituted amino acid residue, and iii) a cyclic portion comprising at least eight amino acid residues; Including, iv) interacting with at least one amino acid selected from the group consisting of Val8, Gly10, Lys16, Glu37, Leu56, Gln70, Tyr71, and Glu98 of the Ras protein; A cyclic peptide compound, a salt thereof, or a solvate thereof.

[132] further interacting with at least one amino acid selected from the group consisting of Val7, Val9, Ala11, Xaa12, Thr58, Ala59, Gly60, Xaa61, Glu62, Glu63, Tyr64, Arg68, Asp69, Met72, Arg73, Phe78, Asp92, Xaa95, Tyr96, Gln99, Ile100, Arg102, and Val103 of the Ras protein; Xaa12 is an amino acid selected from the group consisting of Gly, Asp, Cys, Ser, Val, Ala, and Arg; said Xaa61 is an amino acid selected from the group consisting of Gln, His, Lys, and Leu; and / or Xaa95 is an amino acid selected from the group consisting of Gln, His, and Leu. The cyclic peptide compound or a salt thereof, or a solvate thereof according to

[131] .

[133] further interacting with at least one amino acid selected from the group consisting of Val9, Thr58, Xaa61, Glu62, Tyr64, Arg68, Met72, Asp92, Xaa95, Tyr96, Gln99, Arg102, and Val103 of the Ras protein; said Xaa61 is an amino acid selected from the group consisting of Gln, His, Lys, and Leu; and / or Xaa95 is an amino acid selected from the group consisting of Gln, His, and Leu. The cyclic peptide compound or a salt thereof, or a solvate thereof according to

[131] or

[132] .

[134] further interacting with at least one amino acid selected from the group consisting of Thr58, Xaa61, Arg68, Gln99, and Arg102 of the Ras protein; Xaa61 is an amino acid selected from the group consisting of Gln, His, Lys, and Leu. The cyclic peptide compound or a salt thereof, or a solvate thereof according to any one of

[131] to

[133] .

[135] A cyclic peptide compound or a salt thereof, or a solvate thereof, according to any one of

[131] to

[134] , which interacts with at least one amino acid selected from the group consisting of Gly10, Leu56, Tyr71, and Glu98 of the Ras protein.

[136] further interacting with at least two amino acids selected from the group consisting of Thr58, Xaa61, Arg68, Gln99, and Arg102 of the Ras protein; Xaa61 is an amino acid selected from the group consisting of Gln, His, Lys, and Leu. The cyclic peptide compound or a salt thereof, or a solvate thereof according to any one of

[131] to

[135] .

[137] A cyclic peptide compound or a salt thereof, or a solvate thereof, according to any one of

[131] to

[136] , which interacts with at least two amino acids selected from the group consisting of Gly10, Leu56, Tyr71, and Glu98 of the Ras protein.

[138] A cyclic peptide compound or a salt thereof, or a solvate thereof, according to any one of

[131] to

[137] , wherein the Ras protein is one or more Ras proteins selected from the group consisting of Kras protein, Nras protein, and Hras protein.

[139] The cyclic peptide compound or a salt thereof, or a solvate thereof according to

[138] , wherein the Ras protein is a Kras protein.

[140] A cyclic peptide compound or a salt thereof, or a solvate thereof, according to any one of

[131] to

[139] , wherein the Ras protein is one or more mutant Ras proteins selected from the group consisting of mutant Kras proteins, mutant Nras proteins, and mutant Hras proteins.

[141] the Ras protein is a mutant Kras protein, Xaa12 is an amino acid selected from the group consisting of Asp, Cys, Ser, Val, and Ala, and / or Xaa61 is an amino acid selected from His or Lys; The cyclic peptide compound or a salt thereof, or a solvate thereof according to

[139] or

[140] .

[142] the Ras protein is a mutant Nras protein, Xaa12 is an amino acid selected from Asp or Cys, and / or Xaa61 is an amino acid selected from Lys or Leu; The cyclic peptide compound or a salt thereof, or a solvate thereof according to

[139] .

[143] The cyclic peptide compound consists of 11 amino acid residues, one of the amino acid residues is an amino acid residue having a carbonyl group bonded to the β-carbon of the amino group of the main chain, the amino acid residue may be N-substituted, and the carbonyl group is linked to the adjacent amino acid residue on the C-terminal side; the fourth amino acid residue on the C-terminal side of the amino acid residue having a carbonyl group bonded to the β-carbon of the amino group of the main chain is an N-substituted amino acid residue, The seven amino acid residues on the C-terminal side of the amino acid residue having a carbonyl group bonded to the β-carbon of the amino group of the main chain may be substituted with 1 to 5 groups independently selected from the group consisting of halogen, C1-C4 alkyl, C2-C4 alkynyl, C1-C3 haloalkyl, C1-C3 haloalkoxy, C1-C4 alkoxy, -CN, C1-C3 alkylsulfonyl, hydroxy, and SF5, -(CH2) x -O y -(CH2) z1 -C6-C 10 Aryl or -(CH2) x -O y -(CH2) z2 - 5 to 10 membered heteroaryl, Here, the sum of x, y, and z1 or z2 must be between 1 and 4. x is 1, 2, or 3, y is 0 or 1, z1 is 0, 1, 2, or 3, The cyclic peptide compound or a salt thereof, or a solvate of the same according to any one of

[131] to

[142] , wherein z2 is 1, 2, or 3.

[144] The cyclic peptide compound or salt thereof, or a solvate thereof according to

[143] , wherein the seventh amino acid residue on the C-terminal side of the amino acid residue having a carbonyl group bonded to the β-carbon of the amino group of the main chain is Hph(4-CF3-3-Cl).

[145] The cyclic peptide compound or salt thereof, or a solvate thereof, according to

[143] or

[144] , wherein the amino acid residue four amino acid residues away from the C-terminal side of the amino acid residue having a carbonyl group bonded to the β-carbon of the amino group of the main chain is MeGly or Aze(2).

[146] The cyclic peptide compound or salt thereof, or a solvate thereof, according to any one of

[143] to

[145] , wherein the amino acid residue seven amino acid residues C-terminal to the amino acid residue having a carbonyl group bonded to the β-carbon of the amino group of the main chain interacts with one or more selected from Tyr71, Leu56, and Glu37 of the Ras protein.

[147] The cyclic peptide compound or salt thereof, or a solvate thereof, according to any one of

[143] to

[146] , wherein the amino acid residue four amino acid residues C-terminal to the amino acid residue having a carbonyl group bonded to the β-carbon of the amino group of the main chain interacts with Glu98 of the Ras protein.

[148] A cyclic peptide compound or a salt thereof, or a solvate thereof, according to any one of

[143] to

[147] , wherein the amino acid residues seven and eight away from the C-terminal side of an amino acid residue having a carbonyl group bonded to the beta carbon of the amino group of the main chain each interact with one or more selected from Tyr71, Leu56, Glu37, Lys16 and Gly10 of the Ras protein.

[149] The cyclic peptide compound according to any one of

[131] to

[148] , or a salt thereof, or a solvate thereof, selected from the group consisting of: (488) (5S,8S,11S,15R,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-11-isobutyl-18-isopropyl-5,6,12,15,19,33,36-heptamethyldocosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone, (872) (11S,17S,26S,29S,33S,36S)-11-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-36-cyclohexyl-17-(cyclohexylmethyl)-9-(2-ethoxyethyl)-29-isobutyl-15,18,21,24,30,34,37-heptamethyl-26-[(1S)-1-methylpropyl]-33-(piperidine-1-carbonyl)-6,9,12,15,18,21,24,27,30,34,37-undecazaspiro[4.33]octatriacontane-7,10,13,16,19,22,25,28,31,35,38-undecaone, (1201) (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nona Methyl-4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, (2187) (6S,9S,15S,18S,21S,24S,27S,30R,34S)-15-benzyl-21-[(3-chlorophenyl)methyl]-9-[(4-chlorophenyl)methyl]-24,27-bis[(3-fluoro-4-hydroxyphenyl)methyl]-10,16,30,31-tetramethyl-6-[(1S)-1-methylpropyl]-18-(2-methylsulfonylethyl)-34-(pyrrolidine-1-carbonyl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotetratriacontane-2,5,8,11,14,17,20,23,26,29,32-undecaone, and (2188) (3S,6S,9S,12S,15S,18S,21S,24S,28S,31S)-18,21-dibutyl-12-[(2-chlorophenoxy)methyl]-6-[(5-fluoro-3-pyridyl)methoxymethyl]-4,10,24,25-tetramethyl-15-[(1S)-1-methylpropyl]-3,9-bis(3-pyridylmethyl)-28-(pyrrolidine-1-carbonyl)-1,4,7,10,13,16,19,22,25,29-decazabicyclo[29.3.0]tetratriacontane-2,5,8,11,14,17,20,23,26,30-decone. [149-1] A hydrate of the cyclic peptide compound according to any one of

[131] to

[148] , selected from the group consisting of: (488) (5S,8S,11S,15R,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-11-isobutyl-18-isopropyl-5,6,12,15,19,33,36-heptamethyldocosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone, (872) (11S,17S,26S,29S,33S,36S)-11-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-36-cyclohexyl-17-(cyclohexylmethyl)-9-(2-ethoxyethyl)-29-isobutyl-15,18,21,24,30,34,37-heptamethyl-26-[(1S)-1-methylpropyl]-33-(piperidine-1-carbonyl)-6,9,12,15,18,21,24,27,30,34,37-undecazaspiro[4.33]octatriacontane-7,10,13,16,19,22,25,28,31,35,38-undecaone, (1201) (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nona Methyl-4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, (2187) (6S,9S,15S,18S,21S,24S,27S,30R,34S)-15-benzyl-21-[(3-chlorophenyl)methyl]-9-[(4-chlorophenyl)methyl]-24,27-bis[(3-fluoro-4-hydroxyphenyl)methyl]-10,16,30,31-tetramethyl-6-[(1S)-1-methylpropyl]-18-(2-methylsulfonylethyl)-34-(pyrrolidine-1-carbonyl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotetratriacontane-2,5,8,11,14,17,20,23,26,29,32-undecaone, and (2188) (3S,6S,9S,12S,15S,18S,21S,24S,28S,31S)-18,21-dibutyl-12-[(2-chlorophenoxy)methyl]-6-[(5-fluoro-3-pyridyl)methoxymethyl]-4,10,24,25-tetramethyl-15-[(1S)-1-methylpropyl]-3,9-bis(3-pyridylmethyl)-28-(pyrrolidine-1-carbonyl)-1,4,7,10,13,16,19,22,25,29-decazabicyclo[29.3.0]tetratriacontane-2,5,8,11,14,17,20,23,26,30-decone.

[150] A pharmaceutical composition comprising the cyclic peptide compound or a salt thereof, or a solvate thereof according to any one of

[131] to

[149] .

[151] The pharmaceutical composition according to

[150] , which is a Ras inhibitor.

[152] The pharmaceutical composition according to

[151] , wherein the Ras inhibitor is one or more Ras inhibitors selected from the group consisting of Kras inhibitors, Nras inhibitors, and Hras inhibitors.

[153] The pharmaceutical composition according to any one of

[150] to

[152] for treating or preventing cancer.

[154] The pharmaceutical composition according to

[153] , wherein the cancer is a solid cancer or a blood cancer.

[155] The pharmaceutical composition according to

[153] or

[154] , wherein the cancer is selected from the group consisting of lung cancer, esophageal cancer, gastric cancer, colon cancer, uterine cancer, ovarian cancer, pancreatic cancer, bladder cancer, thyroid cancer, skin cancer, leukemia, malignant lymphoma, and multiple myeloma.

[156] The pharmaceutical composition according to any one of

[153] to

[155] , wherein the cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, colon cancer, rectal cancer, uterine cancer, endometrial cancer, cervical cancer, AML (acute myeloid leukemia), CML (chronic myeloid leukemia), ALL (acute lymphocytic leukemia), CLL (chronic lymphocytic leukemia), Hodgkin lymphoma, and non-Hodgkin lymphoma.

[157] The pharmaceutical composition according to any one of

[153] to

[156] , wherein the cancer is associated with an abnormality in the Ras gene.

[158] The pharmaceutical composition according to

[157] , wherein the abnormality in the Ras gene is a mutation in the coding region of the Ras gene and / or an amplification of the copy number of the Ras gene.

[159] The pharmaceutical composition according to

[157] or

[158] , wherein the Ras gene is one or more Ras genes selected from the group consisting of Kras genes, Nras genes, and Hras genes.

[160] The pharmaceutical composition according to

[159] , wherein the Ras gene is a Kras gene.

[161] The pharmaceutical composition according to any one of

[153] to

[160] , wherein the cancer is associated with the production of mutant Ras protein and / or increased production of Ras protein.

[162] The pharmaceutical composition of

[161] , wherein the cancer is associated with the production of mutant Ras protein.

[163] The pharmaceutical composition of

[161] or

[162] , wherein the mutant Ras protein is one or more mutant Ras proteins selected from the group consisting of mutant Kras proteins, mutant Nras proteins, and mutant Hras proteins.

[164] The pharmaceutical composition according to

[163] , wherein the mutant Ras protein is a mutant Kras protein.

[165] A pharmaceutical composition described in any of

[161] to

[164] , wherein the mutant Ras protein has a mutation at at least one amino acid position selected from the group consisting of G12, G13 and Q61 in the amino acid sequence set forth in SEQ ID NO: 6, 7 or 8.

[166] A pharmaceutical composition described in any of

[161] to

[165] , wherein the mutant Ras protein is a mutant Kras protein and has at least one amino acid mutation selected from the group consisting of G12A, G12C, G12D, G12S, G12V, G13D, Q61H, and Q61K compared to the amino acid sequence set forth in SEQ ID NO: 6.

[167] A pharmaceutical composition described in any one of

[161] to

[163] and

[165] , wherein the mutant Ras protein is a mutant Nras protein and has at least one amino acid mutation selected from the group consisting of G12C, G12D, G13D, G13V, Q61K, and Q61L compared to the amino acid sequence set forth in SEQ ID NO: 7.

[168] A pharmaceutical composition described in any of

[161] to

[163] and

[165] , wherein the mutant Ras protein is a mutant Hras protein and has an amino acid mutation of G13R compared to the amino acid sequence set forth in SEQ ID NO: 8.

[169] The pharmaceutical composition according to any one of

[149] to

[167] , comprising a cyclic peptide compound, a salt thereof, or a solvate thereof, selected from the group consisting of: (488) (5S,8S,11S,15R,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-11-isobutyl-18-isopropyl-5,6,12,15,19,33,36-heptamethyldocosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone, (872) (11S,17S,26S,29S,33S,36S)-11-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-36-cyclohexyl-17-(cyclohexylmethyl)-9-(2-ethoxyethyl)-29-isobutyl-15,18,21,24,30,34,37-heptamethyl-26-[(1S)-1-methylpropyl]-33-(piperidine-1-carbonyl)-6,9,12,15,18,21,24,27,30,34,37-undecazaspiro[4.33]octatriacontane-7,10,13,16,19,22,25,28,31,35,38-undecaone, (1201) (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nona Methyl-4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, (2187) (6S,9S,15S,18S,21S,24S,27S,30R,34S)-15-benzyl-21-[(3-chlorophenyl)methyl]-9-[(4-chlorophenyl)methyl]-24,27-bis[(3-fluoro-4-hydroxyphenyl)methyl]-10,16,30,31-tetramethyl-6-[(1S)-1-methylpropyl]-18-(2-methylsulfonylethyl)-34-(pyrrolidine-1-carbonyl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotetratriacontane-2,5,8,11,14,17,20,23,26,29,32-undecaone, and (2188) (3S,6S,9S,12S,15S,18S,21S,24S,28S,31S)-18,21-dibutyl-12-[(2-chlorophenoxy)methyl]-6-[(5-fluoro-3-pyridyl)methoxymethyl]-4,10,24,25-tetramethyl-15-[(1S)-1-methylpropyl]-3,9-bis(3-pyridylmethyl)-28-(pyrrolidine-1-carbonyl)-1,4,7,10,13,16,19,22,25,29-decazabicyclo[29.3.0]tetratriacontane-2,5,8,11,14,17,20,23,26,30-decone. [169-1] The pharmaceutical composition according to any one of

[149] to

[167] , which comprises a hydrate of a cyclic peptide compound selected from the group consisting of: (488) (5S,8S,11S,15R,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-11-isobutyl-18-isopropyl-5,6,12,15,19,33,36-heptamethyldocosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone, (872) (11S,17S,26S,29S,33S,36S)-11-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-36-cyclohexyl-17-(cyclohexylmethyl)-9-(2-ethoxyethyl)-29-isobutyl-15,18,21,24,30,34,37-heptamethyl-26-[(1S)-1-methylpropyl]-33-(piperidine-1-carbonyl)-6,9,12,15,18,21,24,27,30,34,37-undecazaspiro[4.33]octatriacontane-7,10,13,16,19,22,25,28,31,35,38-undecaone, (1201) (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nona Methyl-4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, (2187) (6S,9S,15S,18S,21S,24S,27S,30R,34S)-15-benzyl-21-[(3-chlorophenyl)methyl]-9-[(4-chlorophenyl)methyl]-24,27-bis[(3-fluoro-4-hydroxyphenyl)methyl]-10,16,30,31-tetramethyl-6-[(1S)-1-methylpropyl]-18-(2-methylsulfonylethyl)-34-(pyrrolidine-1-carbonyl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotetratriacontane-2,5,8,11,14,17,20,23,26,29,32-undecaone, and (2188) (3S,6S,9S,12S,15S,18S,21S,24S,28S,31S)-18,21-dibutyl-12-[(2-chlorophenoxy)methyl]-6-[(5-fluoro-3-pyridyl)methoxymethyl]-4,10,24,25-tetramethyl-15-[(1S)-1-methylpropyl]-3,9-bis(3-pyridylmethyl)-28-(pyrrolidine-1-carbonyl)-1,4,7,10,13,16,19,22,25,29-decazabicyclo[29.3.0]tetratriacontane-2,5,8,11,14,17,20,23,26,30-decone. In the above numbering system, the numbers cited in the dependent claims include their subnumbers unless otherwise specified. For example, [2] cited in a dependent claim includes its subnumbers [2A], [2B], and [2C], and for example,

[95] cited in a dependent claim includes not only

[95] but also its subnumbers [95-1] to [95-53]. The same applies to other numbering systems. [Effects of the Invention]

[0016] According to the present invention, there can be provided a novel cyclic peptide compound having anticancer activity, and a pharmaceutical composition comprising the cyclic peptide compound, a salt thereof, or a solvate thereof. [Brief explanation of the drawings]

[0017] [Figure 1] Figure 1 is a schematic diagram showing the overall structure of the X-ray crystal structure of the complex between human Kras G12D mutant and cyclic peptide compound 488, as shown in Example 6-2. The human Kras G12D mutant is shown as a ribbon representation, and compound 488 and guanosine diphosphate (GDP) are shown as black and gray stick representations, respectively. [Figure 2] Figure 2 is a schematic diagram showing the overall structure of the X-ray crystal structure of the complex between human Kras G12D mutant and cyclic peptide compound 872, as shown in Example 6-3. The human Kras G12D mutant is shown as a ribbon representation, and compound 872 and GDP are shown as black and gray stick representations, respectively. [Figure 3] 3 is a schematic diagram showing the overall structure of the X-ray crystal structure of the complex between human Kras G12D mutant and cyclic peptide compound 1201, as shown in Example 6-4. The human Kras G12D mutant is shown as a ribbon representation, and compound 1201 and GDP are shown as black and gray stick representations, respectively. [Figure 4]Figure 4-(1) is a schematic diagram showing the overall structure of the X-ray crystal structure of the complex between human Kras G12D mutant and cyclic peptide compound 2187, as shown in Example 6-5. The two molecules contained in the asymmetric unit are shown. Figure 4-(2) shows the structure of molecules 1 and 2 superimposed using all atoms of the human Kras G12D mutant. The human Kras G12D mutant is shown as a ribbon representation, and compound 2187 and GDP are shown as black and gray stick representations, respectively. [Figure 5] Figure 5 is a schematic diagram showing the overall structure of the X-ray crystal structure of the complex between human Kras G12D mutant and cyclic peptide compound 2188, as shown in Example 6-6. The human Kras G12D mutant is shown as a ribbon representation, and compound 2188 and GDP are shown as black and gray stick representations, respectively. [Figure 6] Figure 6 is a schematic diagram showing characteristic interaction sites in the X-ray crystal structure of the complex between human Kras G12D mutant and cyclic peptide compound 488. The human Kras G12D mutant is shown in gray ribbon and stick representations, and compound 488 is shown as a black stick representation. Dotted lines indicate interatomic distances. [Figure 7] Figure 7 is a schematic diagram showing characteristic interaction sites in the X-ray crystal structure of the complex between human Kras G12D mutant and cyclic peptide compound 872. The human Kras G12D mutant is shown in gray ribbon and stick representations, and compound 872 is shown as a black stick representation. Dotted lines indicate interatomic distances. [Figure 8] Figure 8 is a schematic diagram showing characteristic interaction sites in the X-ray crystal structure of the complex between human Kras G12D mutant and cyclic peptide compound 1201. The human Kras G12D mutant is shown in gray ribbon and stick representations, and compound 1201 is shown as a black stick representation. Dotted lines indicate interatomic distances. [Figure 9]Figure 9 is a schematic diagram showing characteristic interaction sites in the X-ray crystal structure of the complex between human Kras G12D mutant and cyclic peptide compound 2187. Human Kras G12D mutant is shown in gray ribbon and stick representations, and compound 2187 is shown as a black stick representation. Dotted lines indicate interatomic distances. [Figure 10] Figure 10 is a schematic diagram showing characteristic interaction sites in the X-ray crystal structure of the complex between human Kras G12D mutant and cyclic peptide compound 2188. The human Kras G12D mutant is shown in gray ribbon and stick representations, and compound 2188 is shown as a black stick representation. Dotted lines indicate interatomic distances. [Figure 11] 11 is a diagram showing the amino acid sites and the extent of interaction with the human KrasG12D mutant for each of cyclic peptide compounds 488, 872, 1201, 2187, and 2188. Amino acids containing one or more atoms located within 3.0 Å of any atom of the cyclic peptide compound are shown in black, amino acids containing one or more atoms located at a distance of more than 3.0 Å but within 4.0 Å are shown in diagonal lines, and amino acids containing one or more atoms located at a distance of more than 4.0 Å but within 5.0 Å are shown in gray. DETAILED DESCRIPTION OF THE INVENTION

[0018] (abbreviation) The abbreviations used in the present invention are listed below. AA: Ammonium acetate Alloc group: allyloxycarbonyl group Boc group: tert-butoxycarbonyl group Cbz group: benzyloxycarbonyl group CSA: (+)-10-camphorsulfonic acid DBU: 1,8-diazabicyclo[5.4.0]-7-undecene DCC: N,N'-dicyclohexylcarbodiimide DCM: dichloromethane DCE: 1,2-dichloroethane DEAD: Diethyl azodicarboxylate DMA: N,N-dimethylacetamide DMF: N,N-dimethylformamide DIAD: Diisopropyl azodicarboxylate DIC: N,N'-diisopropylcarbodiimide DIPEA: N,N-diisopropylethylamine DMAP: N,N-dimethyl-4-aminopyridine t-Bu group: tert-butyl group dtbbpy: 4,4′-di-tert-butyl-2,2′-dipyridyl EDTA: Ethylenediaminetetraacetic acid FA: Formic acid Fmoc group: 9-fluorenylmethyloxycarbonyl group NMP: N-methyl-2-pyrrolidone TBME: t-butyl methyl ether TES: Triethylsilane TFA: Trifluoroacetic acid TFE: 2,2,2-trifluoroethanol THF: tetrahydrofuran THP: tetrahydropyranyl TMSCl: Trimethylsilyl chloride HFIP: 1,1,1,3,3,3-hexafluoroisopropyl alcohol HOAt: 1-hydroxy-7-azabenzotriazole HOBt: 1-hydroxybenzotriazole HOOBt: 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine IPAC: Isopropyl acetate oxyma: ethyl cyano(hydroxyimino)acetate PPTS: Pyridinium p-toluenesulfonate Pis: 2-phenylisopropyl WSCI·HCl: 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride TIPS: Triisopropylsilane TfOH: trifluoromethanesulfonic acid HATU: O-(7-aza-1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate DMSO: dimethyl sulfoxide Fmoc-Cl: (9H-fluoren-9-yl)methyl carbonochloridate Fmoc-OSu: N-succinimidyl 9-fluorenylmethyl carbonate Ns group: o-nitrobenzenesulfonyl group Trt group: triphenylmethyl group Troc group: 2,2,2-trichloroethoxycarbonyl group

[0019] Unless otherwise specified, "Ras gene" may be abbreviated as "Ras" herein, and the two terms are used interchangeably. Similarly, "Ras protein" may be abbreviated as "Ras" herein, and the two terms are used interchangeably.

[0020] In this specification, the "amino acid residues" constituting a cyclic peptide compound may be simply referred to as "amino acids." Furthermore, a "cyclic peptide compound" may be simply referred to as a "peptide compound" or "compound."

[0021] As used herein, "one or more" means one or more than one. When "one or more" is used in the context of substituents on a group, the term means from one to the maximum number of substituents permitted by that group. Specific examples of "one or more" include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and / or more.

[0022] As used herein, the term "and / or" includes any combination of "and" and "or." Specifically, for example, "A, B, and / or C" includes the following seven variations: (i) A, (ii) B, (iii) C, (iv) A and B, (v) A and C, (vi) B and C, and (vii) A, B, and C.

[0023] In this specification, the term "to" indicating a range includes both ends of the range. For example, "A to B" means a range that is equal to or greater than A and equal to or less than B.

[0024] As used herein, the term "about" when used in conjunction with a numerical value means a range of values ​​of plus and minus 10% of that numerical value.

[0025] (Definition of functional groups, etc.) As used herein, the term "halogen atom" includes, for example, F, Cl, Br, or I.

[0026] As used herein, "alkyl" refers to a monovalent group derived from an aliphatic hydrocarbon by removing any one hydrogen atom, and does not contain heteroatoms (atoms other than carbon and hydrogen atoms) or unsaturated carbon-carbon bonds in the skeleton, but has a subset of hydrocarbyl or hydrocarbon group structures containing hydrogen and carbon atoms. Alkyl includes not only linear but also branched chain alkyls. Specific examples of alkyl include alkyls having 1 to 20 carbon atoms (C1-C 20 , hereinafter referred to as “C p -C q " means that the number of carbon atoms is p to q), and preferably C1-C 10Alkyl is preferably C1-C6 alkyl. Specific examples of alkyl include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, isobutyl (2-methylpropyl), n-pentyl, s-pentyl (1-methylbutyl), t-pentyl (1,1-dimethylpropyl), neopentyl (2,2-dimethylpropyl), isopentyl (3-methylbutyl), 3-pentyl (1-ethylpropyl), 1,2-dimethylpropyl, 2-methylbutyl, n-hexyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1,1,2,2-tetramethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, etc.

[0027] As used herein, "alkenyl" refers to an alkyl group having at least one double bond (two adjacent SP 2 Alkenyl is a monovalent group having 2-4 carbon atoms. Depending on the configuration of the double bond and the substituents (if any), the geometry of the double bond can be Entgegen (E) or Zusammen (Z), cis or trans. Alkenyl includes not only straight chains but also branched chains. Alkenyl is preferably C2-C 10 Alkenyl, more preferably C2-C6 alkenyl, is exemplified, and specific examples include vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl (including cis and trans), 3-butenyl, pentenyl, 3-methyl-2-butenyl, hexenyl, etc.

[0028] As used herein, "alkynyl" refers to a monovalent group having at least one triple bond (two adjacent SP carbon atoms). Alkynyl includes not only straight chain but also branched chain. Alkynyl is preferably C2-C 10Alkynyl, more preferably C2-C6 alkynyl, is included, and specific examples include ethynyl, 1-propynyl, propargyl, 3-butynyl, pentynyl, hexynyl, 3-phenyl-2-propynyl, 3-(2'-fluorophenyl)-2-propynyl, 2-hydroxy-2-propynyl, 3-(3-fluorophenyl)-2-propynyl, 3-methyl-(5-phenyl)-4-pentynyl, and the like.

[0029] As used herein, the term "cycloalkyl" refers to a saturated or partially saturated cyclic monovalent aliphatic hydrocarbon group, including monocyclic, bicyclic, and spirocyclic rings. Preferred examples of cycloalkyl include C3-C8 cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]heptyl, and spiro[3.3]heptyl.

[0030] As used herein, "aryl" refers to a monovalent aromatic hydrocarbon ring, preferably C6-C 10 Specific examples of the aryl include phenyl and naphthyl (for example, 1-naphthyl and 2-naphthyl).

[0031] As used herein, the term "heterocyclyl" refers to a non-aromatic cyclic monovalent group containing 1 to 5 heteroatoms in addition to carbon atoms. The heterocyclyl may have a double and / or triple bond in the ring, and a carbon atom in the ring may be oxidized to form a carbonyl, and may be a monocyclic or condensed ring. The number of atoms constituting the ring is preferably 4 to 10 (4- to 10-membered heterocyclyl), more preferably 4 to 7 (4- to 7-membered heterocyclyl). Specific examples of heterocyclyl include azetidinyl, oxiranyl, oxetanyl, azetidinyl, dihydrofuryl, tetrahydrofuryl, dihydropyranyl, tetrahydropyranyl, tetrahydropyridyl, tetrahydropyrimidyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, piperidinyl, piperazinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, and isothiazolidinyl. Examples include thiadiazolidinyl, 1,2-thiazinane, thiadiazolidinyl, azetidinyl, oxazolidone, benzodioxanyl, benzoxazolyl, dioxolanyl, dioxanyl, tetrahydropyrrolo[1,2-c]imidazole, thietanyl, 3,6-diazabicyclo[3.1.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 3-oxa-8-azabicyclo[3.2.1]octanyl, sultam, and 2-oxaspiro[3.3]heptyl.

[0032] As used herein, the term "protected heterocyclyl" refers to a group in which one or more functional groups included in the above-defined "heterocyclyl," such as an amino group, are protected with any protecting group, and preferably includes a protected 4- to 7-membered heterocyclyl. Specific examples of the protecting group include Boc, Fmoc, Cbz, Troc, and Alloc, and specific examples of the protected heterocyclyl include Boc-protected azetidine.

[0033] As used herein, "heterocycloalkylidene" refers to a divalent group resulting from the removal of two hydrogen atoms from one carbon atom of the above-defined "heterocyclyl," in which the free valence becomes part of a double bond. Preferred examples of heterocycloalkylidene include 4- to 7-membered heterocycloalkylidenes, and specific examples include tetrahydropyran-4-ylidene and azetidin-3-ylidene.

[0034] As used herein, the term "protected heterocycloalkylidene" refers to a group in which one or more functional groups included in the above-defined "heterocycloalkylidene," such as an amino group, are protected with any protecting group, and preferably includes a protected 4- to 7-membered heterocycloalkylidene. Specific examples of the protecting group include Boc, Fmoc, Cbz, Troc, and Alloc, and specific examples of the protected heterocycloalkylidene include Boc-protected azetidin-3-ylidene.

[0035] As used herein, "heteroaryl" refers to an aromatic cyclic monovalent group containing 1 to 5 heteroatoms in addition to carbon atoms. The ring may be a single ring or a condensed ring with other rings, and may be partially saturated. The number of atoms constituting the ring is preferably 5 to 10 (5- to 10-membered heteroaryl), and more preferably 5 to 7 (5- to 7-membered heteroaryl). Specific examples of heteroaryl include furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, benzofuranyl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzimidazolyl, indolyl, isoindolyl, indazolyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, benzodioxolyl, indolizinyl, and imidazopyridyl.

[0036] As used herein, "alkoxy" refers to an oxy group bonded to an "alkyl" as defined above, and preferably includes C1-C6 alkoxy. Specific examples of alkoxy include methoxy, ethoxy, 1-propoxy, 2-propoxy, n-butoxy, i-butoxy, s-butoxy, t-butoxy, pentyloxy, and 3-methylbutoxy.

[0037] As used herein, "alkenyloxy" refers to an oxy group bonded to the above-defined "alkenyl," and preferably includes C2-C6 alkenyloxy. Specific examples of alkenyloxy include vinyloxy, allyloxy, 1-propenyloxy, 2-propenyloxy, 1-butenyloxy, 2-butenyloxy (including cis and trans), 3-butenyloxy, pentenyloxy, and hexenyloxy.

[0038] As used herein, "cycloalkoxy" refers to an oxy group bonded to a "cycloalkyl" as defined above, and preferably includes C3-C8 cycloalkoxy. Specific examples of cycloalkoxy include cyclopropoxy, cyclobutoxy, cyclopentyloxy, etc.

[0039] As used herein, "aryloxy" refers to an oxy group to which the above-defined "aryl" is bonded, and preferably has a C6-C 10 Specific examples of the aryloxy include phenoxy, 1-naphthyloxy, and 2-naphthyloxy.

[0040] As used herein, "amino" refers to -NH2 in a narrow sense and -NRR' in a broad sense, where R and R' are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, or R and R' together with the nitrogen atom to which they are attached form a ring. Preferred amino groups include -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, and 4- to 8-membered cyclic amino.

[0041] As used herein, "monoalkylamino" refers to a group in which R is hydrogen and R' is an "alkyl" as defined above, among the "amino" groups defined above, and preferably includes mono-C1-C6 alkylamino. Specific examples of monoalkylamino include methylamino, ethylamino, n-propylamino, i-propylamino, n-butylamino, s-butylamino, and t-butylamino.

[0042] As used herein, "dialkylamino" refers to a group in which R and R' are independently "alkyl" as defined above, among the "amino" groups defined above, and preferably includes diC1-C6 alkylamino. Specific examples of dialkylamino include dimethylamino and diethylamino.

[0043] As used herein, "cyclic amino" refers to the above-defined "amino" in which R and R' form a ring together with the nitrogen atom to which they are attached, and preferably includes 4- to 8-membered cyclic amino. Specific examples of cyclic amino include 1-azetidyl, 1-pyrrolidyl, 1-piperidyl, 1-piperazyl, 4-morpholinyl, 3-oxazolidyl, 1,1-dioxidethiomorpholinyl-4-yl, and 3-oxa-8-azabicyclo[3.2.1]octan-8-yl.

[0044] As used herein, the term "protected amino" refers to an amino group protected with any protecting group. Specific examples of the protected amino include amino protected with a protecting group such as Boc, Fmoc, Cbz, Troc, or Alloc.

[0045] As used herein, "aminocarbonyl" refers to a carbonyl group bonded to the above-defined "amino," and preferred examples include -CONH, mono-C1-C6 alkylaminocarbonyl, di-C1-C6 alkylaminocarbonyl, and 4- to 8-membered cyclic aminocarbonyl. Specific examples of aminocarbonyl include -CONH, dimethylaminocarbonyl, 1-azetidinylcarbonyl, 1-pyrrolidinylcarbonyl, 1-piperidinylcarbonyl, 1-piperazinylcarbonyl, 4-morpholinylcarbonyl, 3-oxazolidinylcarbonyl, 1,1-dioxidethiomorpholinyl-4-ylcarbonyl, and 3-oxa-8-azabicyclo[3.2.1]octan-8-ylcarbonyl.

[0046] As used herein, "alkenyloxycarbonyl" refers to a carbonyl group bonded to the above-defined "alkenyloxy," and preferably includes C2-C6 alkenyloxycarbonyl. Specific examples of alkenyloxycarbonyl include vinyloxycarbonyl, allyloxycarbonyl, 1-propenyloxycarbonyl, 2-propenyloxycarbonyl, 1-butenyloxycarbonyl, 2-butenyloxycarbonyl (including cis and trans), 3-butenyloxycarbonyl, pentenyloxycarbonyl, and hexenyloxycarbonyl.

[0047] As used herein, "alkylsulfonyl" refers to a sulfonyl group having an "alkyl" bonded thereto, as defined above, and preferably includes C1-C6 alkylsulfonyl. Specific examples of alkylsulfonyl include methylsulfonyl.

[0048] As used herein, "hydroxyalkyl" refers to a group in which one or more hydrogen atoms of the "alkyl" defined above have been replaced with hydroxyl groups, and C1-C6 hydroxyalkyl is preferred. Specific examples of hydroxyalkyl include hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2-hydroxy-2-methylpropyl, and 5-hydroxypentyl.

[0049] As used herein, "haloalkyl" refers to a group in which one or more hydrogen atoms of the "alkyl" defined above have been substituted with halogen atoms, preferably C1-C6 haloalkyl, more preferably C1-C6 fluoroalkyl. Specific examples of haloalkyl include difluoromethyl, trifluoromethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 3,3-difluoropropyl, 4,4-difluorobutyl, and 5,5-difluoropentyl.

[0050] As used herein, "cyanoalkyl" refers to a group in which one or more hydrogen atoms of the "alkyl" defined above have been replaced with cyano, and C1-C6 cyanoalkyl is preferred. Specific examples of cyanoalkyl include cyanomethyl and 2-cyanoethyl.

[0051] As used herein, "aminoalkyl" refers to a group in which one or more hydrogen atoms of an "alkyl" as defined above are substituted with an "amino" as defined above, and C1-C6 aminoalkyl is preferred. Specific examples of aminoalkyl include 1-pyridylmethyl, 2-(1-piperidyl)ethyl, 3-(1-piperidyl)propyl, and 4-aminobutyl.

[0052] As used herein, "carboxyalkyl" refers to a group in which one or more hydrogen atoms of the "alkyl" defined above are substituted with carboxy, and C2-C6 carboxyalkyl is preferred. Specific examples of carboxyalkyl include carboxymethyl.

[0053] As used herein, "alkenyloxycarbonylalkyl" refers to a group in which one or more hydrogen atoms of an "alkyl" as defined above are substituted with an "alkenyloxycarbonyl" as defined above, with C2-C6 alkenyloxycarbonylC1-C6 alkyl being preferred, and C2-C6 alkenyloxycarbonylC1-C2 alkyl being more preferred. Specific examples of alkenyloxycarbonylalkyl include allyloxycarbonylmethyl and 2-(allyloxycarbonyl)ethyl.

[0054] As used herein, "alkoxyalkyl" refers to a group in which one or more hydrogen atoms of an "alkyl" as defined above are substituted with an "alkoxy" as defined above, with C1-C6 alkoxyC1-C6 alkyl being preferred, and C1-C6 alkoxyC1-C2 alkyl being more preferred. Specific examples of alkoxyalkyl include methoxymethyl, ethoxymethyl, 1-propoxymethyl, 2-propoxymethyl, n-butoxymethyl, i-butoxymethyl, s-butoxymethyl, t-butoxymethyl, pentyloxymethyl, 3-methylbutoxymethyl, 1-methoxyethyl, 2-methoxyethyl, and 2-ethoxyethyl.

[0055] As used herein, "cycloalkylalkyl" refers to a group in which one or more hydrogen atoms of an "alkyl" as defined above are substituted with a "cycloalkyl" as defined above, with C3-C8 cycloalkylC1-C6 alkyl being preferred, and C3-C6 cycloalkylC1-C2 alkyl being more preferred. Specific examples of cycloalkylalkyl include cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, and cyclohexylmethyl.

[0056] As used herein, "cycloalkoxyalkyl" refers to a group in which one or more hydrogen atoms of an "alkyl" as defined above are substituted with a "cycloalkoxy" as defined above, with C3-C8 cycloalkoxyC1-C6 alkyl being preferred, and C3-C6 cycloalkoxyC1-C2 alkyl being more preferred. Specific examples of cycloalkoxyalkyl include cyclopropoxymethyl and cyclobutoxymethyl.

[0057] As used herein, "heterocyclylalkyl" refers to a group in which one or more hydrogen atoms of an "alkyl" as defined above are substituted with a "heterocyclyl" as defined above, and is preferably a 4- to 7-membered heterocyclylC1-C6 alkyl, more preferably a 4- to 7-membered heterocyclylC1-C2 alkyl. Specific examples of heterocyclylalkyl include 2-(tetrahydro-2H-pyran-4-yl)ethyl and 2-(azetidin-3-yl)ethyl.

[0058] As used herein, "alkylsulfonylalkyl" refers to a group in which one or more hydrogen atoms of an "alkyl" as defined above are substituted with an "alkylsulfonyl" as defined above, with C1-C6 alkylsulfonylC1-C6 alkyl being preferred, and C1-C6 alkylsulfonylC1-C2 alkyl being more preferred. Specific examples of alkylsulfonylalkyl include methylsulfonylmethyl and 2-(methylsulfonyl)ethyl.

[0059] As used herein, "aminocarbonylalkyl" refers to a group in which one or more hydrogen atoms of an "alkyl" as defined above are substituted with an "aminocarbonyl" as defined above, preferably an aminocarbonyl C1-C6 alkyl, and more preferably an aminocarbonyl C1-C4 alkyl. Specific examples of aminocarbonylalkyl include methylaminocarbonylmethyl, dimethylaminocarbonylmethyl, t-butylaminocarbonylmethyl, 1-azetidinylcarbonylmethyl, 1-pyrrolidinylcarbonylmethyl, 1-piperidinylcarbonylmethyl, 4-morpholinylcarbonylmethyl, 2-(methylaminocarbonyl)ethyl, 2-(dimethylaminocarbonyl)ethyl, 2-(1-azetidinylcarbonyl)ethyl, 2-(1-pyrrolidinylcarbonyl)ethyl, 2-(4-morpholinylcarbonyl)ethyl, 3-(dimethylaminocarbonyl)propyl, and 4-(dimethylaminocarbonyl)butyl.

[0060] As used herein, "aryloxyalkyl" refers to a group in which one or more hydrogen atoms of an "alkyl" defined above are substituted with an "aryloxy" defined above, and is a C6-C 10 Aryloxy C1-C6 alkyl is preferred, C6-C 10 Aryloxy C1-C2 alkyl is more preferred. Specific examples of aryloxy alkyl include phenoxymethyl and 2-phenoxyethyl.

[0061] As used herein, "aralkyl (arylalkyl)" refers to a group in which at least one hydrogen atom of an "alkyl" as defined above is substituted with an "aryl" as defined above, and is a C7-C 14 Aralkyl is preferred, C7-C 10 Aralkyl is more preferred. Specific examples of aralkyl include benzyl, phenethyl, and 3-phenylpropyl.

[0062] As used herein, "aralkoxy" refers to an oxy group to which the above-defined "aralkyl" is bonded, and is a C7-C 14 Aralkoxy is preferred, C7-C10 Aralkoxy is more preferred. Specific examples of aralkoxy include benzyloxy, phenethyloxy, and 3-phenylpropoxy.

[0063] As used herein, "aralkoxyalkyl" refers to a group in which one or more hydrogen atoms of an "alkyl" defined above are substituted with an "aralkoxy" defined above, and is a C7-C 14 Aralkoxy C1-C6 alkyl is preferred, C7-C 14 Aralkoxy C1-C2 alkyl is more preferred. Specific examples of aralkoxy alkyl include benzyloxymethyl and 1-(benzyloxy)ethyl.

[0064] As used herein, the term "heteroarylalkyl" refers to a group in which at least one hydrogen atom of an "alkyl" as defined above is substituted with a "heteroaryl" as defined above, preferably a 5- to 10-membered heteroaryl C1-C6 alkyl, and more preferably a 5- to 10-membered heteroaryl C1-C2 alkyl. Specific examples of heteroarylalkyl include 3-thienylmethyl, 4-thiazolylmethyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 2-(2-pyridyl)ethyl, 2-(3-pyridyl)ethyl, 2-(4-pyridyl)ethyl, 2-(6-quinolyl)ethyl, 2-(7-quinolyl)ethyl, 2-(6-indolyl)ethyl, 2-(5-indolyl)ethyl, and 2-(5-benzofuranyl)ethyl.

[0065] As used herein, "heteroarylalkoxy" refers to an oxy group bonded to the above-defined "heteroarylalkyl," and is preferably a 5- to 10-membered heteroaryl C1-C6 alkoxy, more preferably a 5- to 10-membered heteroaryl C1-C2 alkoxy. Specific examples of heteroarylalkoxy include 3-thienylmethoxy and 3-pyridylmethoxy.

[0066] As used herein, "heteroarylalkoxyalkyl" refers to a group in which one or more hydrogen atoms of an "alkyl" as defined above are substituted with a "heteroarylalkoxy" as defined above, preferably a 5- to 10-membered heteroaryl C1-C6 alkoxy C1-C6 alkyl, more preferably a 5- to 10-membered heteroaryl C1-C2 alkoxy C1-C2 alkyl. Specific examples of heteroarylalkoxyalkyl include 3-pyridylmethoxymethyl.

[0067] As used herein, "heterocycloalkylidenealkyl" refers to a group in which one or more hydrogen atoms of an "alkyl" defined above are substituted with a "heterocycloalkylidene" defined above, and is preferably a 4- to 7-membered heterocycloalkylideneC1-C6 alkyl, more preferably a 4- to 7-membered heterocycloalkylideneC1-C2 alkyl. Specific examples of heterocycloalkylidenealkyl include tetrahydro-4H-pyran-4-ylidenemethyl and azetidin-3-ylidenemethyl.

[0068] As used herein, "alkoxyalkenyl" refers to a group in which one or more hydrogen atoms of an "alkenyl" as defined above are substituted with an "alkoxy" as defined above, and C1-C6 alkoxyC2-C6 alkenyl is preferred. Specific examples of alkoxyalkenyl include (E)-4-methoxybut-2-en-1-yl.

[0069] As used herein, "aminocarbonylalkenyl" refers to a group in which one or more hydrogen atoms of an "alkenyl" defined above are substituted with an "aminocarbonyl" defined above, and aminocarbonyl C2-C6 alkenyl is preferred. Specific examples of aminocarbonylalkenyl include (E)-3-(dimethylaminocarbonylcarbonyl)-prop-2-en-1-yl.

[0070] As used herein, "haloalkoxy" refers to a group in which one or more hydrogen atoms of the "alkoxy" defined above have been substituted with halogen atoms, and C1-C6 haloalkoxy is preferred. Specific examples of haloalkoxy include difluoromethoxy, trifluoromethoxy, 2,2-difluoroethoxy, and 2,2,2-trifluoroethoxy.

[0071] As used herein, "alkylene" refers to a divalent group derived by further removing one optional hydrogen atom from the aforementioned "alkyl," with C4-C8 alkylene being preferred. Specific examples of alkylene include -CH2-, -(CH2)2-, -(CH2)3-, -CH(CH3)CH2-, -C(CH3)2-, -(CH2)4-, -CH(CH3)CH2CH2-, -C(CH3)2CH2-, -CH2CH(CH3)CH2-, -CH2C(CH3)2-, -CH2CH2CH(CH3)-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, and the like.

[0072] As used herein, "alicyclic ring" refers to a non-aromatic hydrocarbon ring. The alicyclic ring may have an unsaturated bond within the ring, or may be a polycyclic ring having two or more rings. Furthermore, the carbon atoms constituting the ring may be oxidized to form a carbonyl. Preferred examples of the alicyclic ring include 3- to 8-membered alicyclic rings, and specific examples include a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclohexane ring, a cycloheptane ring, a cyclooctane ring, and a bicyclo[2.2.1]heptane ring.

[0073] As used herein, the term "saturated heterocycle" refers to a non-aromatic heterocycle containing 1 to 5 heteroatoms in addition to carbon atoms and no double and / or triple bonds within the ring. The saturated heterocycle may be a monocycle or may form a condensed ring with another ring, for example, an aromatic ring such as a benzene ring. Preferred examples of the saturated heterocycle include 4- to 7-membered saturated heterocycles, such as an azetidine ring, an oxetane ring, a tetrahydrofuran ring, a tetrahydropyran ring, a morpholine ring, a thiomorpholine ring, a pyrrolidine ring, a 4-oxopyrrolidine ring, a piperidine ring, a 4-oxopiperidine ring, a piperazine ring, a pyrazolidine ring, an imidazolidine ring, an oxazolidine ring, an isoxazolidine ring, a thiazolidine ring, an isothiazolidine ring, a thiadiazolidine ring, an oxazolidone ring, a dioxolane ring, a dioxane ring, a thietane ring, an octahydroindole ring, and an indoline ring.

[0074] As used herein, the term "peptide chain" refers to a peptide chain in which 1, 2, 3, 4, or more natural amino acids and / or unnatural amino acids are linked by amide bonds and / or ester bonds. The peptide chain preferably contains 1 to 4 amino acid residues, and more preferably consists of 1 to 4 amino acid residues.

[0075] As used herein, the term "optionally substituted" means that a group may be substituted with any substituent.

[0076] As used herein, the term "optionally protected" means that a group may be protected by any protecting group.

[0077] As used herein, "one or more" means one or more than one. When "one or more" is used in the context of substituents on a group, the term means from one to the maximum number of substituents permitted by that group. Specific examples of "one or more" include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and / or more.

[0078] The compounds disclosed herein can be in the form of salts, preferably chemically or pharmaceutically acceptable salts. The compounds disclosed herein or their salts can also be in the form of solvates, preferably chemically or pharmaceutically acceptable solvates. Examples of salts of the compounds disclosed herein include hydrochlorides, hydrobromides, hydroiodides, phosphates, phosphonates, sulfates, sulfonates such as methanesulfonates and p-toluenesulfonates, carboxylates such as acetates, citrates, malates, tartrates, succinates, and salicylates, alkali metal salts such as sodium salts and potassium salts, alkaline earth metal salts such as magnesium salts and calcium salts, and ammonium salts such as ammonium salts, alkylammonium salts, dialkylammonium salts, trialkylammonium salts, and tetraalkylammonium salts. These salts can be prepared, for example, by contacting the compound with an acid or base that can be used in the manufacture of pharmaceuticals. In the present invention, a solvate of a compound refers to a phenomenon in which solute molecules strongly attract solvent molecules in a solution to form a single molecular group, and when the solvent is water, it is called a hydrate. As the solvate of a compound disclosed herein, a hydrate is preferred, and specific examples of such a hydrate include mono- to decahydrates, preferably mono- to pentahydrates, and more preferably mono- to trihydrates. The solvates of the compounds disclosed herein include solvates with a single solvent such as water, alcohols (e.g., methanol, ethanol, 1-propanol, 2-propanol, etc.), and dimethylformamide, as well as solvates with multiple solvents.

[0079] As used herein, "amino acid" includes natural amino acids and unnatural amino acids. As used herein, "natural amino acids" refers to Gly, Ala, Ser, Thr, Val, Leu, Ile, Phe, Tyr, Trp, His, Glu, Asp, Gln, Asn, Cys, Met, Lys, Arg, and Pro. Examples of unnatural amino acids include, but are not limited to, β-amino acids, γ-amino acids, D-amino acids, N-substituted amino acids, α,α-disubstituted amino acids, amino acids with unnatural side chains, and hydroxycarboxylic acids. As used herein, amino acids may have any configuration. The side chain of an amino acid is not particularly limited and may be freely selected from, in addition to a hydrogen atom, alkyl groups, alkenyl groups, alkynyl groups, aryl groups, heteroaryl groups, aralkyl groups, and cycloalkyl groups. In these groups, one or two non-adjacent methylene groups may be substituted with an oxygen atom, a carbonyl group (-CO-), or a sulfonyl group (-SO-). Each of these may have a substituent, and the substituents are not limited, and may be independently selected from any substituents containing, for example, a halogen atom, an O atom, an S atom, an N atom, a B atom, an Si atom, or a P atom. Examples of such substituents include optionally substituted alkyl groups, alkenyl groups, alkynyl groups, aryl groups, heteroaryl groups, aralkyl groups, and cycloalkyl groups. In a non-limiting embodiment, the amino acid herein may be a compound having a carboxy group and an amino group in the same molecule (even in this case, imino acids such as proline and hydroxyproline are also included in the definition of amino acids).

[0080] The main chain amino group of an amino acid may be unsubstituted (NH group) or substituted (i.e., -NHR group: R represents an alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, or cycloalkyl group which may have a substituent, and one or two non-adjacent methylene groups in these groups may be substituted with an oxygen atom, a carbonyl group (-CO-), or a sulfonyl group (-SO2-), and the carbon chain bonded to the N atom and the carbon atom at the α-position may form a ring, as in proline). The substituent for R is selected in the same manner as the substituent in the amino acid side chain described above. When the main chain amino group is substituted, R is included in the "amino acid side chain" herein. An amino acid having such a substituted main chain amino group is referred to herein as an "N-substituted amino acid." Preferred examples of the "N-substituted amino acid" herein include, but are not limited to, N-alkylamino acid, N-C1-C6 alkylamino acid, N-C1-C4 alkylamino acid, and N-methylamino acid.

[0081] The "amino acids" constituting the peptide compounds herein include all corresponding isotopes. An isotope of an "amino acid" is one in which at least one atom has been replaced with an atom having the same atomic number (number of protons) but a different mass number (sum of the number of protons and neutrons). Examples of isotopes contained in the "amino acids" constituting the peptide compounds disclosed herein include hydrogen atoms, carbon atoms, nitrogen atoms, oxygen atoms, phosphorus atoms, sulfur atoms, fluorine atoms, and chlorine atoms, each of which is 2 H, 3 H, 13 C. 14 C. 15 N, 17 O. 18 O. 31 P, 32 P, 35 S, 18 F, 36 Includes Cl etc.

[0082] In this specification, examples of the substituent containing a halogen atom include an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, an aralkyl group, and the like, each of which has a halogen atom as a substituent, and more specific examples thereof include a fluoroalkyl, a difluoroalkyl, a trifluoroalkyl, and the like.

[0083] Examples of the substituent containing an O atom include hydroxy (-OH), oxy (-OR), carbonyl (-C=OR), carboxy (-COH), oxycarbonyl (-C=O-OR), carbonyloxy (-OC=OR), thiocarbonyl (-C=O-SR), carbonylthio (-SC=OR), aminocarbonyl (-C=O-NHR), carbonylamino (-NH-C=OR), oxycarbonylamino (-NH-C=O-OR), sulfonylamino (-NH-SO-R), aminosulfonyl (-SO-NHR), sulfamoylamino (-NH-SO-NHR), thiocarboxyl (-C=O-SH), and carboxylcarbonyl (-C=O-COH).

[0084] Examples of oxy (—OR) include alkoxy, cycloalkoxy, alkenyloxy, alkynyloxy, aryloxy, heteroaryloxy, aralkyloxy, etc. As alkoxy, C1-C4 alkoxy and C1-C2 alkoxy are preferred, and among these, methoxy or ethoxy is preferred.

[0085] Examples of carbonyl (-C=OR) include formyl (-C=OH), alkylcarbonyl, cycloalkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, arylcarbonyl, heteroarylcarbonyl, aralkylcarbonyl, and the like.

[0086] Examples of oxycarbonyl (-C=O-OR) include alkyloxycarbonyl, cycloalkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkyloxycarbonyl, and the like.

[0087] Examples of carbonyloxy (-OC=OR) include alkylcarbonyloxy, cycloalkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy, aralkylcarbonyloxy, and the like.

[0088] Examples of thiocarbonyl (-C=O-SR) include alkylthiocarbonyl, cycloalkylthiocarbonyl, alkenylthiocarbonyl, alkynylthiocarbonyl, arylthiocarbonyl, heteroarylthiocarbonyl, aralkylthiocarbonyl, and the like.

[0089] Examples of carbonylthio (-SC=OR) include alkylcarbonylthio, cycloalkylcarbonylthio, alkenylcarbonylthio, alkynylcarbonylthio, arylcarbonylthio, heteroarylcarbonylthio, aralkylcarbonylthio, and the like.

[0090] Examples of aminocarbonyl (-C=O-NHR) include alkylaminocarbonyl (e.g., C1-C6 or C1-C4 alkylaminocarbonyl, particularly ethylaminocarbonyl, methylaminocarbonyl, etc.), cycloalkylaminocarbonyl, alkenylaminocarbonyl, alkynylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl, etc. In addition to these, compounds in which the H atom bonded to the N atom in -C=O-NHR is further substituted with alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl are also included.

[0091] Examples of carbonylamino (-NH-C=OR) include alkylcarbonylamino, cycloalkylcarbonylamino, alkenylcarbonylamino, alkynylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, aralkylcarbonylamino, etc. In addition to these, compounds in which the H atom bonded to the N atom in -NH-C=OR is further substituted with alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl are also included.

[0092] Examples of oxycarbonylamino (-NH-C=O-OR) include alkoxycarbonylamino, cycloalkoxycarbonylamino, alkenyloxycarbonylamino, alkynyloxycarbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino, aralkyloxycarbonylamino, etc. In addition to these, compounds in which the H atom bonded to the N atom in -NH-C=O-OR is further substituted with alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl are also included.

[0093] Examples of sulfonylamino (-NH-SO2-R) include alkylsulfonylamino, cycloalkylsulfonylamino, alkenylsulfonylamino, alkynylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, aralkylsulfonylamino, etc. In addition to these, compounds in which the H atom bonded to the N atom in -NH-SO2-R is further substituted with alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl are also included.

[0094] Examples of aminosulfonyl (-SO2-NHR) include alkylaminosulfonyl, cycloalkylaminosulfonyl, alkenylaminosulfonyl, alkynylaminosulfonyl, arylaminosulfonyl, heteroarylaminosulfonyl, aralkylaminosulfonyl, etc. In addition to these, compounds in which the H atom bonded to the N atom in -SO2-NHR is further substituted with alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl are also included.

[0095] Examples of sulfamoylamino (-NH-SO-NHR) include alkylsulfamoylamino, cycloalkylsulfamoylamino, alkenylsulfamoylamino, alkynylsulfamoylamino, arylsulfamoylamino, heteroarylsulfamoylamino, aralkylsulfamoylamino, etc. Furthermore, the two H atoms bonded to the N atom in -NH-SO-NHR may be substituted with substituents independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl, and these two substituents may form a ring.

[0096] Substituents containing an S atom include thiol (-SH), thio (-SR), sulfinyl (-S=OR), sulfonyl (-SO2-R), and sulfo (-SO3H).

[0097] Examples of thio (-SR) are selected from alkylthio, cycloalkylthio, alkenylthio, alkynylthio, arylthio, heteroarylthio, aralkylthio, and the like.

[0098] Examples of sulfonyl (-SO2-R) include alkylsulfonyl, cycloalkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, and the like.

[0099] Examples of substituents containing an N atom include azide (-N3, also referred to as an "azido group"), cyano (-CN), primary amino (-NH2), secondary amino (-NH-R; also referred to as monosubstituted amino), tertiary amino (-NR(R'; also referred to as disubstituted amino), amidino (-C(=NH)-NH2), substituted amidino (-C(=NR)-NR'R"), guanidino (-NH-C(=NH)-NH2), substituted guanidino (-NR-C(=NR''')-NR'R"), aminocarbonylamino (-NR-CO-NR'R"), pyridyl, piperidino, morpholino, and azetidinyl.

[0100] Examples of secondary amino (-NH-R; monosubstituted amino) include alkylamino, cycloalkylamino, alkenylamino, alkynylamino, arylamino, heteroarylamino, aralkylamino, and the like.

[0101] Examples of tertiary amino (-NR(R'); disubstituted amino) include an amino group having any two substituents independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, etc., such as alkyl(aralkyl)amino, and these two substituents may form a ring. Specific examples include dialkylamino, particularly C1-C6 dialkylamino, C1-C4 dialkylamino, dimethylamino, diethylamino, etc. In the present specification, the term "C p -C q "Dialkylamino group" means an amino group with C p -C q A group substituted with two alkyl groups, both C p -C q The alkyl groups may be the same or different.

[0102] Examples of substituted amidino (-C(=NR)-NR'R") include groups in which the three substituents R, R', and R" on the N atom are each independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl, such as alkyl(aralkyl)(aryl)amidino.

[0103] Examples of substituted guanidino (-NR-C(=NR''')-NR'R") include groups in which R, R', R", and R''' are each independently selected from alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl, or groups in which these groups form a ring.

[0104] Examples of aminocarbonylamino (-NR-CO-NR'R") include groups in which R, R', and R" are each independently selected from a hydrogen atom, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, and aralkyl, or groups in which these groups form a ring.

[0105] In this specification, the "amino acid residues" that constitute a peptide compound may be simply referred to as "amino acids".

[0106] In one aspect, the present invention relates to a cyclic peptide compound represented by the following formula (1): or a salt thereof, or a solvate thereof: [ka] In formula (1), a ring is formed from 11 amino acid residues. In this specification, amino acid residues having P1, Q1, R1, and L1 in the formula are referred to as core 1, amino acid residues having P2, Q2, and R2 are referred to as core 2, amino acid residues having P3, Q3, and R3 are referred to as core 3, amino acid residues having P4, Q4, and R4 are referred to as core 4, amino acid residues having P5, Q5, and R5 are referred to as core 5, amino acid residues having P6, Q6, and R6 are referred to as core 6, amino acid residues having P7, Q7, and R7 are referred to as core 7, amino acid residues having P8, Q8, and R8 are referred to as core 8, amino acid residues having P9, Q9, and R9 are referred to as core 9, 10 , Q 10 , and R 10 The amino acid residues having the core 10, P 11 , Q 11 , R 11 , and L 11 The amino acid residues having the following structure are sometimes referred to as core 11 amino acid residues.

[0107] In some embodiments, in formula (1), L1 is a single bond, or -CHM1-, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2) n S(O)2(CH2) m - and L 11 is a single bond or -CHM 11 -, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2) n S(O)2(CH2) m - where L1 and L 11 One of L1 is a single bond. That is, when L1 is a single bond, 11 Ha-CHM 11 -, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2)n S(O)2(CH2) m - and L 11 is a single bond, L1 is -CHM1-, -(CH2) n S(CH2) m -, -(CH2) n S(O)(CH2) m - or -(CH2) n S(O)2(CH2) m M1 is hydrogen, except when R1 and M1 form a 3- to 8-membered alicyclic ring. 11 is R 11 and M 11 is hydrogen except when it forms a 3- to 8-membered alicyclic ring.

[0108] L1 or L 11 But -(CH2) n S(CH2) m -, -(CH2) n S(CH2) m Specific examples of - include -CH2SCH2-, -CH2CH2SCH2-, -CH2SCH2CH2-, -CH2CH2SCH2CH2-, and the like.

[0109] L1 or L 11 But -(CH2) n S(O)(CH2) m -, -(CH2) n S(O)(CH2) m Specific examples of - include -CH2S(O)CH2-, -CH2CH2S(O)CH2-, -CH2S(O)CH2CH2-, -CH2CH2S(O)CH2CH2-, and the like.

[0110] L1 or L 11 But -(CH2) n S(O)2(CH2) m -, -(CH2) n S(O)2(CH2) mSpecific examples of - include -CH2S(O)2CH2-, -CH2CH2S(O)2CH2-, -CH2S(O)2CH2CH2-, -CH2CH2S(O)2CH2CH2-, and -CH2CH2S(O)2CH2CH2-.

[0111] In one embodiment, in formula (1), R1 is hydrogen, C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, or C3-C8 cycloalkoxyC1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino), and C1-C6 alkylsulfonyl.

[0112] When Core 1 is an α-amino acid (i.e., L1 is a single bond), R1 is preferably C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkylsulfonylC1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl (the C1-C6 alkoxyC1-C6 alkyl is optionally substituted with one or more halogen, aminocarbonyl (the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino), or hydroxy), C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, or C3-C8 cycloalkoxyC1-C6 alkyl.

[0113] In this embodiment, R1 is more preferably C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C4 hydroxyalkyl, methylsulfonylC1-C2 alkyl, C2-C3 alkynyl; C1-C6 alkoxyC1-C2 alkyl optionally substituted with one or more fluorines, monoC1-C4 alkylaminocarbonyl, or hydroxy; C3-C6 cycloalkyl, C3-C6 cycloalkylC1-C2 alkyl, or C3-C6 cycloalkoxyC1-C2 alkyl.

[0114] In this embodiment, specific examples of R1 include methyl, ethyl, i-propyl, n-propyl, 2-methylpropyl, 1-methylpropyl, n-butyl, n-hexyl, 3-methylbutyl, 2-methylbutyl, n-pentyl, but-3-yn-1-yl, propargyl, (2-hydroxy-2-methyl-propyloxy)methyl, (2-(t-butylamino)-2-oxoethoxy)methyl, 3,3-difluorobutyl, n-propoxymethyl, hydroxymethyl, 2,2,2-trifluoroethyl, 5,5-difluoropentyl, methoxymethyl, 3-methylbutoxymethyl, 1-hydroxyethyl, cyclobutoxymethyl, (2,2,2-trifluoroethoxy)methyl, 1-methoxyethyl, 2-methoxyethyl, 2-methylsulfonylethyl, cyclohexyl, cyclobutyl, cyclopropyl, cyclopentyl, cyclohexylmethyl, cyclopentylmethyl, cyclobutylmethyl, cyclopropylmethyl, cyclopropoxymethyl, and the like.

[0115] When Core 1 is a β-amino acid (ie, L1 is -CHM1-), R1 is preferably hydrogen.

[0116] In one embodiment, in formula (1), R1 and P1 can be joined together with the carbon atom to which R1 is bonded and the nitrogen atom to which P1 is bonded to form a 4- to 7-membered saturated heterocycle.

[0117] When R1 and P1 form a 4- to 7-membered saturated heterocycle, the 4- to 7-membered saturated heterocycle is preferably an azetidine ring, a pyrrolidine ring, a piperidine ring, a piperazine ring, or a morpholine ring.

[0118] In some embodiments, in formula (1), R1 and Q1 can be taken together with the carbon atoms to which they are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring.

[0119] When R1 and Q1 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, the 3- to 8-membered alicyclic ring is preferably a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, or a cyclohexane ring, and the 4- to 7-membered saturated heterocyclic ring is preferably a tetrahydrofuran ring or a tetrahydropyran ring.

[0120] In one embodiment, in formula (1), when Core 1 is a β-amino acid, R1 and M1 can be joined together with the carbon atom to which R1 is bonded and the carbon atom to which M1 is bonded to form a 3- to 8-membered alicyclic ring.

[0121] When R1 and M1 form a 3- to 8-membered alicyclic ring, the 3- to 8-membered alicyclic ring is preferably a cyclopentane ring or a cyclohexane ring.

[0122] In one embodiment, in formula (1), when Core 1 is a β-amino acid, M1 is hydrogen, except when R1 and M1 form a 3- to 8-membered alicyclic ring.

[0123] In one embodiment, in formula (1), except when R1 and P1 form a 4- to 7-membered saturated heterocycle, P1 is hydrogen or C1-C6 alkyl, and the C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino).

[0124] P1 is preferably hydrogen or C1-C6 alkyl, and specific examples of such P1 include hydrogen, methyl, ethyl, and n-propyl.

[0125] In certain embodiments, Q1 is hydrogen or C1-C6 alkyl, preferably hydrogen, except when R1 and Q1 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring.

[0126] When core 1 is an α-amino acid, specific examples of core 1 include MeAla, Ala, Pic(2), MeLeu, MeCha, MeVal, EtAla, nPrAla, MeSer(tBuOH), MeSer(NtBu-Aca), MeAla(cPent), MeAla(cBu), MeAla(cPr), MeChg, MeGly(cPent), MeGly(cBu), MeGly(cPr), MeAbu, MeNva, MeNle, and V. al, Leu, MeAOC(2), MeNva(5-F2), MeHle, MeIle, MeSer(nPr), MeSer(cPr), MeSer, MeAbu(4-F3), MeHnl, MeHnl(7-F2), MePRA , MeSer(Me), MeSer(iPen), MeThr, MeSer(cBu), MeSer(Tfe), MeThr(Me), MeHse(Me), MeMet(O2), MeAhxy(2), and EtLeu.

[0127] When core 1 is a β-amino acid, specific examples of core 1 include bAla and bMeAla.

[0128] In certain embodiments, in formula (1), R2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, or C3-C8 cycloalkoxyC1-C6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, cyano, and C1-C6 alkylsulfonyl.

[0129] R2 is preferably C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkylsulfonylC1-C6 alkyl, C1-C6 cyanoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl optionally substituted with one or more halogens, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, or C3-C8 cycloalkoxyC1-C6 alkyl.

[0130] More preferably, R2 is C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C4 hydroxyalkyl, methylsulfonylC1-C2 alkyl, C2-C6 alkenyl, C2-C3 alkynyl, C1-C6 alkoxyC1-C2 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylC1-C2 alkyl, or C3-C6 cycloalkoxyC1-C2 alkyl.

[0131] Specific examples of R2 include methyl, ethyl, n-propyl, i-propyl, n-butyl, 2-methylpropyl, 1-methylpropyl, n-pentyl, 3-methylbutyl, 2-methylbutyl, pentan-3-yl, n-propoxymethyl, cyclopropoxymethyl, hydroxymethyl, 2,2,2-trifluoroethyl, 5,5-difluoropentyl, methoxymethyl, 3-methyl-butoxy-methyl, 2-hydroxyethyl, cyclobutoxymethyl, (2,2,2-trifluoroethoxy)methyl, cyanomethyl, 1-methoxyethyl, 2-methoxyethyl, 2-methylsulfonylethyl, allyl, 3-methylbut-2-en-1-yl, propargyl, cyclohexyl, cyclopentyl, cyclobutyl, cyclopropyl, cyclohexylmethyl, cyclopentylmethyl, cyclobutylmethyl, and cyclopropylmethyl.

[0132] In one embodiment, in formula (1), R2 and P2 can be joined together with the carbon atom to which R2 is bonded and the nitrogen atom to which P2 is bonded to form a 4- to 7-membered saturated heterocycle.

[0133] When R2 and P2 form a 4- to 7-membered saturated heterocycle, the 4- to 7-membered saturated heterocycle is preferably an azetidine ring, a pyrrolidine ring, a piperidine ring, a piperazine ring, or a morpholine ring.

[0134] In some embodiments, in formula (1), R2 and Q2 can be taken together with the carbon atoms to which they are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring.

[0135] When R2 and Q2 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, the 3- to 8-membered alicyclic ring is preferably a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, or a cyclohexane ring, and the 4- to 7-membered saturated heterocyclic ring is preferably a tetrahydrofuran ring or a tetrahydropyran ring.

[0136] In one embodiment, in formula (1), except when R2 and P2 form a 4- to 7-membered saturated heterocycle, P2 is hydrogen or C1-C6 alkyl, and the C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino). P2 is preferably hydrogen.

[0137] In certain embodiments, Q2 is hydrogen or C1-C6 alkyl, preferably hydrogen, except when R2 and Q2 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring.

[0138] Specific examples of core 2 include Ala, Val, Leu, Ile, Nle, PRA, Chg, Cha, Ala(cPent), Ala(cBu), Ala(cPr), Gly(cPent), Gly(cBu), Gly(cPr), Hle, Ser(nPr), Ser(cPr), Ser, Abu(4-F3), Ahp(2), Abu, Nva, Hnl(7-F2), Ser(Me), Ser(iPen), Thr, Algly, Pregly, Ser(cBu), Ser(Tfe), Ala(CN), Thr(Me), Hse(Me), Met(O2), and Nva(3-Et).

[0139] In certain embodiments, in formula (1), R3 is hydrogen, C1-C6 alkyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C3-C8 cycloalkoxyC1-C6 alkyl, or C7-C 14and aralkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of hydroxy, and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino).

[0140] R3 is preferably hydrogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxyC1-C6 alkyl (the C1-C6 alkoxyC1-C6 alkyl may be substituted with aminocarbonyl (the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino) or hydroxy), aminocarbonylC1-C6 alkyl (the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino), C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C3-C8 cycloalkoxyC1-C6 alkyl, or C7-C 14 It is aralkyl.

[0141] More preferably, R3 is hydrogen, C1-C6 alkyl, C1-C4 hydroxyalkyl, mono-C1-C4 alkylaminocarbonyl, C1-C6 alkoxyC1-C2 alkyl optionally substituted with hydroxy, mono-C1-C4 alkylaminocarbonylC1-C2 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylC1-C2 alkyl, benzyl, or phenethyl.

[0142] Specific examples of R3 include hydrogen, methyl, ethyl, n-propyl, i-propyl, n-butyl, 2-methylpropyl, 3-methylbutyl, (2-hydroxy-2-methyl-propyloxy)methyl, (2-(tert-butylamino)-2-oxoethoxy)methyl, n-propoxymethyl, cyclopropoxymethyl, 3-methylbutoxymethyl, 1-hydroxyethyl, 3-methylamino-3-oxo-propyl, cyclohexyl, cyclobutyl, cyclopropyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, benzyl, and phenethyl.

[0143] In one embodiment, in formula (1), R3 and P3 can be joined together with the carbon atom to which R3 is bonded and the nitrogen atom to which P3 is bonded to form a 4- to 7-membered saturated heterocycle.

[0144] When R3 and P3 form a 4- to 7-membered saturated heterocycle, the 4- to 7-membered saturated heterocycle is preferably an azetidine ring, a pyrrolidine ring, a piperidine ring, a piperazine ring, or a morpholine ring.

[0145] In some embodiments, in formula (1), R3 and Q3 can be taken together with the carbon atoms to which they are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring.

[0146] When R3 and Q3 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, the 3- to 8-membered alicyclic ring is preferably a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, or a cyclohexane ring, and the 4- to 7-membered saturated heterocyclic ring is preferably a tetrahydrofuran ring or a tetrahydropyran ring.

[0147] In one embodiment, in formula (1), except when R3 and P3 form a 4- to 7-membered saturated heterocycle, P3 is hydrogen, C1-C6 alkyl, C1-C6 alkoxyC1-C6 alkyl, or C3-C8 cycloalkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino).

[0148] P3 is preferably hydrogen, C1-C6 alkyl, C1-C6 aminoalkyl (the amino is -NH2, protected amino, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which may be substituted with one or more halogens), or C3-C8 cycloalkyl.

[0149] More preferably, P3 is hydrogen, C1-C6 alkyl, C1-C4 alkoxyC1-C2 alkyl, 4- to 8-membered cyclic aminoC1-C2 alkyl optionally substituted with one or more halogens, or C3-C6 cycloalkyl. Specific examples of such P3 include hydrogen, methyl, ethyl, n-propyl, i-propyl, cyclopropyl, n-butyl, i-butyl, 2-ethoxyethyl, and 2-(4,4-difluoro-1-piperidyl)ethyl.

[0150] In certain embodiments, Q3 is hydrogen or C1-C6 alkyl, preferably hydrogen, except when R3 and Q3 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring.

[0151] Specific examples of core 3 include MeAla, Ala, Pic(2), MeLeu, MeCha, MeVal, EtAla, MeSer(tBuOH), MeSer(NtBu-Aca), MeAla(cPent), MeAla(cBu), MeAla(cPr), MeChg, MeGly(cBu), MeGly(cPr), MeAbu, MeNva, MeNle, MeHle, MeSer(nPr), MeSer(cPr), MeSer(iPen), MeThr, Abu, MeGly, EtGly, Gly, nBuGly, iPrGly, cPrGly, nPrGly, iBuGly, (EtOEt)NGly, 2-(pip-4-F2)-EtGly, Pro, Aze(2), MeGln(Me), MePhe, and MeHph.

[0152] In one embodiment, in formula (1), R4 is hydrogen or C1-C6 alkyl, preferably hydrogen or C1-C4 alkyl. Specific examples of R4 include hydrogen and methyl.

[0153] In one embodiment, in formula (1), R4 and P4 can be combined with the carbon atom to which R4 is bonded and the nitrogen atom to which P4 is bonded to form a 4- to 7-membered saturated heterocycle (preferably a 4- or 5-membered saturated heterocycle).

[0154] When R4 and P4 form a 4- to 7-membered saturated heterocycle, the 4- to 7-membered saturated heterocycle is preferably an azetidine ring, a pyrrolidine ring, a piperidine ring, a piperazine ring, or a morpholine ring.

[0155] In some embodiments, in formula (1), R4 and Q4 can be taken together with the carbon atoms to which they are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring.

[0156] When R4 and Q4 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, the 3- to 8-membered alicyclic ring is preferably a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, or a cyclohexane ring, and the 4- to 7-membered saturated heterocyclic ring is preferably a tetrahydrofuran ring or a tetrahydropyran ring.

[0157] In one embodiment, in formula (1), except when R4 and P4 form a 4- to 7-membered saturated heterocycle, P4 is hydrogen, C1-C6 alkyl, or C1-C6 alkoxyC1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino).

[0158] Preferably for P4, P4 is C1-C6 alkyl or C1-C6 alkoxyC1-C6 alkyl.

[0159] P4 is more preferably hydrogen, C1-C6 alkyl, or C1-C4 alkoxyC1-C2 alkyl.Specific examples of P4 include methyl, ethyl, n-propyl, n-butyl, i-propyl, i-pentyl, and 2-ethoxyethyl.

[0160] In certain embodiments, Q4 is hydrogen or C1-C6 alkyl, preferably hydrogen, except when R4 and Q4 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring.

[0161] Specific examples of core 4 include MeAla, Pic(2), MeGly, EtGly, nBuGly, nPrGly, (EtOEt)NGly, Pro, Aze(2), and iPenGly.

[0162] In one embodiment, in formula (1), R5 is selected from the group consisting of C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C3-C8 cycloalkoxyC1-C6 alkyl, C7-C 14 Aralkyl, C6-C 10 Aryloxy C1-C6 alkyl, C7-C 14 aralkoxyC1-C6 alkyl, or 5- to 10-membered heteroarylC1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, cyano, and C1-C6 alkylsulfonyl.

[0163] R5 is preferably C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C2-C6 alkenyl, C1-C6 alkylsulfonylC1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl optionally substituted with one or more halogens, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C3-C8 cycloalkoxyC1-C6 alkyl, C7-C 14 Aralkyl (C7-C 14 Aralkyl is a C-C alkyl group optionally substituted by one or more halogens, C-C alkoxy, C-C haloalkyl, C-C haloalkoxy, or cyano, optionally substituted by one or more halogens. 10 Aryloxy C1-C6 alkyl, C7-C 14 It is aralkoxyC1-C6 alkyl, or 5-10 membered heteroarylC1-C6 alkyl.

[0164] More preferred examples of R5 include C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C4 hydroxyalkyl, C2-C3 alkenyl, C2-C3 alkynyl, methylalkylsulfonylC1-C2 alkyl, C1-C6 alkoxyC1-C2 alkyl optionally substituted with one or more fluorines, C3-C6 cycloalkyl, C3-C6 cycloalkylC1-C2 alkyl, C3-C6 cycloalkoxyC1-C2 alkyl, benzyl or phenethyl optionally substituted with one or more halogens, methyl, methoxy, trifluoromethyl, trifluoromethoxy, or cyano, phenoxyC1-C2 alkyl optionally substituted with one or more halogens, benzyloxyC1-C2 alkyl, and 5- to 6-membered heteroarylC1-C2 alkyl.

[0165] Specific examples of R5 include methyl, ethyl, n-propyl, i-propyl, n-butyl, 2-methylpropyl, 1-methylpropyl, 2-methylbutyl, 3-methylbutyl, n-pentyl, propargyl, 3,3-difluorobutyl, n-propoxymethyl, cyclopropoxymethyl, hydroxymethyl, 2,2,2-trifluoroethyl, 5,5-difluorobutyl, methoxymethyl, 3-methylbutoxymethyl, 1-hydroxyethyl, cyclobutoxymethyl, (2,2,2-trifluoroethoxy)methyl, 1-methoxyethyl, 2-methoxyethyl, 2-methylsulfonylethyl, (2-chlorophenoxy)methyl, allyl, cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclopentylmethyl, cyclohexylmethyl, Cyclobutylmethyl, cyclopropylmethyl, pyridin-3-ylmethyl, phenethyl, 4-chlorobenzyl, 2-cyanobenzyl, 3-cyanobenzyl, 4-ethynylbenzyl, 2-fluorobenzyl, 2-chlorobenzyl, 3-chlorobenzyl, 3-bromobenzyl, 4-bromobenzyl, 2-methylbenzyl, 3-methylbenzyl, 4-methylbenzyl, 2-(trifluoromethyl)benzyl, 3-(trifluoromethyl)benzyl, 4-(trifluoromethyl)benzyl, 4-methoxybenzyl, 2-(trifluoromethoxy)benzyl, 3-(trifluoromethoxy)benzyl, 4-(trifluoromethoxy)benzyl, 3,4-difluorobenzyl, 4-iodobenzyl, benzyl, 3-fluorobenzyl, 4-fluorobenzyl and the like.

[0166] In one embodiment, in formula (1), R5 can be combined with R8 to form a C4-C8 alkylene. As the C4-C8 alkylene, -(CH2)8- is preferred.

[0167] In one embodiment, in formula (1), R5 and P5 can be joined together with the carbon atom to which R5 is bonded and the nitrogen atom to which P5 is bonded to form a 4- to 7-membered saturated heterocycle.

[0168] When R5 and P5 form a 4- to 7-membered saturated heterocycle, the 4- to 7-membered saturated heterocycle is preferably an azetidine ring, a pyrrolidine ring, a piperidine ring, a piperazine ring, or a morpholine ring.

[0169] In some embodiments, in formula (1), R5 and Q5 can be taken together with the carbon atoms to which they are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring.

[0170] When R5 and Q5 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, the 3- to 8-membered alicyclic ring is preferably a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, or a cyclohexane ring, and the 4- to 7-membered saturated heterocyclic ring is preferably a tetrahydrofuran ring or a tetrahydropyran ring.

[0171] In one embodiment, in formula (1), except when R5 and P5 form a 4- to 7-membered saturated heterocycle, P5 is hydrogen or C1-C6 alkyl, and the C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino).

[0172] P5 is preferably hydrogen or C1-C2 alkyl, and specific examples include hydrogen, methyl, and ethyl.

[0173] In certain embodiments, Q5 is hydrogen or C1-C6 alkyl, preferably hydrogen, except when R5 and Q5 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring.

[0174] Specific examples of core 5 include MeAla, MeLeu, MeCha, MeVal, MeAla(cPent), MeAla(cBu), MeAla(cPr), MeChg, MeGly(cPent), MeGly(cBu), MeGly(cPr), MeAbu, MeNva, MeNle, MeNva(5-F2), MeHle, MeIle, MeSer(nPr), and MeSer. (cPr), MeSer, MeAbu(4-F3), MeHnl, MeHnl(7-F2), MePRA, MeSer(Me), MeSer(iPen), MeThr, MeSer(cBu), MeSer(Tfe), MeThr(Me), MeHse(Me), MeMet(O2), MePhe, MeHph, MePhe(4-Cl), MeThr(Bn), EtPhe(4-Cl), M ePhe(2-CN), MePhe(3-CN), MePhe(4-CN), MePhe(2-F), MePhe(3-F), MePhe(4-F), MePhe(2-Cl), MePhe(3 -Cl), MePhe(3-Br), MePhe(4-Br), MePhe(2-Me), MePhe(3-Me), MePhe(4-Me), MePhe(2-CF3), MePhe(3-CF 3), MePhe(4-CF3), MeTyr(Me), MePhe(2-OCF3), MePhe(3-OCF3), MePhe(4-OCF3), MeSer(Ph-2-Cl), MeAlgly, MePhe(34-F2), MeAla(3-Pyr), MePhe(4-I), EtCha, EtPhe(4-Me), EtPhe(4-CF3), and Phe(4-Me).

[0175] In one embodiment, in formula (1), R6 is hydrogen or C1-C6 alkyl, preferably hydrogen or C1-C3 alkyl. Specific examples of R6 include hydrogen and methyl.

[0176] In one embodiment, in formula (1), R6 and P6 can be joined together with the carbon atom to which R6 is bonded and the nitrogen atom to which P6 is bonded to form a 4- to 7-membered saturated heterocycle.

[0177] When R6 and P6 form a 4- to 7-membered saturated heterocycle, the 4- to 7-membered saturated heterocycle is preferably an azetidine ring, a pyrrolidine ring, a piperidine ring, a piperazine ring, or a morpholine ring.

[0178] In some embodiments, in formula (1), R6 and Q6 can be taken together with the carbon atoms to which they are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring.

[0179] When R6 and Q6 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, the 3- to 8-membered alicyclic ring is preferably a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, or a cyclohexane ring, and the 4- to 7-membered saturated heterocyclic ring is preferably a tetrahydrofuran ring or a tetrahydropyran ring.

[0180] In one embodiment, in formula (1), except when R6 and P6 form a 4- to 7-membered saturated heterocycle, P6 is C1-C6 alkyl or C3-C8 cycloalkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxyamino (the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino).

[0181] P6 is preferably C1-C6 alkyl or C3-C8 cycloalkyl, more preferably C1-C4 alkyl or C3-C6 cycloalkyl. Specific examples of such P6 include methyl, ethyl, cyclopropyl, etc.

[0182] In certain embodiments, Q6 is hydrogen or C1-C6 alkyl, preferably hydrogen, except when R6 and Q6 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring.

[0183] Specific examples of core 6 include MeAla, MeGly, EtGly, cPrGly, D-Pro, D-MeAla, and D-Pic(2).

[0184] In some embodiments, in formula (1), R7 is C6-C 10 Aryloxy C1-C6 alkyl, C7-C 14 Aralkyl, C7-C 14 aralkoxyC1-C6 alkyl, or 5-10 membered heteroarylC1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkoxy, cyano, C1-C6 alkylsulfonyl, and SF5.

[0185] R7 is preferably C6-C 10 Aryloxy C1-C6 alkyl (the C6-C 10 AryloxyC1-C6 alkyl may be substituted by one or more groups independently selected from the group consisting of halogen and C1-C6 haloalkyl), C7-C 14 Aralkyl (C7-C 14 Aralkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkynyl, cyano, C1-C6 alkylsulfonyl, and SF5), C7-C6 optionally substituted by one or more halogens. 14 aralkoxyC1-C6 alkyl, or 5-10 membered heteroarylC1-C6 alkyl (the 5-10 membered heteroarylC1-C6 alkyl is optionally substituted by one or more halogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxy).

[0186] More preferably, R7 is -(CH2) optionally substituted by 1 to 5 groups independently selected from the group consisting of halogen, C1-C4 alkyl (preferably methyl), C2-C4 alkynyl (preferably ethynyl), C1-C3 haloalkyl (preferably difluoromethyl, trifluoromethyl), C1-C3 haloalkoxy (preferably difluoromethoxy, trifluoromethoxy), C1-C4 alkoxy (preferably methoxy, ethoxy, isopropoxy, n-butoxy, t-butoxy), -CN, C1-C3 alkylsulfonyl (preferably methylsulfonyl), and SF5. x -O y -(CH2) z1 -C6-C 10 Aryl or -(CH2) x -O y -(CH2) z2 -5 to 10-membered heteroaryl, where x is 1, 2, or 3, y is 0 or 1, z1 is 0, 1, 2, or 3, and z2 is 1, 2, or 3, provided that the sum of x, y, and z1 or z2 is 1 to 4. Such -(CH2) x -O y -(CH2) z1 -C6-C 10 Aryl or -(CH2) x -O y -(CH2) z2 -5 to 10-membered heteroaryl is preferably -CH2-C6-C 10 Aryl or -(CH2)2-C6-C 10 Aryl, which may be substituted by the above groups. -(CH2) x -O y -(CH2) z1 -C6-C 10 When the aryl has a substituent, the substituent is a C-C 10 Preferably on the aryl, -(CH2) x -O y -(CH2) z2 When the 5- to 10-membered heteroaryl has a substituent, the substituent is preferably on the 5- to 10-membered heteroaryl in the group.

[0187] Specific examples of R7 include ((4-chlorobenzyl)oxy)methyl, 2-(4-chlorophenoxy)ethyl, 2-(3,4-dichlorophenoxy)ethyl, 2-(4-(trifluoromethylphenoxy))ethyl, (4-chlorophenoxy)methyl, ((3-chlorobenzyl)oxy)methyl, ((2-chlorobenzyl)oxy)methyl, 3-iodobenzyl, 3-chlorobenzyl, 3-methylbenzyl, 3-fluorobenzyl, 3,5-difluorobenzyl, 4-methylphenethyl, 4-(trifluoromethyl)phenoxy, ethyl, 3-chloro-5-fluorobenzyl, 3-cyanobenzyl, 3-(trifluoromethoxy)benzyl, benzyl, 4-fluorophenethyl, 2-fluoro-4-(trifluoromethyl)phenethyl, 3-chlorophenethyl, 4-chlorophenethyl, 3-fluoro-4-(trifluoromethyl)phenethyl, 2,3,4,5,6-pentafluorophenethyl, 2,4,5-trifluorophenethyl, 2,5-difluorophenethyl, 2-fluoro-4-chlorophenethyl, 2,4-difluorophenethyl, 2-fluoro-6-chlorophenethyl chlorophenethyl, 2,4,6-trifluorophenethyl, 3-chloro-4-(trifluoromethyl)phenethyl, 3-trifluoromethylphenethyl, 4-(pentafluoro-λ6-sulfanyl)phenethyl, 3,5-difluoro-4-(trifluoromethyl)phenethyl, 3-methoxybenzyl, 3,5-dichlorobenzyl, 3-chloro-4-fluorobenzyl, phenethyl, 3,4-dichlorophenethyl, 3-bromobenzyl, 4-fluorobenzyl, 2-fluoro-5-iodobenzyl, 2-chloro-5-iodobenzyl, 3-ethynylbenzyl, 3-fluorophenethyl, 3-phenylpropyl, 2-fluorobenzyl, 2-fluoro-3-iodobenzyl, 2-fluoro-3-bromobenzyl, 3-iodo-5-fluorobenzyl, 3-iodo-5-chlorobenzyl, 3-bromo-5-fluorobenzyl, 2-bromo-5-iodobenzyl, 2-methyl-5-iodobenzyl, 2-fluoro-5-methylbenzyl, 2-chloro-5-bromobenzyl, 2-methyl-5-bromobenzyl, 2,3-difluorobenzyl, 2,5-difluorobenzyl, 2,6-Difluorobenzyl, 3-fluoro-4-(difluoromethoxy)phenethyl, 3-cyano-4-(trifluoromethyl)phenethyl, 3-methoxy-4-(trifluoromethyl)phenethyl, 2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)ethyl, 3-chloro-4-(trifluoromethoxy)phenethyl, 3-fluoro-4-(trifluoromethoxy)phenethyl, 4-(methylsulfonyl)phenethyl, 3-fluoro-4-(difluoromethyl)phenethyl, 3,4,5-trichlorophenethyl, 3,4-dichloro-5-methoxyphenethyl, 3,4-dichloro-5-cyanophenethyl, 3,4-dichloro-5-isopropoxyphenethyl, 3,4-dichloro-5-(n-butoxy)phenethyl, 3,4- Examples include dichloro-5-(t-butoxy)phenethyl, 3-(4-(trifluoromethyl)phenyl)propyl, (5-chlorothiophen-2-yl)methyl, (5-bromothiophen-2-yl)methyl, (5-bromopyridin-3-yl)methyl, 2-(6-(trifluoromethyl)pyridin-3-yl)ethyl, 2-(quinolin-6-yl)ethyl, 2-(1-methyl-1H-indol-6-yl)ethyl, 2-(1-methyl-1H-indol-5-yl)ethyl, 2-(6-methoxypyridin-3-yl)ethyl, 2-(benzofuran-5-yl)ethyl, 2-(6-(difluoromethyl)pyridin-3-yl)ethyl, 2-(5-(trifluoromethyl)pyridin-2-yl)ethyl, and 2-(quinolin-7-yl)ethyl.

[0188] In one embodiment, in formula (1), R7 and P7 can be joined together with the carbon atom to which R7 is bonded and the nitrogen atom to which P7 is bonded to form a 4- to 7-membered saturated heterocycle.

[0189] When R7 and P7 form a 4- to 7-membered saturated heterocycle, the 4- to 7-membered saturated heterocycle is preferably an azetidine ring, a pyrrolidine ring, a piperidine ring, a piperazine ring, or a morpholine ring.

[0190] In some embodiments, in formula (1), R7 and Q7 can be taken together with the carbon atoms to which they are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring.

[0191] When R7 and Q7 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, the 3- to 8-membered alicyclic ring is preferably a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, or a cyclohexane ring, and the 4- to 7-membered saturated heterocyclic ring is preferably a tetrahydrofuran ring or a tetrahydropyran ring.

[0192] In one embodiment, in formula (1), except when R7 and P7 form a 4- to 7-membered saturated heterocycle, P7 is hydrogen or C1-C6 alkyl, and the C1-C6 alkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), and aminocarbonyl (the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino). P7 is preferably hydrogen.

[0193] In some embodiments, Q7 is hydrogen, C1-C6 alkyl, or C7-C7 alkyl, except when R7 and Q7 form a 3-8 membered alicyclic ring or a 4-7 membered saturated heterocyclic ring. 14 It is aralkyl, preferably hydrogen.

[0194] Specifically as the core 7, for example, Phe(3-Cl), Phe(3-Me), Phe(3-F), Phe(35-F2), Hph(4-Me), Hph(4-CF3), Phe(3-Cl-5-F), Phe(3-I), Phe(3-CN), Phe(3-OCF3), Phe, Hph(4-F), Hph(4-CF3-2-F), Hph(3-Cl), Hph(4-Cl), Hph(4-CF3-3-F), Hph(F5), Hph(245-F3), Hph(2-F-5-Cl), Hph(2-F-4-Cl), Hph(24-F2), Hph(2-F-6-Cl), Hph(246-F3), Hph(4-CF3-3-Cl), Hph(3-CF3), Hph(4-SF5), Hph(4-CF3-35-F2), Phe(3-OMe), Phe(35-Cl2), Phe(3-Cl-4-F), Hph, Hph(34-Cl2), Phe(3-Br), Phe(4-F), Phe(2-F-5-I), Phe(2-Cl-5-I), Ala(2-Thie-5-Cl), Ala(2-Thie-5-Br), (Me)Phe(3-I), Phe(3-C#C), Hph(3-F), Phe3, Phe(2-F), Phe(2-F-3-I), Phe(2-F-3-Br), Phe(3-I-5-F), Phe(3-I-5-Cl), Ala(3-Pyr-5-Br), Phe(3-Br-5-F), Phe(2-Br-5-I), Phe(2-Me-5-I), Phe(2-F-5-Br), Phe(2-Cl-5-Br), Phe(2-Me-5-Br), Phe(23-F2), Phe(25-F2), Phe(26-F2), Hph(3-F-4-OCHF2), Hph(3-CN-4-CF3), Hph(3-OMe-4-CF3), Abu(3-Pyr-4-CF3), Abu(34-Cate(CF2)), Hph(3-Cl-4-OCF3), Hph(3-F-4-OCF3), Abu(6-Quino), Abu(1-Me-6-Indo), Abu(1-Me-5-Indo), Abu(3-Pyr-4-OMe), Abu(5-Bzfr), Abu(3-Pyr-4-CHF2), Abu(2-Pyr-4-CF3), Hph(4-SO2Me), Hph(3-F-4-CHF2), Abu(7-Quino), Hph(345-Cl3), Hph(34-Cl2-5-OMe)Hph(34-Cl2-5-CN), Hph(34-Cl2-5-OiPr), Hph(34-Cl2-5-OnBu), Hph(34-Cl2-5-OtBu), Phe3(4-CF3), Ser(Bn- 4-Cl), Hse(Ph-4-Cl), Hse(Ph-34-Cl2), Hse(Ph-4-CF3), Ser(Ph-4-Cl), Ser(Bn-3-Cl), and Ser(Bn-2-Cl). ,

[0195] In one embodiment, in formula (1), R8 is selected from the group consisting of hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C2-C6 alkenyloxycarbonylC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C6-C 10 Aryloxy C1-C6 alkyl, C7-C 14 Aralkyl, C7-C 14 aralkoxyC1-C6 alkyl, 5-10 membered heteroarylC1-C6 alkyl, or 5-10 membered heteroarylC1-C6 alkoxyC1-C6 alkyl, each of which is halogen, hydroxy, carboxy, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkoxy, cyano, amino (the amino is -NH2, protected amino, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or a 4- to 8-membered cyclic alkylamino). and optionally substituted by one or more groups independently selected from the group consisting of amino, each of which is optionally substituted with halogen), aminocarbonyl (the amino is —NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), 4- to 7-membered heterocycloalkylidene, protected 4- to 7-membered heterocycloalkylidene, 4- to 7-membered heterocyclyl, and protected 4- to 7-membered heterocyclyl.

[0196] R8 is preferably hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 carboxyalkyl, C1-C6 aminoalkyl (the amino is -NH2, protected amino, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which may be substituted with one or more halogens), aminocarbonylC1-C6 alkyl (the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which may be substituted with one or more halogens), protected optionally protected 4- to 7-membered heterocyclyl C1-C6 alkyl, optionally protected 4- to 7-membered heterocycloalkylidene C1-C6 alkyl, C1-C6 alkoxy C1-C6 alkyl (the C1-C6 alkoxy C1-C6 alkyl may be substituted by aminocarbonyl (the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino) or hydroxy), C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkenyloxycarbonyl C1-C6 alkyl, C2-C6 alkynyl, C6-C 10 Aryloxy C1-C6 alkyl, C7-C 14 Aralkyl (C7-C 14 The aralkyl is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, and cyano), a 5- to 10-membered heteroarylC1-C6 alkyl (the 5- to 10-membered heteroarylalkyl is optionally substituted by one or more groups selected from the group consisting of C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, and cyano), or a 5- to 10-membered heteroarylC1-C6 alkoxyC1-C6 alkyl optionally substituted by one or more halogens.

[0197] More preferred examples of R8 include hydrogen, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C4 hydroxyalkyl, C1-C4 carboxyalkyl, protected amino C1-C4 alkyl, mono C1-C4 alkylaminocarbonyl C1-C2 alkyl, di C1-C4 alkylaminocarbonyl C1-C2 alkyl, 4- to 8-membered cyclic aminocarbonyl C1-C2 alkyl optionally substituted with one or more fluorines, 4- to 8-membered cyclic aminoC1-C2 alkyl optionally substituted with one or more fluorines, optionally protected 4- to 7-membered heterocyclyl C1-C2 alkyl, optionally protected 4- to 7-membered heterocycloalkylidene C1-C2 alkyl, mono C1-C4 alkylaminocarbonylmethyloxy C1-C2 alkyl, C1-C4 alkoxy optionally substituted with hydroxy. benzyl or phenethyl optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, methyl, difluoromethyl, trifluoromethyl, methoxy, trifluoromethoxy, hydroxy, and cyano; 5-6-membered heteroaryl C1-C2 alkyl optionally substituted by one or more groups selected from the group consisting of methyl, trifluoromethyl, methoxy, and cyano; or 5-6-membered heteroarylmethoxy C1-C2 alkyl optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, methyl, difluoromethyl, trifluoromethyl, methoxy, and cyano; or 5-6-membered heteroarylmethoxy C1-C2 alkyl optionally substituted by one or more halogens.

[0198] In one embodiment, R8 is more preferably —(CH2) optionally substituted by 1 to 5 groups independently selected from the group consisting of halogen, C1-C4 alkyl (preferably methyl), C2-C4 alkynyl (preferably ethynyl), C1-C3 haloalkyl (preferably difluoromethyl, trifluoromethyl), C1-C3 haloalkoxy (preferably trifluoromethoxy), C1-C4 alkoxy (preferably methoxy), —CN, C1-C3 alkylsulfonyl (preferably methylsulfonyl), hydroxy, and SF5. x -O y -(CH2) z1 -C6-C 10 Aryl or -(CH2) x -O y -(CH2) z2 -5-10 membered heteroaryl, where x is 1, 2, or 3, y is 0 or 1, z1 is 0, 1, 2, or 3, and z2 is 1, 2, or 3, provided that the sum of x, y, and z1 or z2 is 1 to 4. -(CH2) x -O y -(CH2) z1 -C6-C 10 When the aryl has a substituent, the substituent is a C-C 10 Preferably on the aryl, -(CH2) x -O y -(CH2) z2 When the 5- to 10-membered heteroaryl has a substituent, the substituent is preferably on the 5- to 10-membered heteroaryl in the group.

[0199] Specific examples of R8 include hydrogen, methyl, ethyl, i-propyl, n-propyl, n-butyl, 2-methylpropyl, 1-methylpropyl, neopentyl, (2-hydroxy-2-methyl-propyloxy)methyl, (2-(tert-butylamino)-2-oxoethoxy)methyl, 3,3-difluorobutyl, n-propoxymethyl, 3-methylbutoxymethyl, 1-hydroxyethyl, 2-methoxyethyl, 2-methylbutyl, 5,5-difluoropentyl, 3-methylamino-3-oxopropyl, ((5-fluoropyridin-3-yl)methoxy)methyl, 4-(((allyloxy)carbonyl)amino)butyl, 2-hydroxy-2-oxoethyl, (5-fluoropyridin-3-yl ... 2-(3,3-difluoro-azetidin-1-yl)methyl, 2-(3,3-difluoropiperidinyl)ethyl, 2-(4,4-difluoropiperidinyl)-2-oxo-ethyl, 2-(allyloxy)-2-oxo-ethyl, phenoxymethyl, hydroxymethyl, 2-(tetrahydro-4H-pyran-4-ylidene)ethyl, 2-(tetrahydro-2H-pyran-4-yl)ethyl, 2-(1-(t-butoxycarbonyl)azetidin-3-ylidene)ethyl, 2-(1-(t-butoxycarbonyl)azetidin-3-yl)ethyl, 2-(3,3-difluoro-azetidin-1-yl)-2-oxoethyl, 2-(3,3-difluoro-azetidin-1-yl)-ethyl, 3-(dimethylamino)3-oxopropyl, 3-(3,3-Difluoro-azetidin-1-yl)-3-oxopropyl, 3-(azetidin-1-yl)-3-oxopropyl, 2-(piperidinyl)-2-oxo-propyl, 3-(pyrrolidin-1-yl)-3-oxopropyl, 3-(morpholin-1-yl)-3-oxopropyl, 2-(dimethylamino)-2-oxoethyl, 2-(azetidinyl)-2-oxo-ethyl, 2-(piperidinyl)-2-oxo-ethyl, 2-(pyrrolidinyl)-2-oxo-ethyl, 2-(morpholin-1-yl) -2-oxoethyl, allyl, 2-methylallyl, 3-methylbut-2-en-1-yl, pent-4-en-1-yl, propargyl, 3-allyloxy-3-oxopropyl, cyclohexyl, cyclopentylmethyl, cyclopropylmethyl, benzyl, phenethyl, 4-chlorobenzyl, 3-cyanobenzyl, 4-ethynylbenzyl, 2-fluorobenzyl, 2-chlorobenzyl, 3-chlorobenzyl, 3-bromobenzyl, 4-bromobenzyl, 2-methylbenzyl, 3-methylbenzyl, 4 -methylbenzyl, 4-methoxybenzyl, 3-(trifluoromethoxy)benzyl, 4-(trifluoromethoxy)benzyl, 3,4-difluorobenzyl, 4-iodobenzyl, 4-fluorobenzyl, 4-difluoromethylbenzyl, 3-fluoro-4-hydroxybenzyl, 4-(trifluoromethyl)benzyl, 2-trifluoromethylbenzyl, 2-methoxybenzyl, 3-trifluoromethylbenzyl, 2-(trifluoromethoxy)benzyl, 3-methoxybenzyl, 3-iodobenzyl Examples of the methylpyridin-3-yl methyl include 2-(pyridin-3-yl)ethyl, 2-(pyridin-4-yl)ethyl, 2-(pyridin-4-yl)ethyl, and the like.

[0200] In one embodiment, in formula (1), R8 can be combined with R5 to form a C4-C8 alkylene. As the C4-C8 alkylene, -(CH2)8- is preferred.

[0201] In one embodiment, in formula (1), R8 and P8 can form a 4- to 7-membered saturated heterocycle (preferably a 4- or 5-membered saturated heterocycle) together with the carbon atom to which R8 is bonded and the nitrogen atom to which P8 is bonded. The 4- to 7-membered saturated heterocycle may be condensed with a saturated carbocycle or an aromatic ring. The 4- to 7-membered saturated heterocycle may be condensed with a halogen, oxo, C6-C 10 It may be substituted by aryl, 5-10 membered heteroaryl, 4-8 membered cyclic amino (the cyclic amino may be substituted by one or more halogens), or OS8, where S8 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C7-C 14 aralkyl (the aralkyl may be optionally substituted by one or more halogen, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy), or 5-10 membered heteroaryl C1-C6 alkyl.

[0202] When R8 and P8 form a 4- to 7-membered saturated heterocycle, the 4- to 7-membered saturated heterocycle is preferably an azetidine ring, a pyrrolidine ring, a piperidine ring, a piperazine ring, or a morpholine ring. These saturated heterocycles may be condensed with a 3- to 8-membered saturated carbocycle (preferably a cyclohexane ring) or a 6- to 10-membered aromatic ring (preferably a benzene ring). When the 4- to 7-membered saturated heterocycle has one or more substituents, the 4- to 7-membered saturated heterocycle may have one or more of halogen, hydroxy, oxo, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 hydroxyalkoxy, C6-C 10 Aryl, 5-10 membered heteroaryl, C1-C6 alkoxy, C7-C 14 Aralkoxy (C7-C 14The aralkoxy is preferably substituted by one or more halogens, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy), a 4- to 8-membered cyclic amino optionally substituted by one or more halogens, or a 5- to 10-membered heteroaryl. More preferred substituents on the 4- to 7-membered saturated heterocycle include halogen, hydroxy, oxo, ethoxy, 2-hydroxyethyl, phenyl, and difluoroethoxy; benzyloxy optionally substituted by one or more substituents independently selected from the group consisting of halogen, methyl, trifluoromethyl, methoxy, and difluoromethoxy; 5- to 6-membered heteroarylmethoxy, a 4- to 8-membered cyclic amino optionally substituted by one or more fluorines, phenyl, and a 5- to 6-membered heteroaryl.

[0203] In some embodiments, in formula (1), R8 and Q8 can be taken together with the carbon atoms to which they are attached to form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring.

[0204] When R8 and Q8 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, the 3- to 8-membered alicyclic ring is preferably a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, or a cyclohexane ring, and the 4- to 7-membered saturated heterocyclic ring is preferably a tetrahydrofuran ring or a tetrahydropyran ring.

[0205] In one embodiment, in formula (1), except when R8 and P8 form a 4- to 7-membered saturated heterocycle, P8 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkoxyC1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxyC2-C6 alkenyl, C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, 4- to 7-membered heterocyclylC1-C6 alkyl, C6-C 10 Aryl, C7-C 14aralkyl, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl C1-C6 alkyl, each of which is optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, amino (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen or C1-C6 alkyl), and aminocarbonyl (wherein the amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino).

[0206] P8 is preferably hydrogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxyC1-C6 alkyl (the C1-C6 alkoxyC1-C6 alkyl is optionally substituted with one or more halogens, hydroxy, diC1-C6 alkylaminocarbonyl, C1-C6 alkoxy, or amino (the amino is -NH2, monoC1-C6 alkylamino, diC1-C6 alkylamino, or 4- to 8-membered cyclic amino)), aminocarbonylC1-C6 alkyl (the amino is -NH2, monoC1-C6 alkylamino, diC1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with one or more halogens), or C1-C6 aminoalkyl. (The amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4-8 membered cyclic amino, each of which is optionally substituted with one or more halogens or C1-C6 alkyl), C2-C6 alkenyl, C2-C6 hydroxyalkenyl, aminocarbonylC2-C6 alkenyl (The amino is -NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4-8 membered cyclic amino), C1-C6 alkoxyC2-C6 alkenyl, C3-C8 cycloalkyl optionally substituted with one or more halogens, 4- to 7-membered heterocyclyl, 4- to 7-membered heterocyclylC1-C6 alkyl, C6-C8 optionally substituted with one or more halogens, 10 Aryl, C7-C14 It is aralkyl, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl C1-C6 alkyl.

[0207] More preferred examples of P8 include hydrogen, C1-C6 alkyl, C1-C6 hydroxyalkyl; C1-C4 alkoxyC1-C2 alkyl optionally substituted with one or more fluorines, hydroxy, dimethylaminocarbonyl, methoxy, amino, methylamino, and dimethylamino; dimethylaminocarbonylC1-C4 alkyl, aminoC1-C4 alkyl (the amino is —NH2), 4-8 membered cyclic aminoC1-C4 alkyl optionally substituted with one or more fluorines or methyl, C2-C3 alkenyl, C2-C6 hydroxyalkenyl, dimethylaminocarbonylC2-C3 alkenyl, methoxyC2-C6 alkenyl, C3-C8 cycloalkyl optionally substituted with one or more fluorines, 4-7 membered heterocyclyl, 4-7 membered heterocyclylC1-C2 alkyl, phenyl optionally substituted with one or more halogens, benzyl, 5-6 membered heteroaryl, and 5-6 membered heteroarylC1-C2 alkyl.

[0208] Specific examples of P8 include hydrogen, methyl, ethyl, n-butyl, allyl, 2-hydroxyethyl, 2-ethoxyethyl, 2-(dimethylaminocarbonylmethoxy)ethyl, 2-(2-hydroxy-2-methylpropoxy)ethyl, 4-aminobutyl, 2-piperazin-1-ylethyl, 2-(4-methylpiperazin-1-yl)ethyl, 2-(2,2,2-trifluoroethoxy)ethyl, 2-(2-methoxyethoxy)ethyl, 2-(2,2-difluoroethoxy)ethyl, 2-(2-aminoethoxy)ethyl, 2-[2-(methylamino)ethoxy]ethyl, 2-[2-(dimethylamino)ethoxy]ethyl, 5-hydroxypentyl, phenyl, 3-chlorophenyl, 4-chlorophenyl, benzyl, ( (E)-3-(dimethylaminocarbonyl)-prop-2-en-1-yl, (E)-5-hydroxypent-2-en-1-yl, (E)-4-hydroxy-4-methyl-pent-2-en-1-yl, (E)-5-hydroxy-5-methyl-hex-2-en-1-yl, (E)-4-methoxybut-2-en-1-yl, 3-(dimethylaminocarbonyl)propyl, 2,2-difluorospiro[3.3]heptan-6-yl, 3-thienyl, 3-pyridylmethyl, 2-oxaspiro[3.3]heptan-6-yl, oxetan-3-ylmethyl, 2-(azetidin-3-yl)ethyl, 2-(4,4-difluoro-1-piperidyl)ethyl, 3-(4,4-difluoro-1-piperidyl)propyl and the like.

[0209] In certain embodiments, Q8 is hydrogen or C1-C6 alkyl, preferably hydrogen, except when R8 and Q8 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring.

[0210] MeAla, Ala, Pic(2), MeLeu, EtAla, MeSer(tBuOH) and MeS er(NtBu-Aca)、MeAla(cPent)、MeAla(cPr)、MeNva、MeNle、Val、Leu、MeNva (5-F2)、MeSer(nPr)、MeHnl(7-F2)、MeSer(iPen)、MeThr、MeHse(Me)、Ile、 Nle、PRA、Chg、Abu、Hnl(7-F2)、Ser(iPen)、Algly、Pregly、EtGly、nBuGly、( EtOEt)NGly、Pro、Aze(2)、MeGln(Me),MePhe、MePhe(4-Cl)、MePhe(3-CN)、 MePhe(4-CN)、MePhe(2-F)、MePhe(3-F)、MePhe(4-F)、MePhe(2-Cl)、MePhe (3-Cl)、MePhe(3-Br)、MePhe(4-Br)、MePhe(2-Me)、MePhe(3-Me)、MePhe(4 -Me)、MeTyr(Me)、MePhe(3-OCF3)、MePhe(4-OCF3)、MeAlgly、MePhe(34-F2) 、MeAla(3-Pyr)、MePhe(4-I)、Phe(4-Me)、D-MeAla、Phe(3-Me)、Phe、Hph、P he(4-F)、Phe(2-F)、Hyp(Et)、Tle、Pro(4-F2)、Ser(tBuOH)、Ser(NtBu-Aca )、Ser(3-F-5-Me-Pyr)、Glu(OAl)、Oic、Hyp、cisHyp、Lys(Alloc)、Phe(4-C HF2)、Hyp(Bzl)、cisHyp(Et)、Hyp(Bzl(2-Cl))、cisHyp(Bzl(2-Cl))、cisHy p(Bzl(3-Cl))、cisHyp(Bzl(4-Cl))、Hyp(Bzl(3-Cl))、Hyp(Bzl(4-Cl))、H yp(Bzl(2-Me))、Hyp(Bzl(3-Me))、Hyp(Bzl(3-OMe))、Hyp(Bzl(4-Me))、Hy p(Bzl(4-OCHF2))、cisHyp(Bzl(2-Me))、cisHyp(Bzl(3-Me))、cisHyp(Bzl (3-OMe))、cisHyp(Bzl(4-Me))、cisHyp(Bzl(4-OCHF2))、Methagly、MeAsp、Pro(4-keto)、Pic(2)(4-Oxo)、Mor(3)、Thiopro、MeAla(4-Thz)、MeSer(3-F-5-Me-Pyr)、MeTyr(3-F)、MeAla(3-Pyr-4-CN)、Ahpe(2)、Hyp(3-Me-Pyr)、cisHyp(3-Me-Pyr)、cisHyp(Et(2-F2))、Hyp(Et(2-F2))、Tyr(Me)、Phe(4-CF3)、Phe(4-Cl)、Phe(2-CF3)、Phe(2-Cl)、Phe(2-Me)、Phe(2-OMe)、Phe(3-CF3)、MeAbu(pip-3-F2)、MeAsn(pip-4-F2)、Pro(4-pip-4-F2)、cisPro(4-pip-4-F2)、MeAsp(OAl)、Pro(4R-Tri)、Pro(4S-Tri)、Ser(Ph)、IDC、Pro(4R-Ph)、Pro(4S-Ph)、MeAla(3-Pyr-4-OMe)、MeAla(3-Pyr-4-CF3)、MeAla(3-Pyr-5-Me)、MeAla(3-Pyr-5-OMe)、MeAla(4-Pyr)、MeAla(3-Pyr-4-Me)、Hyp(3-thie-Me)、PhGly、cisHyp(2-EtOH)、Hyp(2-EtOH)、Phe(2-OCF3)、BnGly、(3-Thienyl)Gly、(Ph-3-Cl)Gly、(Ph-4-Cl)Gly、(F2cBucBu)Gly、(OxeMe)Gly、(OxecBu)Gly、D-Ala、D-MeSer(iPen)、D-MeSer、D-Mor(3)、D-MePhe、D-MeAbu、MePhe(4-CHF2)、MeAbu(3-Pyr)、MeAbu(4-Pyr)、MeAbu(THPdene)、MeAbu(THP)、MeAbu(BocAzedene)、MeAbu(BocAze)、(pip(4-F2)Et)Gly、(pip(4-F2)nPr)Gly、(Et(2-F2)OEt)Gly、(MeOEtOEt)Gly、(Et(2-F3)OEt)Gly、(4-pyr-Et)Gly、(3-pyr-Et)Gly、(4-pyr-Me)Gly、(3-pyr-Me)Gly、AllylGly、(HOEt)Gly、(HOiPrallyl)Gly、(DMFallyl)Gly、(HOEtallyl)Gly、(5-OH-nPent)Gly, MeAsn(Aze-3-F2), MeAbu(Aze-3-F2), (Me2NCOnPr)Gly, (HOtBuall)Gly, (HOtBuOEt)Gly, (DMA OEt)Gly, (MeOMeallyl)Gly, MeGln(Me2), MeGln(Aze-3-F2), MeGln(Aze), MeGln(pip), MeGln(pyrro), MeGln(mor), M eAsn(Me2), MeAsn(Aze), MeAsn(pip), MeAsn(pyrro), MeAsn(mor), MePhe(3-OMe), MePhe(3-I), EtPhe(2-Cl), (4-Me- ...

Claims

1. A cyclic peptide compound comprising 8 to 15 amino acid residues that binds to a Ras protein comprising the amino acid sequence set forth in SEQ ID NO:9, i) at least three N-substituted amino acid residues; ii) at least one non-N-substituted amino acid residue, and iii) a cyclic portion comprising at least eight amino acid residues; Including, iv) interacting with at least one amino acid selected from the group consisting of Val8, Gly10, Lys16, Glu37, Leu56, Gln70, Tyr71, and Glu98 of the Ras protein; A cyclic peptide compound, a salt thereof, or a solvate thereof.

2. further interacts with at least one amino acid selected from the group consisting of Val7, Val9, Ala11, Xaa12, Thr58, Ala59, Gly60, Xaa61, Glu62, Glu63, Tyr64, Arg68, Asp69, Met72, Arg73, Phe78, Asp92, Xaa95, Tyr96, Gln99, Ile100, Arg102, and Val103 of the Ras protein; Xaa12 is an amino acid selected from the group consisting of Gly, Asp, Cys, Ser, Val, Ala, and Arg; and / or said Xaa61 is an amino acid selected from the group consisting of Gln, His, Lys, and Leu; Xaa95 is an amino acid selected from the group consisting of Gln, His, and Leu. The cyclic peptide compound according to claim 1, or a salt thereof, or a solvate thereof.

3. Further interacting with at least one amino acid selected from the group consisting of Val9, Thr58, Xaa61, Glu62, Tyr64, Arg68, Met72, Asp92, Xaa95, Tyr96, Gln99, Arg102, and Val103 of the Ras protein; and / or said Xaa61 is an amino acid selected from the group consisting of Gln, His, Lys, and Leu; Xaa95 is an amino acid selected from the group consisting of Gln, His, and Leu. The cyclic peptide compound according to claim 1, or a salt thereof, or a solvate thereof.

4. Further interacting with at least one amino acid selected from the group consisting of Thr58, Xaa61, Arg68, Gln99, and Arg102 of the Ras protein; Xaa61 is an amino acid selected from the group consisting of Gln, His, Lys, and Leu. The cyclic peptide compound according to claim 1, or a salt thereof, or a solvate thereof.

5. A cyclic peptide compound or a salt thereof, or a solvate thereof, according to claim 1, which interacts with at least one amino acid selected from the group consisting of Gly10, Leu56, Tyr71, and Glu98 of the Ras protein.

6. Further interacting with at least two amino acids selected from the group consisting of Thr58, Xaa61, Arg68, Gln99, and Arg102 of the Ras protein; Xaa61 is an amino acid selected from the group consisting of Gln, His, Lys, and Leu. The cyclic peptide compound according to claim 1, or a salt thereof, or a solvate thereof.

7. A cyclic peptide compound or a salt thereof, or a solvate thereof, described in claim 1, which interacts with at least two amino acids selected from the group consisting of Gly10, Leu56, Tyr71, and Glu98 of the Ras protein.

8. A cyclic peptide compound or a salt thereof, or a solvate thereof, described in any one of claims 1 to 7, wherein the Ras protein is one or more Ras proteins selected from the group consisting of Kras proteins, Nras proteins, and Hras proteins.

9. The cyclic peptide compound or a salt thereof, or a solvate thereof, according to claim 8, wherein the Ras protein is a Kras protein.

10. The cyclic peptide compound or its salt or solvate thereof described in claim 8, wherein the Ras protein is one or more mutant Ras proteins selected from the group consisting of mutant Kras proteins, mutant Nras proteins, and mutant Hras proteins.

11. The Ras protein is a mutant Kras protein, Xaa12 of the Ras protein is an amino acid selected from the group consisting of Asp, Cys, Ser, Val, and Ala; and / or Xaa61 of the Ras protein is an amino acid selected from His or Lys; The cyclic peptide compound according to claim 10, or a salt thereof, or a solvate thereof.

12. The Ras protein is a mutant Nras protein, Xaa12 of the Ras protein is an amino acid selected from Asp or Cys, and / or Xaa61 of the Ras protein is an amino acid selected from Lys or Leu; The cyclic peptide compound according to claim 10, or a salt thereof, or a solvate thereof.

13. The cyclic peptide compound consists of 11 amino acid residues, one of the amino acid residues is an amino acid residue having a carbonyl group bonded to the β-carbon of the amino group of the main chain, the amino acid residue may be N-substituted, and the carbonyl group is linked to an adjacent amino acid residue on the C-terminus side; the four amino acid residues on the C-terminal side of the amino acid residue having a carbonyl group bonded to the β-carbon of the amino group of the main chain are N-substituted amino acid residues, the seven amino acid residues on the C-terminal side of the amino acid residue having a carbonyl group bonded to the β-carbon of the amino group of the main chain comprise -(CH2)x-Oy-(CH2)z1-C6-C10 aryl or -(CH2)x-Oy-(CH2)z2-5-10 membered heteroaryl, optionally substituted with 1 to 5 groups independently selected from the group consisting of halogen, C1-C4 alkyl, C2-C4 alkynyl, C1-C3 haloalkyl, C1-C3 haloalkoxy, C1-C4 alkoxy, -CN, C1-C3 alkylsulfonyl, hydroxy, and SF5; Here, the sum of x, y, and z1 or z2 is 1 to 4, x is 1, 2, or 3; y is 0 or 1; z1 is 0, 1, 2, or 3; The cyclic peptide compound or its salt, or a solvate thereof according to any one of claims 1 to 7, wherein z2 is 1, 2, or 3.

14. The cyclic peptide compound or its salt or solvate thereof described in claim 13, wherein the seven amino acid residues on the C-terminal side of the amino acid residue having a carbonyl group bonded to the β-carbon of the amino group of the main chain are Hph(4-CF3-3-Cl).

15. The cyclic peptide compound or its salt or solvate thereof described in claim 13, wherein the amino acid residue four residues away on the C-terminal side of the amino acid residue having a carbonyl group bonded to the β-carbon of the amino group of the main chain is MeGly or Aze(2).

16. The cyclic peptide compound or its salt or solvate thereof described in claim 13, wherein the amino acid residue seven residues C-terminal to the amino acid residue having a carbonyl group bonded to the β carbon of the amino group of the main chain interacts with one or more selected from Tyr71, Leu56 and Glu37 of the Ras protein.

17. A cyclic peptide compound or a salt thereof, or a solvate thereof, as described in claim 13, wherein the amino acid residue four amino acid residues to the C-terminus of an amino acid residue having a carbonyl group bonded to the beta carbon of the amino group of the main chain interacts with Glu98 of the Ras protein.

18. The cyclic peptide compound or its salt or solvate thereof described in claim 13, wherein the amino acid residues seven and eight away on the C-terminal side of an amino acid residue having a carbonyl group bonded to the beta carbon of the amino group of the main chain each interact with one or more selected from Tyr71, Leu56, Glu37, Lys16 and Gly10 of the Ras protein.

19. The cyclic peptide compound according to any one of claims 1 to 7, or a salt thereof, or a solvate thereof, selected from the group consisting of: (488) (5S,8S,11S,15R,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-11-isobutyl-18-isopropyl-5,6,12,15,19,33,36-heptamethyldocosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone, (872) (11S,17S,26S,29S,33S,36S)-11-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-36-cyclohexyl-17-(cyclohexylmethyl)-9-(2-ethoxyethyl)-29-isobutyl-15,18,21,24,30,34,37-heptamethyl-26-[(1S)-1-methylpropyl]-33-(piperidine-1-carbonyl)-6,9,12,15,18,21,24,27,30,34,37-undecazaspiro[4.33]octatriacontane-7,10,13,16,19,22,25,28,31,35,38-undecaone, (1201) (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nonaphthalene Methyl-4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, (2187) (6S,9S,15S,18S,21S,24S,27S,30R,34S)-15-benzyl-21-[(3-chlorophenyl)methyl]-9-[(4-chlorophenyl)methyl]-24,27-bis[(3-fluoro-4-hydroxyphenyl)methyl]-10,16,30,31-tetramethyl-6-[(1S)-1-methylpropyl]-18-(2-methylsulfonylethyl)-34-(pyrrolidine-1-carbonyl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotetratriacontane-2,5,8,11,14,17,20,23,26,29,32-undecaone, and (2188) (3S,6S,9S,12S,15S,18S,21S,24S,28S,31S)-18,21-dibutyl-12-[(2-chlorophenoxy)methyl]-6-[(5-fluoro-3-pyridyl)methoxymethyl]-4,10,24,25-tetramethyl-15-[(1S)-1-methylpropyl]-3,9-bis(3-pyridylmethyl)-28-(pyrrolidine-1-carbonyl)-1,4,7,10,13,16,19,22,25,29-decazabicyclo[29.3.0]tetratriacontane-2,5,8,11,14,17,20,23,26,30-decone.

20. A hydrate of the cyclic peptide compound according to any one of claims 1 to 7, selected from the group consisting of: (488) (5S,8S,11S,15R,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-11-isobutyl-18-isopropyl-5,6,12,15,19,33,36-heptamethyldocosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone, (872) (11S,17S,26S,29S,33S,36S)-11-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-36-cyclohexyl-17-(cyclohexylmethyl)-9-(2-ethoxyethyl)-29-isobutyl-15,18,21,24,30,34,37-heptamethyl-26-[(1S)-1-methylpropyl]-33-(piperidine-1-carbonyl)-6,9,12,15,18,21,24,27,30,34,37-undecazaspiro[4.33]octatriacontane-7,10,13,16,19,22,25,28,31,35,38-undecaone, (1201) (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nonaphthalene Methyl-4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, (2187) (6S,9S,15S,18S,21S,24S,27S,30R,34S)-15-benzyl-21-[(3-chlorophenyl)methyl]-9-[(4-chlorophenyl)methyl]-24,27-bis[(3-fluoro-4-hydroxyphenyl)methyl]-10,16,30,31-tetramethyl-6-[(1S)-1-methylpropyl]-18-(2-methylsulfonylethyl)-34-(pyrrolidine-1-carbonyl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotetratriacontane-2,5,8,11,14,17,20,23,26,29,32-undecaone, and (2188) (3S,6S,9S,12S,15S,18S,21S,24S,28S,31S)-18,21-dibutyl-12-[(2-chlorophenoxy)methyl]-6-[(5-fluoro-3-pyridyl)methoxymethyl]-4,10,24,25-tetramethyl-15-[(1S)-1-methylpropyl]-3,9-bis(3-pyridylmethyl)-28-(pyrrolidine-1-carbonyl)-1,4,7,10,13,16,19,22,25,29-decazabicyclo[29.3.0]tetratriacontane-2,5,8,11,14,17,20,23,26,30-decone.

21. A pharmaceutical composition comprising a cyclic peptide compound or a salt thereof, or a solvate thereof, according to any one of claims 1 to 7.

22. The pharmaceutical composition of claim 21, which is a Ras inhibitor.

23. The pharmaceutical composition described in claim 22, wherein the Ras inhibitor is one or more Ras inhibitors selected from the group consisting of Kras inhibitors, Nras inhibitors and Hras inhibitors.

24. The pharmaceutical composition of claim 21 for treating or preventing cancer.

25. The pharmaceutical composition described in claim 24, wherein the cancer is a solid cancer or a blood cancer.

26. The pharmaceutical composition described in claim 24, wherein the cancer is selected from the group consisting of lung cancer, esophageal cancer, gastric cancer, colon cancer, uterine cancer, ovarian cancer, pancreatic cancer, bladder cancer, thyroid cancer, skin cancer, leukemia, malignant lymphoma, and multiple myeloma.

27. ​​The pharmaceutical composition of claim 24, wherein the cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, colon cancer, rectal cancer, uterine cancer, endometrial cancer, cervical cancer, AML (acute myeloid leukemia), CML (chronic myeloid leukemia), ALL (acute lymphocytic leukemia), CLL (chronic lymphocytic leukemia), Hodgkin lymphoma, and Non-Hodgkin lymphoma.

28. The pharmaceutical composition described in claim 24, wherein the cancer is associated with an abnormality in the Ras gene.

29. The pharmaceutical composition described in claim 28, wherein the abnormality in the Ras gene is a mutation in the coding region of the Ras gene and / or an amplification of the copy number of the Ras gene.

30. The pharmaceutical composition described in claim 28, wherein the Ras gene is one or more Ras genes selected from the group consisting of Kras genes, Nras genes and Hras genes.

31. The pharmaceutical composition described in claim 30, wherein the Ras gene is a Kras gene.

32. The pharmaceutical composition of claim 24, wherein the cancer is associated with production of a mutant Ras protein and / or increased production of a Ras protein.

33. The pharmaceutical composition described in claim 32, wherein the cancer is associated with the production of a mutant Ras protein.

34. The pharmaceutical composition described in claim 32, wherein the mutant Ras protein is one or more mutant Ras proteins selected from the group consisting of mutant Kras proteins, mutant Nras proteins, and mutant Hras proteins.

35. The pharmaceutical composition described in claim 34, wherein the mutant Ras protein is a mutant Kras protein.

36. The pharmaceutical composition described in claim 32, wherein the mutant Ras protein has a mutation at at least one amino acid position selected from the group consisting of G12, G13 and Q61 in the amino acid sequence set forth in SEQ ID NO: 6, 7 or 8.

37. The pharmaceutical composition described in claim 32, wherein the mutant Ras protein is a mutant Kras protein and has at least one amino acid mutation selected from the group consisting of G12A, G12C, G12D, G12S, G12V, G13D, Q61H, and Q61K compared to the amino acid sequence set forth in SEQ ID NO:

6.

38. The pharmaceutical composition described in claim 32, wherein the mutant Ras protein is a mutant Nras protein and has at least one amino acid mutation selected from the group consisting of G12C, G12D, G13D, G13V, Q61K, and Q61L compared to the amino acid sequence set forth in SEQ ID NO:

7.

39. The pharmaceutical composition described in claim 32, wherein the mutant Ras protein is a mutant Hras protein and has an amino acid mutation of G13R compared to the amino acid sequence set forth in SEQ ID NO:

8.

40. The pharmaceutical composition of claim 21, comprising a cyclic peptide compound or a salt thereof, or a solvate thereof, selected from the group consisting of: (488) (5S,8S,11S,15R,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-11-isobutyl-18-isopropyl-5,6,12,15,19,33,36-heptamethyldocosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone, (872) (11S,17S,26S,29S,33S,36S)-11-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-36-cyclohexyl-17-(cyclohexylmethyl)-9-(2-ethoxyethyl)-29-isobutyl-15,18,21,24,30,34,37-heptamethyl-26-[(1S)-1-methylpropyl]-33-(piperidine-1-carbonyl)-6,9,12,15,18,21,24,27,30,34,37-undecazaspiro[4.33]octatriacontane-7,10,13,16,19,22,25,28,31,35,38-undecaone, (1201) (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nonaphthalene Methyl-4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, (2187) (6S,9S,15S,18S,21S,24S,27S,30R,34S)-15-benzyl-21-[(3-chlorophenyl)methyl]-9-[(4-chlorophenyl)methyl]-24,27-bis[(3-fluoro-4-hydroxyphenyl)methyl]-10,16,30,31-tetramethyl-6-[(1S)-1-methylpropyl]-18-(2-methylsulfonylethyl)-34-(pyrrolidine-1-carbonyl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotetratriacontane-2,5,8,11,14,17,20,23,26,29,32-undecaone, and (2188) (3S,6S,9S,12S,15S,18S,21S,24S,28S,31S)-18,21-dibutyl-12-[(2-chlorophenoxy)methyl]-6-[(5-fluoro-3-pyridyl)methoxymethyl]-4,10,24,25-tetramethyl-15-[(1S)-1-methylpropyl]-3,9-bis(3-pyridylmethyl)-28-(pyrrolidine-1-carbonyl)-1,4,7,10,13,16,19,22,25,29-decazabicyclo[29.3.0]tetratriacontane-2,5,8,11,14,17,20,23,26,30-decone.

41. The pharmaceutical composition of claim 21, comprising a hydrate of a cyclic peptide compound selected from the group consisting of: (488) (5S,8S,11S,15R,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-29-(3-chloro-4-(trifluoromethyl)phenethyl)-35-(cyclohexylmethyl)-11-isobutyl-18-isopropyl-5,6,12,15,19,33,36-heptamethyldocosahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-4,7,10,13,17,20,23,28,31,34,37(14H,22H)-undecaone, (872) (11S,17S,26S,29S,33S,36S)-11-[2-[3-chloro-4-(trifluoromethyl)phenyl]ethyl]-36-cyclohexyl-17-(cyclohexylmethyl)-9-(2-ethoxyethyl)-29-isobutyl-15,18,21,24,30,34,37-heptamethyl-26-[(1S)-1-methylpropyl]-33-(piperidine-1-carbonyl)-6,9,12,15,18,21,24,27,30,34,37-undecazaspiro[4.33]octatriacontane-7,10,13,16,19,22,25,28,31,35,38-undecaone, (1201) (5S,8S,11S,15S,18S,23aS,25R,29S,35S,37aS)-8-((S)-sec-butyl)-35-(cyclohexylmethyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-25-ethoxy-11-isobutyl-N,N,5,6,12,16,19,33,36-nonaphthalene Methyl-4,7,10,13,17,20,23,28,31,34,37-undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide, (2187) (6S,9S,15S,18S,21S,24S,27S,30R,34S)-15-benzyl-21-[(3-chlorophenyl)methyl]-9-[(4-chlorophenyl)methyl]-24,27-bis[(3-fluoro-4-hydroxyphenyl)methyl]-10,16,30,31-tetramethyl-6-[(1S)-1-methylpropyl]-18-(2-methylsulfonylethyl)-34-(pyrrolidine-1-carbonyl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotetratriacontane-2,5,8,11,14,17,20,23,26,29,32-undecaone, and (2188) (3S,6S,9S,12S,15S,18S,21S,24S,28S,31S)-18,21-dibutyl-12-[(2-chlorophenoxy)methyl]-6-[(5-fluoro-3-pyridyl)methoxymethyl]-4,10,24,25-tetramethyl-15-[(1S)-1-methylpropyl]-3,9-bis(3-pyridylmethyl)-28-(pyrrolidine-1-carbonyl)-1,4,7,10,13,16,19,22,25,29-decazabicyclo[29.3.0]tetratriacontane-2,5,8,11,14,17,20,23,26,30-decone.